
<html lang="en"     class="pb-page"  data-request-id="7d5d85f9-798b-4ef5-8256-43d7ce11af62"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm501649k;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications" /></meta><meta name="dc.Creator" content="Andreas  Maderna" /></meta><meta name="dc.Creator" content="Matthew  Doroski" /></meta><meta name="dc.Creator" content="Chakrapani  Subramanyam" /></meta><meta name="dc.Creator" content="Alexander  Porte" /></meta><meta name="dc.Creator" content="Carolyn A.  Leverett" /></meta><meta name="dc.Creator" content="Beth C.  Vetelino" /></meta><meta name="dc.Creator" content="Zecheng  Chen" /></meta><meta name="dc.Creator" content="Hud  Risley" /></meta><meta name="dc.Creator" content="Kevin  Parris" /></meta><meta name="dc.Creator" content="Jayvardhan  Pandit" /></meta><meta name="dc.Creator" content="Alison H.  Varghese" /></meta><meta name="dc.Creator" content="Suman  Shanker" /></meta><meta name="dc.Creator" content="Cynthia  Song" /></meta><meta name="dc.Creator" content="Sai Chetan K.  Sukuru" /></meta><meta name="dc.Creator" content="Kathleen A.  Farley" /></meta><meta name="dc.Creator" content="Melissa M.  Wagenaar" /></meta><meta name="dc.Creator" content="Michael J.  Shapiro" /></meta><meta name="dc.Creator" content="Sylvia  Musto" /></meta><meta name="dc.Creator" content="My-Hanh  Lam" /></meta><meta name="dc.Creator" content="Frank  Loganzo" /></meta><meta name="dc.Creator" content="Christopher J.  O’Donnell" /></meta><meta name="dc.Description" content="Auristatins, synthetic analogues of the antineoplastic natural product Dolastatin 10, are ultrapotent cytotoxic microtubule inhibitors that are clinically used as payloads in antibody–drug conjugat..." /></meta><meta name="Description" content="Auristatins, synthetic analogues of the antineoplastic natural product Dolastatin 10, are ultrapotent cytotoxic microtubule inhibitors that are clinically used as payloads in antibody–drug conjugat..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 9, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm501649k" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm501649k" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm501649k" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm501649k" /></link>
        
    
    

<title>Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm501649k" /></meta><meta property="og:title" content="Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0017.jpeg" /></meta><meta property="og:description" content="Auristatins, synthetic analogues of the antineoplastic natural product Dolastatin 10, are ultrapotent cytotoxic microtubule inhibitors that are clinically used as payloads in antibody–drug conjugates (ADCs). The design and synthesis of several new auristatin analogues with N-terminal modifications that include amino acids with α,α-disubstituted carbon atoms are described, including the discovery of our lead auristatin, PF-06380101. This modification of the peptide structure is unprecedented and led to analogues with excellent potencies in tumor cell proliferation assays and differential ADME properties when compared to other synthetic auristatin analogues that are used in the preparation of ADCs. In addition, auristatin cocrystal structures with tubulin are being presented that allow for the detailed examination of their binding modes. A surprising finding is that all analyzed analogues have a cis-configuration at the Val-Dil amide bond in their functionally relevant tubulin bound state, whereas in solution this bond is exclusively in the trans-configuration. This remarkable observation shines light onto the preferred binding mode of auristatins and serves as a valuable tool for structure-based drug design." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm501649k"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm501649k">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm501649k&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm501649k&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm501649k&amp;href=/doi/10.1021/jm501649k" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 10527-10543</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm5016022" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm501527z" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Maderna">Andreas Maderna</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Doroski">Matthew Doroski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chakrapani++Subramanyam">Chakrapani Subramanyam</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander++Porte">Alexander Porte</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carolyn+A.++Leverett">Carolyn A. Leverett</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Beth+C.++Vetelino">Beth C. Vetelino</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zecheng++Chen">Zecheng Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hud++Risley">Hud Risley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Parris">Kevin Parris</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jayvardhan++Pandit">Jayvardhan Pandit</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alison+H.++Varghese">Alison H. Varghese</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suman++Shanker">Suman Shanker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cynthia++Song">Cynthia Song</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sai+Chetan+K.++Sukuru">Sai Chetan K. Sukuru</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen+A.++Farley">Kathleen A. Farley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Melissa+M.++Wagenaar">Melissa M. Wagenaar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Shapiro">Michael J. Shapiro</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sylvia++Musto">Sylvia Musto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=My-Hanh++Lam">My-Hanh Lam</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Frank++Loganzo">Frank Loganzo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++O%E2%80%99Donnell">Christopher J. O’Donnell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Worldwide Medicinal Chemistry, Oncology, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Oncology Research Unit, Pfizer Worldwide Research and Development, 401 North Middletown Road, Pearl River, New York 10965, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 860-715 6498. Fax: 860-686-5506. E-mail: <a href="/cdn-cgi/l/email-protection#5b3a353f293e3a2875363a3f3e29353a1b2b3d32213e2975383436"><span class="__cf_email__" data-cfemail="e3828d8791868290cd8e828786918d82a393858a998691cd808c8e">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm501649k&amp;href=/doi/10.1021%2Fjm501649k" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 10527–10543</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 28, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 October 2014</li><li><span class="item_label"><b>Published</b> online</span>9 December 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 December 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm501649k" title="DOI URL">https://doi.org/10.1021/jm501649k</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10527%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndreas%2BMaderna%252C%2BMatthew%2BDoroski%252C%2BChakrapani%2BSubramanyam%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D24%26contentID%3Djm501649k%26title%3DDiscovery%2Bof%2BCytotoxic%2BDolastatin%2B10%2BAnalogues%2Bwith%2BN-Terminal%2BModifications%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10543%26publicationDate%3DDecember%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm501649k"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2935</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">84</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm501649k" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Maderna&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Doroski&quot;},{&quot;first_name&quot;:&quot;Chakrapani&quot;,&quot;last_name&quot;:&quot;Subramanyam&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;Porte&quot;},{&quot;first_name&quot;:&quot;Carolyn&quot;,&quot;last_name&quot;:&quot;A. Leverett&quot;},{&quot;first_name&quot;:&quot;Beth&quot;,&quot;last_name&quot;:&quot;C. Vetelino&quot;},{&quot;first_name&quot;:&quot;Zecheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Hud&quot;,&quot;last_name&quot;:&quot;Risley&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Parris&quot;},{&quot;first_name&quot;:&quot;Jayvardhan&quot;,&quot;last_name&quot;:&quot;Pandit&quot;},{&quot;first_name&quot;:&quot;Alison&quot;,&quot;last_name&quot;:&quot;H. Varghese&quot;},{&quot;first_name&quot;:&quot;Suman&quot;,&quot;last_name&quot;:&quot;Shanker&quot;},{&quot;first_name&quot;:&quot;Cynthia&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Sai&quot;,&quot;last_name&quot;:&quot;Chetan K. Sukuru&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;A. Farley&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;M. Wagenaar&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Shapiro&quot;},{&quot;first_name&quot;:&quot;Sylvia&quot;,&quot;last_name&quot;:&quot;Musto&quot;},{&quot;first_name&quot;:&quot;My-Hanh&quot;,&quot;last_name&quot;:&quot;Lam&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;Loganzo&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. O’Donnell&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;10527-10543&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm501649k&quot;},&quot;abstract&quot;:&quot;Auristatins, synthetic analogues of the antineoplastic natural product Dolastatin 10, are ultrapotent cytotoxic microtubule inhibitors that are clinically used as payloads in antibody–drug conjugates (ADCs). The design and synthesis of several new auristatin analogues with N-terminal modifications that include amino acids with α,α-disubstituted carbon atoms are described, including the discovery of our lead auristatin, PF-06380101. This modification of the peptide structure is unprecedented and led to analogues with excellent potencies in tumor cell proliferation assays and differential ADME properties when compared to other synthetic auristatin analogues that are used in the preparation of ADCs. In addition, auristatin cocrystal structures with tubulin are being presented that allow for the detailed examination of their binding modes. A surprising finding is that all analyzed analogues have a cis-configuration at the Val-Dil amide bond in their functionally relevant tubulin bound state, whereas in solution t&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501649k&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501649k" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501649k&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501649k" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501649k&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501649k" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm501649k&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501649k&amp;href=/doi/10.1021/jm501649k" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm501649k" /></input><a href="/doi/pdf/10.1021/jm501649k" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm501649k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm501649k%26sid%3Dliteratum%253Aachs%26pmid%3D25431858%26genre%3Darticle%26aulast%3DMaderna%26date%3D2014%26atitle%3DDiscovery%2Bof%2BCytotoxic%2BDolastatin%2B10%2BAnalogues%2Bwith%2BN-Terminal%2BModifications%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D24%26spage%3D10527%26epage%3D10543%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292161" title="Modification">Modification</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jmcmar.2014.57.issue-24/20141226/jmcmar.2014.57.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Auristatins, synthetic analogues of the antineoplastic natural product Dolastatin 10, are ultrapotent cytotoxic microtubule inhibitors that are clinically used as payloads in antibody–drug conjugates (ADCs). The design and synthesis of several new auristatin analogues with N-terminal modifications that include amino acids with α,α-disubstituted carbon atoms are described, including the discovery of our lead auristatin, PF-06380101. This modification of the peptide structure is unprecedented and led to analogues with excellent potencies in tumor cell proliferation assays and differential ADME properties when compared to other synthetic auristatin analogues that are used in the preparation of ADCs. In addition, auristatin cocrystal structures with tubulin are being presented that allow for the detailed examination of their binding modes. A surprising finding is that all analyzed analogues have a <i>cis</i>-configuration at the Val-Dil amide bond in their functionally relevant tubulin bound state, whereas in solution this bond is exclusively in the <i>trans</i>-configuration. This remarkable observation shines light onto the preferred binding mode of auristatins and serves as a valuable tool for structure-based drug design.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 1987, Pettit et al. described the discovery of Dolastatin 10 (<b>1</b>), a highly cytotoxic peptide that was isolated from the sea hare <i>Dolabella auricularia</i> in the Indian Ocean.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> This remarkable discovery was the result of 15 years of research in which a number of cytotoxic peptides were isolated from this sea creature, with Dolastatin 10 (<b>1</b>) being the most potent analogue in tumor cell proliferation assays. It was soon recognized that this compound was an extremely potent mitotic spindle poison and one of several compounds produced by cyanobacteria in the intestines of <i>Dolabella auricularia</i> that were postulated to act as defense agents against predators.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2-4)</a> It was demonstrated that, in addition to inhibiting tubulin polymerization, <b>1</b> has a strong inhibitory effect on tubulin dependent GTP hydrolysis.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> To obtain sufficient quantities for structure identification and biological testing, Pettit et al. collected 1000 kg of wet animal material whose combined ethanol/2-propanol extract yielded 28.7 mg of pure Dolastatin 10 after extensive purification (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of Dolastatin 10 (<b>1</b>) and key amino acid components.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Dolastatin 10 (<b>1</b>) is comprised of the four amino acids dolavaline (Dov), valine (Val), dolaisoleuine (Dil), and dolaproine (Dap) and the C-terminal amine dolaphenine (Doe).<a onclick="showRef(event, 'ref1 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref5">(1, 5)</a> The binding site for <b>1</b> is located adjacent to the vinca binding site at the α,β-tubulin heterodimer interface (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Dolastatin 10 (<b>1</b>) was advanced into clinical trials, but despite encouraging preclinical efficacy data, no appreciable therapeutic index could be attained due to its significant toxicity at the maximum tolerated dose (MTD).<a onclick="showRef(event, 'ref7 ref8 ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10 ref11 ref12 ref13">(7-13)</a> Shortly after the discovery of <b>1</b>, a large number of synthetic analogues, termed auristatins, were prepared by Pettit et al., Miyazaki et al., and other groups with the goal to investigate the influence of structural changes on cell-based potencies in tumor cell proliferation assays (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14-16)</a> These efforts have been extensively reviewed.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of key auristatin analogues with three different C-termini. Top: Dolastatin 10 (<b>1</b>) and monomethyl auristatin-D (MMAD, <b>2</b>). Middle: auristatin-E (<b>3</b>) and monomethyl auristatin-E (MMAE, <b>4</b>). Bottom: auristatin-PHE (<b>5</b>) and monomethyl auristatin-F (MMAF, <b>6</b>). Color coding of C-termini: dolaphenine, (orange), (1<i>S</i>,2<i>R</i>)-(+)-norephedrine (yellow), and phenylalanine (green). Red arrow: removal of one <i>N</i>-Me group does not lead to significant potency loss.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> shows key auristatin analogues containing the three different C-termini groups dolaphenine, (1<i>S</i>,2<i>R</i>)-(+)-norephedrine, and phenylalanine. All three analogues were first described by Pettit. et al. as their <i>N</i>,<i>N</i>-dimethyl valine (dolavaline) N-termini constructs.<a onclick="showRef(event, 'ref1 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref1 ref18 ref19">(1, 18, 19)</a> Miyazaki et al. discovered that removal of one methyl group from the N-terminal amine of the natural product Dolastatin 10 (<b>1</b>) gave monomethyl auristatin-D (MMAD, <b>2</b>) and did not compromise in vivo antitumor activity.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This finding was later recognized by Senter et al., who made the remarkable discovery that these auristatins having a secondary amine at their N-terminus could be attached to a linker and subsequently conjugated to monoclonal antibodies. This clever idea led to generation of highly potent and efficacious antibody–drug conjugates (ADC’s).<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20-22)</a></div><div class="NLM_p">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> displays the auristatin core structure and indicates the locations where the majority of chemical variations have been published. Notably, after the original publications of Pettit et al. and Miyazaki et al., most of the subsequent auristatin research has focused on analogues with C-terminal modifications and N-terminal extensions without modifications of the peptide structure (<i>N</i>-Me)Val-Val-Dil-Dap with only few exceptions.<a onclick="showRef(event, 'ref14 ref23 ref24 ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref14 ref23 ref24 ref25 ref26 ref27 ref28">(14, 23-28)</a> Of particular note in this regard is the naturally occurring analogue Symplostatin 1 that differs from Dolastatin 10 (<b>1</b>) by the presence of a terminal <i>N</i>,<i>N</i>-dimethylisoleucine instead of a terminal dolavaline residue.<a onclick="showRef(event, 'ref3 ref29'); return false;" href="javascript:void(0);" class="ref ref3 ref29">(3, 29)</a> The cytotoxicity of Symplostatin 1 is reported to be only slightly less when compared to <b>1</b>. To evaluate potential opportunities for structural modification, analysis of the detailed binding mode of the auristatins to tubulin is important. At the start of our studies, the only reported auristatin cocrystal structure using the [(Tc)2R] tubulin construct was obtained with the analogue soblidotin (TZT-1027) (<b>7</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> by Cormier, Knossow, et al.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The structure was disordered in some regions of the cocrystal complex but allowed for the basic assessment of the orientation and binding mode in the nucleotide exchange binding cleft of the tubulin construct used in this study. However, due to the low resolution of the structure, no detailed information on specific receptor interactions could be ascertained with good confidence. Nevertheless, when studying the cocrystal structure of <b>7</b> with tubulin, we noted a binding void around the N-terminus which suggested the potential for additional substitutions on the N-terminal carbon atom (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). We hypothesized that N-terminal amino acids with a α,α-dialkyl carbon substitutions could lead to potent new auristatin analogues. Additionally, we were interested in determining if changes on the N-terminus would lead to different in vitro ADME properties. Of particular interest was the potential modulation of in vitro intrinsic clearance profiles because our ultimate goal was to use these molecules as payloads for the next generation of antibody drug conjugates (ADC’s).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The design rationale was that an ADC payload with high plasma clearance would be desirable, as this could reduce toxicity resulting from premature release of the payload from the antibody.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Hotspots for structural modifications of auristatin analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of soblidotin (TZT-1027) (<b>7</b>) with the (Tc)2R tubulin construct as described by Cormier, Knossow, et al.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> View of the N-terminus with the arrow indicating the N-terminal secondary carbon atom of interest. The structure of <b>7</b> is depicted with the correct stereochemical assignments as reported for <b>7</b><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> but deviates from that reported in ref <a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">6</a>, see text. A binding void is apparent in the receptor pocket that indicates the potential for further substitutions. Protein residues are displayed with their van der Waals radii and color coded based on atom type (dark-blue, nitrogen; red, oxygen; light-blue, β subunit carbon; green, α subunit carbon). For the overall orientation of auristatin analogues at the α,β-tubulin interface, see Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> and ref <a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">6</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Herein, we describe new N-terminal modifications with α,α-disubstituted amino acids that led to auristatin analogues with excellent potencies in tumor cell proliferation assays. We also present cocrystal structures of four analogues, with tubulin having improved atomic resolution, allowing for the first time the detailed examination of the auristatin binding mode. Furthermore, we investigate selected in vitro ADME characteristics of the new analogues and describe the pharmacokinetic profiling of the lead auristatin analogue <b>20a</b> (PF-06380101).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36454" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36454" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pettit et al. first described the total synthesis of Dolastatin 10 (<b>1</b>) in 1989 and also described the preparation of the monomer building blocks dolaisoleuine (Dil), dolaproine (Dap), and dolaphenine (Doe).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Because of the interest in Dolastatin 10 (<b>1</b>) and related analogues, the preparation of the monomers has been improved over time. While there are multiple convergent methods of preparing the linear <b>1</b> molecule, Pettit et al. utilized the convergent method of separately preparing the left-hand Dov-Val-Dil tripeptide (<b>8</b>) and right-hand Dap-Doe dimer (<b>9</b>) (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref5 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref5 ref30 ref31">(5, 30, 31)</a></div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0013.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Convergent Synthesis of Dolalstatin 10 (<b>1</b>) Based on Tripeptide <b>8</b> and Dimer <b>9</b>.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We were interested in designing a flexible route that would allow for both N- and eventually C-terminal modifications in a modular fashion. For this purpose, we sought to modify the synthetic route to enable introduction of the terminal amino acid at the last reaction step from <b>18</b>. Additionally, compound <b>18</b> could be generated by coupling of the dimers <b>15</b> and <b>16</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0014.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the Tetramer Val-Dil-Dap-Doe (<b>18</b>) by Using a Modular Approach from Dimers <b>15</b> and <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TFA/DCM for <b>15</b>; (b) HCl dioxane for <b>16</b>; (c) HATU, <i>i</i>-Pr<sub>2</sub>NEt, DCM, 78%; (d) Et<sub>2</sub>NH, THF, rt, 87%. Boc-protected <b>18</b> was previously prepared by an alternative method.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a></p></p></figure><div class="NLM_p">The tetramer <b>18</b> was then utilized as a building block for the auristatin analogues as shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. The amino acids <b>19a</b>–<b>l</b> as their corresponding <i>N</i>-Boc or <i>N</i>-Fmoc protected analogues were coupled to the tetramer <b>18</b> using HATU with diisopropylethyl amine, then deprotected using either trifluoroacetic acid or diethylamine to give the auristatin analogues <b>20a</b>–<b>l</b>.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0015.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of New Auristatin Analogues <b>20a</b>–<b>l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HATU, Et<sub>3</sub>N, DMF; (b) Et<sub>2</sub>NH, THF (<b>a</b>–<b>e</b>) or TFA, DCM (<b>f</b>–<b>l</b>), (yields: 27–67% over two steps). N-Pg: protected amine.</p></p></figure><div class="NLM_p">Additionally, three specific examples of the above auristatin analogues were prepared with phenylalanine as the C-terminus instead of the dolaphenine C-terminus (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>). For this purpose, we applied similar chemistry procedures using the previously described tetramer Val-Dil-Dap-Phe-OMe (<b>21</b>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This tetramer was coupled to protected Aib (<b>19a</b>), <i>N</i>-Me-Aib (<b>19b</b>), and (<i>S</i>)-2-methylpyrrolidine-2-carboxylic acid (<b>19g</b>), followed by saponification of the methyl ester and deprotection of the terminal amines.</div><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0016.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of New Auristatin Analogues <b>22a</b>,<b>b</b>,<b>g</b> Containing a Phenylalanine- Instead of the Dolaphenine C-Terminus Present in <b>20a</b>–<b>l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HATU, Et<sub>3</sub>N, DMF (b) LiOH, MeOH; (c) TFA, DCM (additional step for <b>22g</b>). Yields: 33–56% over two steps.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60271" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60271" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Cell Potencies of Selected Reference Compounds and Aib-Modified Auristatins</h3><div class="NLM_p">On the basis of the crystal structure of <b>7</b> with tubulin, our hypothesis was that replacing the N-terminal amino acid of Dolastatin 10 (<b>1</b>) with an amino acid having two substituents at the α-position should be tolerated. However, it is well-known that amino acids with two alkyl substituents at the α-position can lead to distortions of the peptidic structure due to induction of helical turns resulting from the Thorpe–Ingold effect, i.e., as exemplified with the amino acid Aib (2-aminoisobutyric acid).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The potential for success of this structural variation was nonobvious based on work by Miyazaki et al., who replaced the terminal dolavaline with <i>N</i>,<i>N</i>-dimethyl alanine and <i>N</i>,<i>N</i>-dimethyl glycine. Remarkably, the change from dolavaline to <i>N</i>,<i>N</i>-dimethyl glycine increased in vivo efficacy in xenograft studies, whereas <i>N</i>,<i>N</i>-dimethyl alanine at this position completely abolished any efficacy.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This observation appeared to indicate the sensitive nature of the N-terminus with respect to structural modifications. Consequently, other positions on the peptide, i.e., the C-terminus, were deemed more favorable for potential structural modifications.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> However, the interpretation of in vivo efficacy results in the absence of any data regarding cell-based potency, in vitro ADME, and pharmacokinetics needs to be done with great caution. At the onset of our studies, we investigated selected reference auristatins in tumor cell proliferation assays and two new analogues that contain 2-aminoisobutyric acid (Aib) at the N-terminus. GI<sub>50</sub> values of cell viability were used as the primary potency readout, taking into account all compounds in this manuscript showed good inhibition in the cell-free tubulin polymerization assay (data not shown). However, the tubulin polymerization assay generally requires significantly higher compound concentrations compared to cell-based studies and is not suited for detailed SAR studies that examine subtle structural changes.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Of consideration is that cell potencies are a direct function of target affinity, cell-membrane permeability, and potential active and passive transport processes, among other factors. It was determined that the passive cell permeability for all of the analogues prepared was generally low (RRCK cell line: <i>P</i><sub>app</sub> AB < 0.5 × 10<sup>–6</sup> cm/s),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and unless active uptake transport or other cell-uptake mechanisms (i.e., endocytosis) are involved, the cell GI<sub>50</sub> values are likely driven by only a fraction of the extracellular compound concentration that is present inside of the cells. Hence, any change in observed cell potencies could reflect not just different tubulin binding affinities but also altered cell permeability, cell uptake, and transporter profiles. Of note is that none of the investigated cell lines described here had ABCB1 (MDR1) efflux transporters expressed. Having this limitation regarding cell-based assay analysis in mind, BT474 cells (breast carcinoma), N87 cells (liver metastasis of gastric carcinoma), and MDA-MB-361-DYT2 cells (breast carcinoma) were selected for the potency readout (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). As expected, excellent potency was observed for the reference compounds MMAD (<b>2</b>), MMAE (<b>4</b>), and MMAF-OMe (<b>6</b>-OMe) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) that all share the <i>N</i>-methyl valine N-terminus. To our surprise, the <i>N</i>-methyl glycine and <i>N</i>-methyl alanine analogues <b>23</b> and <b>24</b> retained good cell potencies despite the lack of the terminal isopropyl group. To the best of our knowledge, this is the first time that detailed cellular potencies are described for MMAD (<b>2</b>), the <i>N</i>-Me-glycine– (<b>23</b>), and <i>N</i>-Me-alanine (<b>24</b>) analogues. Gratifyingly, the new Aib analogues <b>20a</b> and <b>20b</b> having an α,α-geminal dimethyl group at the N-terminus showed a high degree of potency in all three investigated cell lines. Interestingly, the potency of these two compounds was not dependent on whether or not the terminal amino group was methylated. This stands in contrast to the corresponding N-terminal valine matched pair <b>2</b> (MMAD) and <b>25</b>, where the absence of the <i>N</i>-methyl group in <b>25</b> led to a significant reduction in potency.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Cell Potency in Tumor Cell Viability Assays Expressed in GI<sub>50</sub> Values with Two Significant Figures as Arithmetic Means in Nanomolar Concentrations<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center">BT474 [nM]</th><th class="colsep0 rowsep0" align="center">MDA-MB-361-DYT2 [nM]</th><th class="colsep0 rowsep0" align="center">N87 [nM]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b> (MMAE)</td><td class="colsep0 rowsep0" align="center"><b>0.22</b></td><td class="colsep0 rowsep0" align="center"><b>0.49</b></td><td class="colsep0 rowsep0" align="center"><b>0.54</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.15, 9)</td><td class="colsep0 rowsep0" align="center">(±0.15, 15)</td><td class="colsep0 rowsep0" align="center">(±0.35, 22)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b>-<b>OMe</b> (MMAF-OMe)</td><td class="colsep0 rowsep0" align="center"><b>0.24</b></td><td class="colsep0 rowsep0" align="center"><b>0.21</b></td><td class="colsep0 rowsep0" align="center"><b>0.44</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.18, 24)</td><td class="colsep0 rowsep0" align="center">(±0.15, 14)</td><td class="colsep0 rowsep0" align="center">(±0.54, 20)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b> (MMAD)</td><td class="colsep0 rowsep0" align="center"><b>0.12</b></td><td class="colsep0 rowsep0" align="center"><b>0.090</b></td><td class="colsep0 rowsep0" align="center"><b>0.30</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.094, 12)</td><td class="colsep0 rowsep0" align="center">(±0.013, 6)</td><td class="colsep0 rowsep0" align="center">(±0.22, 13)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="center"><b>0.49</b></td><td class="colsep0 rowsep0" align="center"><b>0.69</b></td><td class="colsep0 rowsep0" align="center"><b>1.2</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.15, 3)</td><td class="colsep0 rowsep0" align="center">(±0.26, 3)</td><td class="colsep0 rowsep0" align="center">(±0.39, 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="center"><b>0.23</b></td><td class="colsep0 rowsep0" align="center"><b>0.25</b></td><td class="colsep0 rowsep0" align="center"><b>0.42</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.014,3)</td><td class="colsep0 rowsep0" align="center">(±0.081, 4)</td><td class="colsep0 rowsep0" align="center">(±0.15, 4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="center"><b>5.3</b></td><td class="colsep0 rowsep0" align="center"><b>9.0</b></td><td class="colsep0 rowsep0" align="center"><b>10</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.91, 3)</td><td class="colsep0 rowsep0" align="center">(±2.4, 2)</td><td class="colsep0 rowsep0" align="center">(±2.2, 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b> (PF-06380101)</td><td class="colsep0 rowsep0" align="center"><b>0.26</b></td><td class="colsep0 rowsep0" align="center"><b>0.19</b></td><td class="colsep0 rowsep0" align="center"><b>0.27</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.37, 16)</td><td class="colsep0 rowsep0" align="center">(±0.073, 19)</td><td class="colsep0 rowsep0" align="center">(±0.16, 18)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20b</b></td><td class="colsep0 rowsep0" align="center"><b>0.045</b></td><td class="colsep0 rowsep0" align="center"><b>0.076</b></td><td class="colsep0 rowsep0" align="center"><b>0.12</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.012, 3)</td><td class="colsep0 rowsep0" align="center">(±0.047, 4)</td><td class="colsep0 rowsep0" align="center">(±0.10, 4)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">Standard deviations and the count of individual assay runs (<i>n</i>). Each individual assay run is a duplicate readout. N-terminal amino acids: <b>23</b>, <i>N</i>-Me-glycine; <b>24</b>, <i>N</i>-Me-<span class="smallcaps smallerCapital">l</span>-alanine; <b>25</b>, <span class="smallcaps smallerCapital">l</span>-valine; <b>20a</b>, aib; <b>20b</b>, <i>N</i>-Me-aib. Aib: 2-aminoisobutyric acid.</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Crystal Structure Analysis of <b>20a</b> (PF-06380101)</h3><div class="NLM_p">Encouraged by the excellent cell potency of <b>20a</b> (PF-06380101), we sought to further analyze the binding mode by crystallography using the (Tc)2R tubulin construct.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Numerous tubulin crystal structures have been published, most notably by elegant work from Gigant, Knossow, et al.<a onclick="showRef(event, 'ref6 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref6 ref36 ref37">(6, 36, 37)</a> These structures give insight into the mechanism of polymerization of tubulin as well as the method of inhibition of polymerization via costructure with various inhibitor classes. For most of these costructures, the resolution is between 3.5 and 4 Å. This low resolution limits the clarity of which the interaction with tubulin can be visualized with these inhibitors. In the case of the auristatin compound soblidotin (TZT-1027) (<b>7</b>), examination of the structure and data deposited in the Protein Data Bank (entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3E22">3E22</a>) show that the last two C-terminal residues are disordered at 3.8 Å and cannot be placed with confidence.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Recent advances in tubulin crystallography have provided crystals that diffract to significantly higher resolution prior to soaking compounds.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Using this new information, we undertook the structure determination of auristatin compounds bound to tubulin with the goal of providing a higher resolution costructure to aid our structure-based design of tubulin inhibitors. This work is exemplified by the costructure of tubulin with <b>20a</b>, which was solved at an improved 3.1 Å resolution.</div><div class="NLM_p">As previously described by Cormier et al., the binding site of auristatins is in close proximity to the β-tubulin nucleotide exchange region and the auristatin binding event leads to direct interference with the GTP/GDP hydrolysis process, resulting in compromised tubulin polymerization and mitotic arrest (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In the costructure of <b>20a</b>, all residues of the compound can be fit-to-density and as a result the examination of the interaction of this compound with tubulin was possible with greater clarity than in the 3.8 Å structure solved by Cormier et al.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Co-crystal structure of <b>20a</b> with the (Tc)2R tubulin construct. Overview of the binding mode with relative orientation of construct components. <b>20a</b> binds at the α,β-tubulin interface. A second molecule of <b>20a</b> is also associated with the exterior β-subunit. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1I">4X1I</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this higher resolution tubulin–<b>20a</b> cocrystal structure (Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>,<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), the protein chain tracings are identical to that which has been described previously with the T5 loop flipped out, exposing Asp β197 to solvent.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> This movement of the T5 loop is required when compounds bind in the vinca domain peptide region and is regularly observed. Upon insertion of an entity into the vinca domain region, additional curvature is induced into the protein assembly. For example, atoms in β-2 subunit move by almost 3 Å and the C-terminal residues of the stathmin domain move by over 5 Å. It is presumably this inhibitor-induced curvature that is the basis for the diffraction sensitivity of the soaked protein crystals. The Aib N-terminus is easily accommodated in this pocket, and slightly larger groups can be tolerated. The N-2 valine interacts with the β-1 subunit by inserting into a large pocket formed by the side chains of Val177, Tyr210, and Leu227 (not shown). Notable polar interactions include a hydrogen bond network between the terminal protonated amino group with Asp β197 located on the T5 loop and the amide carbonyl of Phe α351, a bifocal interaction of the N-2 valine with Asn α329 and a critical hydrogen bond interaction between the backbone amide of Tyr β224 with the terminal carbonyl groups of Dap and Doe in <b>20a</b>. This latter hydrogen bond network arranges the aromatic ring Tyr β224 in a π-stacking interaction with the nucleobase of GDP, preventing its dissociation from β-tubulin. The trapping of GDP is believed to be a key mechanism by which auristatins exert their tubulin-interfering effect. As stated above, the remaining residues including the C-terminus interact primarily with the β-tubulin subunit and their mode of binding arranges the peptide such that the carbonyl associated with the final residue is located at the tip of helix H7 aligned with the helix dipole (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding mode of <b>20a</b> observed in the 3.1 Å costructure with tubulin with selected key receptor interactions at the N-terminus. Red, β-subunit; blue, α-subunit; GDP in green. For simplicity, the structure of <b>20a</b> is drawn with <i>trans</i>-configuration of the Val-Dil amide bond (indicated with arrow), but in the cocrystal structure the Val-Dil amide bond of <b>20a</b> bound at the tubulin β1/α2 interface has <i>cis</i>-configuration, see text. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1I">4X1I</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding mode of <b>20a</b> observed in the 3.1 Å costructure with tubulin, view on the C-terminus. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1I">4X1I</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition to the molecule of <b>20a</b> found at the interface of the β1 and α2 subunits, a second molecule of <b>20a</b> is bound unproductively to the distal β2 subunit (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). There is no α subunit associated with the β2 subunit, but the compound interacts with the β subunit in a similar way as seen at the internal α/β interface.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Configurational Analysis</h3><div class="NLM_p">We do observe a major configurational difference between the two bound molecules <b>20a</b>, as the <b>20a</b> molecule found at the β1/α2 tubulin interface has a <i>cis</i>-configuration near the N-terminus between the amino acids Val-Dil while the compound associated with β2 tubulin has <i>trans</i>-configuration at the Val-Dil amide bond. Superimposing the β subunits and examining the fit-to-density for the compounds shows that this difference is real. By adopting the <i>cis</i>-configuration, <b>20a</b> is able to provide complementary interactions to Asn α329 as seen in Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>. These interactions are not possible if the Val-Dil amide bond has <i>trans</i>-configuration. The lack of a corresponding α subunit for the exterior copy of <b>20a</b> explains why the <i>cis</i>-configuration in the second <b>20a</b> molecule is not observed.</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Configurational differences between the valine (Val) and dolaisoleuine (Dil) residues of compound <b>20a</b>, as observed at the β1/α2 tubulin interface (cyan) and observed bound to β2 tubulin (orange), is highlighted by the red circle. Only in the <i>cis</i>-configuration the carbonyl of the valine residue is able to make a productive interaction with Asn α329 from the α2 subunit. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1I">4X1I</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">An important observation is that the Val-Dil amide bond of <b>20a</b> in solution has <i>trans</i>-configuration, with no observable <i>cis</i>-isomer detected by NMR at room temperature (DMSO), whereas the amide bond in between Dap and Dil is a mixture of both <i>trans</i>- and <i>cis</i>-rotamers. However, in the tubulin cocrystal structure, the Val-Dil amide bond of the functionally relevant bound form of <b>20a</b> at the β1/α2 tubulin interface is seen to be in <i>cis</i>-configuration. At first glance this might be surprising because none of this form seems to be present in solution as detected by NMR, suggesting the energy difference between <i>trans</i>- and <i>cis</i> forms is greater than 2.7 kcal/mol. For tertiary amides, the barrier of rotation around the amide bond is often 17–20 kcal/mol.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> At this energy, it is still possible to access both <i>trans</i>-and <i>cis</i>-forms kinetically because the exchange between <i>trans</i>- and <i>cis</i>-forms by rotation around the amide bond is in the millisecond to second range. Thus, tubulin can select the most favorable form, giving the lowest overall Δ<i>G</i> of binding. Apparently, the energy expenditure for the rotation of the Val-Dil amide bond in <b>20a</b> from <i>trans</i> (solution state) to <i>cis</i> (tubulin bound) is more than compensated for by the resulting high binding energy of <b>20a</b> having picomolar dissociation constants (tubulin binding assay by fluorescence polarization, data not shown). Interestingly, the other unproductively bound molecule of <b>20a</b> appears to not make favorable interactions with tubulin and it remains associated in its <i>trans</i> form as previously shown. This is in agreement with two studies by Alattia et al. and Benedetti et al., who investigated the NMR solution structure of <b>1</b>.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> In addition, the crystallographic analysis of the tubulin-unbound isodolastatin 10, an epimer of <b>1</b>, also only showed the <i>trans</i>-configuration between Val and Dil.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> It is interesting to speculate what the binding energy would be in analogues having preorganized <i>cis</i>-amide bonds at the Val-Dil juncture.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Activities of Additional N-Modified Analogues</h3><div class="NLM_p">On the basis of the structural information obtained with <b>20a</b>, additional new analogues with N-terminal modifications were explored (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). In particular, there was an interest to investigate how various cyclic motifs would be tolerated at the N-terminus and whether the configuration of the stereocenter present in the chiral amino acids would influence potency. Also, β-amino acids represented by <b>20e</b>,<b>f</b> and fluorine containing analogues <b>20i</b>,<b>j</b> were prepared to determine the impact of these modifications on activity. Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> indicates that all prepared compounds showed good cell-based potencies comparable with those of MMAE (<b>4</b>) and MMAF-OMe (<b>6</b>-OMe) with only subtle differences. However, as pointed out previously, the high activity of <b>20a</b> (PF-06380101) is notable in that it possesses a primary amine, a trend that is not observed for the natural valine N-terminus present in MMAD (<b>2</b>), where the N-Me group is necessary for potency (see matched molecular pair <b>2</b> and <b>25</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Cell Potency in Tumor Cell Viability Assays of Additional Auristatin Analogues Expressed in GI<sub>50</sub> Values with Two Significant Figures As Arithmetic Means in Nanomolar Concentrations<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center">BT474 [nM]</th><th class="colsep0 rowsep0" align="center">MDA-MB-361-DYT2 [nM]</th><th class="colsep0 rowsep0" align="center">N87 [nM]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b> (MMAE)</td><td class="colsep0 rowsep0" align="center"><b>0.22</b></td><td class="colsep0 rowsep0" align="center"><b>0.49</b></td><td class="colsep0 rowsep0" align="center"><b>0.54</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.15, 9)</td><td class="colsep0 rowsep0" align="center">(±0.15, 15)</td><td class="colsep0 rowsep0" align="center">(±0.35, 22)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6-OMe</b> (MMAF-OMe)</td><td class="colsep0 rowsep0" align="center"><b>0.24</b></td><td class="colsep0 rowsep0" align="center"><b>0.21</b></td><td class="colsep0 rowsep0" align="center"><b>0.44</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.18, 24)</td><td class="colsep0 rowsep0" align="center">(±0.15, 14)</td><td class="colsep0 rowsep0" align="center">(±0.54, 20)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b> (MMAD)</td><td class="colsep0 rowsep0" align="center"><b>0.12</b></td><td class="colsep0 rowsep0" align="center"><b>0.090</b></td><td class="colsep0 rowsep0" align="center"><b>0.30</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.094, 14)</td><td class="colsep0 rowsep0" align="center">(±0.013, 8)</td><td class="colsep0 rowsep0" align="center">(±0.22, 13)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b> (PF-06380101)</td><td class="colsep0 rowsep0" align="center"><b>0.26</b></td><td class="colsep0 rowsep0" align="center"><b>0.19</b></td><td class="colsep0 rowsep0" align="center"><b>0.27</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.37, 16)</td><td class="colsep0 rowsep0" align="center">(±0.073, 19)</td><td class="colsep0 rowsep0" align="center">(±0.16, 18)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20b</b></td><td class="colsep0 rowsep0" align="center"><b>0.045</b></td><td class="colsep0 rowsep0" align="center"><b>0.076</b></td><td class="colsep0 rowsep0" align="center"><b>0.12</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.012, 3)</td><td class="colsep0 rowsep0" align="center">(±0.047, 4)</td><td class="colsep0 rowsep0" align="center">(±0.10, 4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20c</b></td><td class="colsep0 rowsep0" align="center"><b>2.9</b></td><td class="colsep0 rowsep0" align="center"><b>5.6</b></td><td class="colsep0 rowsep0" align="center"><b>6.4</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±1.1, 5)</td><td class="colsep0 rowsep0" align="center">(±1.6, 2)</td><td class="colsep0 rowsep0" align="center">(±3.8, 4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20d</b></td><td class="colsep0 rowsep0" align="center"><b>0.28</b></td><td class="colsep0 rowsep0" align="center"><b>0.35</b></td><td class="colsep0 rowsep0" align="center"><b>0.33</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.11, 10)</td><td class="colsep0 rowsep0" align="center">(±0.20, 8)</td><td class="colsep0 rowsep0" align="center">(±0.14, 10)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20e</b></td><td class="colsep0 rowsep0" align="center"><b>0.25</b></td><td class="colsep0 rowsep0" align="center"><b>0.81</b></td><td class="colsep0 rowsep0" align="center"><b>1.4</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.10, 3)</td><td class="colsep0 rowsep0" align="center">(±0.49, 3)</td><td class="colsep0 rowsep0" align="center">(±1.5, 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20f</b></td><td class="colsep0 rowsep0" align="center"><b>0.25</b></td><td class="colsep0 rowsep0" align="center"><b>0.41</b></td><td class="colsep0 rowsep0" align="center"><b>1.1</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.058, 3)</td><td class="colsep0 rowsep0" align="center">(±0.19, 3)</td><td class="colsep0 rowsep0" align="center">(±0.53, 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20g</b></td><td class="colsep0 rowsep0" align="center"><b>0.14</b></td><td class="colsep0 rowsep0" align="center"><b>0.20</b></td><td class="colsep0 rowsep0" align="center"><b>0.15</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.019, 3)</td><td class="colsep0 rowsep0" align="center">(±0.19, 4)</td><td class="colsep0 rowsep0" align="center">(±0.036, 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20h</b></td><td class="colsep0 rowsep0" align="center"><b>0.11</b></td><td class="colsep0 rowsep0" align="center"><b>0.21</b></td><td class="colsep0 rowsep0" align="center"><b>0.36</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.040, 3)</td><td class="colsep0 rowsep0" align="center">(±0.11, 3)</td><td class="colsep0 rowsep0" align="center">(±0.15, 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20i</b></td><td class="colsep0 rowsep0" align="center"><b>0.16</b></td><td class="colsep0 rowsep0" align="center"><b>0.25</b></td><td class="colsep0 rowsep0" align="center"><b>0.59</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(0.019, 3)</td><td class="colsep0 rowsep0" align="center">(±0.069, 3)</td><td class="colsep0 rowsep0" align="center">(±0.33, 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20j</b></td><td class="colsep0 rowsep0" align="center"><b>0.29</b></td><td class="colsep0 rowsep0" align="center"><b>0.60</b></td><td class="colsep0 rowsep0" align="center"><b>1.1</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.057, 3)</td><td class="colsep0 rowsep0" align="center">(±0.24, 3)</td><td class="colsep0 rowsep0" align="center">(±1.7, 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20k</b></td><td class="colsep0 rowsep0" align="center"><b>0.16</b></td><td class="colsep0 rowsep0" align="center"><b>0.20</b></td><td class="colsep0 rowsep0" align="center"><b>0.25</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.023, 3)</td><td class="colsep0 rowsep0" align="center">(±0.11, 3)</td><td class="colsep0 rowsep0" align="center">(±0.16, 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20l</b></td><td class="colsep0 rowsep0" align="center"><b>0.35</b></td><td class="colsep0 rowsep0" align="center"><b>0.40</b></td><td class="colsep0 rowsep0" align="center"><b>0.52</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">(±0.091, 3)</td><td class="colsep0 rowsep0" align="center">(±0.011, 3)</td><td class="colsep0 rowsep0" align="center">(±0.22, 3)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">Standard deviations and the count of individual assay runs (<i>n</i>). Each individual assay run is a duplicate readout.</p></div></div></div><div class="NLM_p last">The β-amino acid versions <b>20e</b> and <b>20f</b> are only slightly less potent than the corresponding α-amino acid counterparts <b>20a</b> and <b>20b</b> in the DYT2 and N87 cells, once again showing little influence of the <i>N</i>-methylation status on potency. The cyclopropyl analogue <b>20c</b> is less active than the cyclopentyl derivative <b>20d</b>. Of note are the high activities of the pyrrolidine and piperidine analogues (<b>20g</b>,<b>h</b> and <b>20k</b>,<b>l</b>) with seemingly no influence of the configuration of the stereocenter, once more highlighting that structural modifications on the N-terminus are possible without compromising potency.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Crystal Structure Analysis of <b>22a</b>, <b>22b</b>, and <b>22g</b></h3><div class="NLM_p">The good activity of the N-terminal pyrrolidine was predicted based on the analysis of the crystal structure of <b>20a</b>, which suggested that five- and six-membered saturated rings could be tolerated in the binding pocket that accommodates the auristatin N-terminus. Critical receptor interactions of <b>20a</b> were identified to be the hydrogen bond network of the primary amino group in <b>20a</b> with the Asp β179 located on the T-5 loop, the carbonyl backbone of Phe α351, as well as the bifocal interaction with Asn α329. Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a> shows the superimposed cocrystal structures of <b>22a</b> and <b>22g</b>, allowing the direct comparison of the binding mode of the respective N-termini. For both compounds, the C-terminus was chosen to be phenylalanine instead of dolaphenine to facilitate the crystallization. This change in the C-terminus did not perturb the overall binding conformation of the auristatin peptide. The inspection of Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a> reveals that the overall binding mode of <b>22a</b> and <b>22g</b> is very comparable with good alignment of both bound conformations. Of particular interest is that in both compounds the N-termini engage in the Asp β179, Phe α351, and Asn α329 hydrogen bond network. Both analogues retain high tubulin binding affinity at a level comparable to that of the dolaphenine analogues <b>20a</b> and <b>20g</b> (data not shown). Detailed cell-free tubulin binding affinity studies using a newly developed fluorescence polarization competition assay will be described in a subsequent publication.</div><figure id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Overlayed cocrystal structures of <b>22a</b> and <b>22g</b>. Left: structure complexes in the binding domain superimposed and showing entire peptide structures of <b>22a</b> and <b>22g</b>. Right: close-up view of N-terminus. Visible is the critical hydrogen bond network of both N-termini with Asp β179, Phe α351, and Asn α329, interactions that are preserved in both molecules and believed to be important for binding affinity. The Val-Dil amide bonds are in <i>cis</i>-configuration. RDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1K">4X1K</a> (<b>22a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X20">4X20</a> (<b>22g</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a> shows the N-terminal view of the superimposed cocrystal structures of <b>22b</b> and <b>22g</b>. The analogue <b>22b</b> differs from <b>22a</b> by the presence of a secondary <i>N</i>-Me amino group, which does not compromise the hydrogen network of the terminal amino group with Asp β179, Phe α351, and Asn α329. Of particular note is the difference in the relative orientation of the methyl group in <b>22g</b> as compared to the position of both geminal dimethyl groups in <b>22a</b> and <b>22b</b>. The <i>N</i>-methyl group in <b>22b</b> adjusts the positioning of the N-terminus of the compound relative to <b>20a</b>. The N-terminal nitrogen moves ∼2 Å, and the <i>N</i>-methyl group is vectored into a channel between the α and β subunits. This vector is one that can easily accommodate large linear groups.</div><figure id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0011.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Overlayed cocrystal structures of <b>22b</b> and <b>22g</b>, view of the N-terminus. Notable is the relative orientation of the pyrrolidine Me-group and the two geminal methyl groups in <b>22b</b>. In both analogues, the Val-Dil amide bonds have <i>cis</i>-configuration and engage with Asn α329 via bifocal interaction. RDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1Y">4X1Y</a> (<b>22b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X20">4X20</a> (<b>22g</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It should be noted that in the deposited structure of soblidotin (TZT-1027) (<b>7</b>), the Val-Dil amide bond is in the <i>trans</i>-configuration. In contrast, the Val-Dil amide bonds in the functionally relevant tubulin-bound structures of all the four auristatin analogues (<b>20a</b>, <b>22a</b>, <b>22b</b>, and <b>22g</b>) presented here are in the <i>cis</i>-configuration. In addition to this discrepancy, in the published crystal structure of <b>7</b>, three chiral centers (positions 9, 18, and 19a) have different stereochemical assignments than those originally reported for <b>7</b>.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> In contrast, all compounds described here have stereochemical assignments that are consistent with those published for Dolastatin 10 and other auristatin analogues. The unexpected finding of the <i>cis</i>-configured Val-Dil amide bond in all crystallized analogues described here, that have a functionally relevant binding mode at the β1/α2 tubulin interface, is remarkable and reveals a preferred auristatin binding mode that was not previously recognized for this compound class. The high potency and conserved binding modes of the described N-terminal analogues highlight how structural modifications at the N-terminus can be tolerated without loss of binding affinity. This is also apparent when inspecting the cell-based potencies of the pyrrolidine epimers <b>20g</b> and <b>20h</b> as well as the piperidine epimers <b>20k</b> and <b>20l</b>, which indicate that inversion of the pyrrolidine or piperidine stereocenter does not compromise target affinity or cell-based activities.</div><div class="NLM_p last">In summary, all new compounds show an appreciable amount of activity when compared to the benchmark auristatins with very little variation in cell-based potencies. This result is surprising, as previous studies suggested that the N-terminal modifications would be less tolerated. All investigated compounds have generally low passive cell-membrane permeability with only minor differences (data not shown). Potential explanations for the high cell-potencies, despite the poor passive cell-membrane permeability, include the possibility for active uptake mediated by transporters or endocytosis pathways that have been previously described for peptides.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> It also remains a possibility that the high cell activity is caused by only a fraction of the drug that penetrates the cell membrane by passive permeation.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Human Liver Microsome Intrinsic Clearance</h3><div class="NLM_p">Upon profiling of new analogues using an in vitro ADME panel, it was observed that all new compounds with α,α-disubstitution showed significantly elevated human liver microsome (HLM) apparent intrinsic clearance values (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><figure id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0012.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>X</i>-axis: log scale, human liver microsome (HLM) apparent intrinsic clearance values of selected analogues [μL/min/mg], dose: 1 μM. <i>Y</i>-axis: Compound row number, without dimension. Compounds in the yellow box are compounds with reference N-termini. Significant increase in HLM clearance values for new analogues was recorded and is graphically represented by the green arrow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Of particular interest are the matched molecular pairs <b>2</b>/<b>20b</b>, <b>23</b>/<b>20b</b>, and <b>24</b>/<b>20b</b>. These pairs only differ at the N-terminal α-carbon atom, with <b>2</b>, <b>23</b>, and <b>24</b> having a primary and secondary α-carbon atom and <b>20b</b> having a tertiary α-carbon atom. The significant increase in the HLM values in these matched pairs from moderate levels (HLM: 17–50) to very high levels (HLM: 173) is remarkable given the only small structural variation present in <b>20b</b>. It was reported that MMAE (<b>4</b>), the auristatin payload present in the antibody drug conjugate (ADC) brentuximab vedotin, is mainly cleared by liver oxidative metabolism mediated by CYP3A4.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> In a clinical study, it was found that codosing of brentuximab vedotin with the CYP3A4 inducer rifampin led to significantly reduced plasma concentrations of unconjugated MMAE (<b>4</b>) payload.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> This data establish a direct correlation between the intrinsic clearance capacities of the CYP P450 enzymes with clinical plasma exposure levels of MMAE (<b>4</b>). Considering the high cytotoxicity of the auristatins, one desirable goal of developing antibody drug conjugates is to minimize systemic payload exposure after ADC dosing. In this regard, auristatins with rapid clearance from systemic circulation could provide a safety advantage. Even though the systemic plasma payload exposure after ADC dosing is generally very low compared to the corresponding ADC, the absolute exposure values of the unconjugated payload can nevertheless significantly exceed its GI<sub>50</sub> values in cell viability assays, even when corrected for plasma protein binding. Hence, the contribution of free payload to general toxicity cannot be underestimated and is a true concern. The relationship between CYP P450 clearance capacity, systemic plasma exposure, and toxicity has been clearly established for chemotherapeutics such as docetaxel, which is also cleared by oxidative hepatic metabolism like MMAE (<b>4</b>) and <b>20a</b>.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In this regard, it is important to understand if active metabolites exist. These studies are currently ongoing with <b>20a</b> and related analogues and will be reported in due course. Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> shows a direct comparison of <b>20a</b>, MMAD (<b>2</b>), and MMAE (<b>4</b>) with respect to apparent intrinsic clearance values obtained with human liver microsomes and human liver hepatocytes. The comparison shows that <b>20a</b> has the highest intrinsic clearance values compared to MMAE (<b>4</b>) and MMAD (<b>2</b>) in both human microsomes and human liver hepatocytes.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Apparent Intrinsic Clearance Values of <b>20a</b> (PF-06380101), MMAD (<b>2</b>), and MMAE (<b>4</b>) with Human Liver Microsome (HLM) and Human Liver Hepatocytes (HHEP) (Dose: 1 μM)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">HLM Cl(int, app) [μL/min/mg]</th><th class="colsep0 rowsep0" align="center" char=".">HHEP Cl(int, app) [μL/min/million]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b></td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="char" char=".">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b> MMAD</td><td class="colsep0 rowsep0" align="char" char=".">48</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b> MMAE</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr></tbody></table></div></div><div class="NLM_p last">For the selection as an ADC payload, many parameters are important in addition to intrinsic clearance profiles. The full selection criteria, in particular in context of compound <b>20a</b>, will be reported in a future publication.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Pharmacokinetic Analysis of <b>20a</b> (PF-06380101)</h3><div class="NLM_p">After an IV dose of <b>20a</b> at 20 μg/kg to Wistar Han rats, <b>20a</b> exhibited a mean systemic clearance (Cl) of 70 mL/min/kg and a volume of distribution (<i>V</i><sub>ss</sub>) of 14.70 L/kg, resulting in a terminal elimination half-life (<i>t</i><sub>1/2</sub>) of approximately 6 h (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Following repeat IV dosing of <b>20a</b> to Wistar Han rats, mean systemic exposure increased with increasing dose. Mean <i>C</i><sub>max</sub> and AUC ratios on day 29 relative to day 1 were generally similar to ratios (day 29/day 1) less than 2.0, suggesting there was no accumulation of <b>20a</b> observed over the dosing interval. <b>20a</b> was moderately to highly bound to plasma proteins (fraction unbound <i>f</i><sub>u</sub> at 0.1 μM dose is 0.24 for monkey, 0.10 for rat, and 0.07 for human plasma).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Parameters for <b>20a</b> after a Single iv Dose of 20 μg/kg in Male Wistar Han Rats (<i>n</i> = 3) Determined by LC-MS/MS<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char="±">19.4 ± 2.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub></td><td class="colsep0 rowsep0" align="char" char="±">0.14 ± 0.050</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>t</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="char" char="±">4.51 ± 1.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/min/kg)</td><td class="colsep0 rowsep0" align="char" char="±">70.0 ± 12.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>SS</sub> (L/kg)</td><td class="colsep0 rowsep0" align="char" char="±">14.70 ± 3.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="±">5.85 ± 1.17</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>a</sup><p class="last">AUC<sub>t</sub> = area under the concentration time curve from time zero to the last measurable concentration calculated; Cl = systemic serum clearance; <i>C</i><sub>max</sub> = observed peak concentration; <i>t</i><sub>1/2</sub> = apparent terminal elimination half-life; <i>T</i><sub>max</sub> = observed time to reach <i>C</i><sub>max</sub>; <i>V</i><sub>ss</sub> = apparent volume of distribution.</p></div></div></div><div class="NLM_p last">After a single 36 μg/kg IV dose (bolus) of <b>20a</b> to Wistar Han rats (<i>n</i> = 3) and Sprague–Dawley rats (<i>n</i> = 3), approximately 8% of <b>20a</b> dose was recovered in urine and approximately 4% in bile, respectively. In vitro studies with nonradiolabeled compound suggest that <b>20a</b> preferentially distributes into human plasma relative to whole blood and that <b>20a</b> is a P-glycoprotein (P-gp) substrate. A preliminary assessment of the metabolism of <b>20a</b> using nonradiolabeled compound was conducted using rat, monkey, and human liver S9 fractions and human recombinant cytochrome P450 (rCYP) enzymes. All metabolites were oxidative in nature and β-nicotinamide adenine dinucleotide phosphate (NADPH)-dependent, with no amide hydrolysis products or glucuronide conjugates observed. There was no evidence of human specific metabolites. Initial reaction phenotyping experiments suggest that CYP3A4 is the predominant enzyme involved in the metabolism of <b>20a</b> with hydroxylation occurring on the N-terminus. On the basis of the in vitro drug–drug interaction (DDI) studies (direct inhibition, metabolism-dependent inhibition, and induction), <b>20a</b> is anticipated to be of low risk to perpetrate pharmacokinetic drug interactions with compounds for which CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and/or CYP3A4/5-mediated metabolism constitutes the primary mechanism of clearance. However, because <b>20a</b> is primarily metabolized by CYP3A4, there is potential for DDIs if coadministered with moderate and/or potent clinical inhibitors and/or inducers of CYP3A4.</div></div></div><div id="sec99" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03642" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03642" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have described the design and synthesis of several auristatin analogues with N-terminal modifications that include amino acids with α,α-disubstituted carbon atoms. This modification of the peptide structure is unprecedented and led to analogues with excellent potencies in tumor cell proliferation assays. All new analogues show good potency with only subtle differences in activities. We have disclosed, for the first time, auristatin crystal structures with improved resolution, further enabling the detailed examination of their binding modes. The analysis revealed that the N-terminal geminal dimethyl groups present in <b>20a</b> (PF-06380101) and <b>20b</b> are well accommodated in the receptor pocket without compromising the overall binding affinity of the molecules. In particular, key interactions were identified that allowed the subsequent design of active analogues. Critical interactions that were conserved for all analogues include the H-bond network with Asp β179 and Phe α351 and the bifocal interaction with Asn α329 of the α2 subunit. A significant and surprising finding is that all analyzed analogues have a <i>cis</i>-configuration at the Val-Dil amide bond while in their functionally relevant tubulin bound state, whereas in solution this bond is exclusively in the <i>trans</i>-configuration. This remarkable observation shines light onto the preferred binding mode of auristatins, which is suggestive for further designs of novel analogues with preoriented <i>cis</i>-amide bonds in between Val and Dil. All new N-terminal modifications led to a significant increase in apparent intrinsic clearance values, a fact that could provide a safety advantage when systemic exposure needs to be minimized, i.e., for the application of these compounds as payloads in antibody–drug conjugates.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The utility of the new auristatin analogues as ADC payloads including the development of the lead analogue <b>20a</b> (PF-06380101) will be reported in due course.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50235" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50235" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Experiments were generally carried out under inert atmosphere (nitrogen or argon), particularly in cases where oxygen- or moisture-sensitive reagents or intermediates were employed. Commercial solvents and reagents were typically used without further purification, including anhydrous solvents where appropriate. Amino acid <b>19i</b> and <b>19</b>j were prepared previously, and the absolute stereochemistry was confirmed herein as described in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Products were dried under vacuum before being carried on to further reactions or submitted for biological testing. Compound names were generated with ACD Laboratories software. All compounds were >95% purity as determined by HPLC. All flash chromatographic separations were performed using Redisep R<sub>f</sub> gold normal phase silica columns or RediSep R<sub>f</sub> reversed-phase C18 columns. Preparative reversed phase HPLC was performed on various instruments including: Method A: Gilson with Phenomenex Luna C18, 100 mm × 30 mm, 10 μm; flow rate 20 mL/min; detection, DAD 210 nm, 254 nm. Method B: Shimadzu with Phenomenex Gemini C18, 21.2 mm × 250 mm, 5 μm; flow rate 35 mL/min; detection, DAD 220 nm MS (+) range 100–1200 Da; MS trigger. Method C: Waters Sunfire C18 19 mm × 100 mm, 5 μm; flow rate 25 mL/min; detection, DAD 215 nm MS (+) range 160–1000 Da. LC-MS was obtained with UPLC/MS system Waters Acquity UPLC (Acquity Binary Solvent Manager, 2777C-Autosampler, Acquity PDA, Acquity ELS, and Acquity Column Manager) and Waters Acquity SQ systems from Waters Corporation, Milford, MA utilizing: Waters Acquity UPLC BEH, C18, (2.1 mm × 50 mm, 1.7 μm); mobile phase A, 0.1% formic acid in water (v/v); mobile phase B, 0.1% formic acid in CH<sub>3</sub>CN (v/v); gradient, 5% B over 0.1 min, 5–95% B over 0.7 min, 95% B over 0.1 min; flow rate 1.25 mL/min; temperature, 60 °C; detection, 200–450 nm; MS (+) range 100–1200 Da; injection volume, 5 μL. All NMR spectra were collected on one of three instruments: (1) Bruker 500 Avance III with a 5 mm DCH helium cryoprobe (500.13 MHz for <sup>1</sup>H; 125.77 MHz for <sup>13</sup>C), (2) Bruker 500 Avance III with a 5 mm Prodigy BBO cryoprobe (499.82 MHz for <sup>1</sup>H; 125.69 MHz for <sup>13</sup>C), (3) Bruker 400 Avance III with a 5 mm BBFO probe (399.72 MHz for <sup>1</sup>H; 100.52 MHz for <sup>13</sup>C) using DMSO-<i>d</i><sub>6</sub> as the solvent and referencing the residual solvent peak. Accurate mass spectrometry analyses were conducted on an Agilent 6220 TOF mass spectrometer (Agilent Technologies, Wilmington, DE) in positive or negative electrospray mode. The system was calibrated to greater than 1 ppm accuracy across the mass range prior to analyses according to manufacturer’s specifications. The samples were separated using UHPLC on an Agilent 1200 (Agilent Technologies, Wilmington, DE) system prior to mass spectrometric analysis. The resulting spectra were automatically lockmass corrected and the target mass ions and any confirming adducts (Na<sup>+</sup>, NH<sub>4</sub><sup>+</sup>) were extracted and combined as a chromatogram. The mass accuracy was calculated for all observed isotopes against the theoretical mass ions derived from the chemical formula using MassHunter software (Agilent Technologies, Wilmington, DE).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthesis of (2<i>R</i>,3<i>R</i>)-3-Methoxy-2-methyl-<i>N</i>-[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]-3-[(2<i>S</i>)-pyrrolidin-2-yl]propanamide, Hydrochloric Acid Salt</h3><div class="NLM_p last">To a solution of Boc-DAP-DOE (<b>16</b>)<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> (5.0 g, 10.56 mmol) in dioxane (25 mL) was added a solution of 4 N HCl (dioxane, 10 mL). After 3 h, the reaction was concentrated in vacuo to give the deprotected product (3.9 g, 100%) as a light-yellow solid, which was used in the next step without further purification; <i>m</i>/<i>z</i> 374.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Synthesis of (3<i>R</i>,4<i>S</i>,5<i>S</i>)-4-[{<i>N</i>-[(9<i>H</i>-Fluoren-9-ylmethoxy)carbonyl]-<span class="smallcaps smallerCapital">l</span>-valyl}(methyl)amino]-3-methoxy-5-methylheptanoic Acid</h3><div class="NLM_p last">To a solution of Fmoc-Val-Dil-O<i>t</i>Bu <b>15</b><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> (1.62 g, 2.79 mmol) in DCM (10 mL) was added TFA (3 mL). After 3 h, the mixture was concentrated in vacuo to give the deprotected acid (1.42 g, 97%), which was used in the next step without further purification; <i>m</i>/<i>z</i> 525.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Synthesis of <i>N</i>∼2∼[(1-Aminocyclopentyl)carbonyl]-<i>N</i>-[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide (<b>17</b>)</h3><div class="NLM_p last">To a solution of Fmoc-Val-Dil-OH (5.48 g, 10.1 mmol) and DAP-DOE (3.90 g, 10.1 mmol) in DCM (50 mL) was added HATU (4.91 g, 12.5 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (5.51 mL, 31.3 mmol). After stirring at rt overnight, the mixture was concentrated in vacuo and redissolved in EtOAc (100 mL). The organic layer was washed with 1 N HCl (2 × 30 mL) and brine (30 mL). The organic solution was dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent decanted and removed in vacuo. The crude oil was purified by silica gel chromatography (0–50% acetone in heptane) to give the desired product (7.2 g, 78%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub> presumed to be a mixture of <i>cis</i>/<i>trans</i> rotamers): δ [8.83 (d, <i>J</i> = 8.7 Hz) and 8.60 (d, <i>J</i> = 8.4 Hz), 1H], 7.88 (d, <i>J</i> = 7.6 Hz, 2H), [7.78 (d, <i>J</i> = 3.2 Hz) and 7.76 (d, <i>J</i> = 3.3 Hz), 1H], 7.71 (d, <i>J</i> = 7.4 Hz, 2H), [7.64 (d, <i>J</i> = 3.2 Hz) and 7.61 (d, <i>J</i> = 3.2 Hz), 1H], 7.56–7.11 (m, 10H), [5.51 (ddd, <i>J</i> = 12.5, 8.7, and 4.1 Hz) and 5.39 (ddd, <i>J</i> = 11.1, 8.3, and 4.3 Hz), 1H], 4.38–4.12 (m, 3H), 3.98 (d, <i>J</i> = 8.2 Hz, 2H), 3.82–3.30 (m, 8H), [3.24 (s) and 3.19 (s), 3H], [3.21 (s) and 3.17 (s), 3H], 3.03 (s) and 2.95 (s), 3H], 2.44–1.13 (m, 16H), [1.09 (d, <i>J</i> = 6.6 Hz) and 1.05 (d, <i>J</i> = 6.7 Hz), 3H], 0.97–0.83 (m, 9H), 0.72 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.83, 173.57, 173.55, 173.16, 169.42, 169.08, 156.68, 144.36, 144.33, 144.20, 143.03, 142.84, 141.16, 141.13, 138.30, 138.12, 129.43, 129.14, 128.52, 128.08, 127.50, 127.46, 126.78, 126.63, 125.90, 125.86, 125.73, 120.52, 120.39, 120.29, 85.53, 81.63, 77.99, 66.22, 61.42, 60.68, 58.95, 58.65, 57.67, 57.54, 56.86, 56.74, 55.36, 52.14, 51.21, 47.56, 47.14, 46.62, 43.88, 43.59, 37.75, 35.61, 32.79, 32.18, 31.72, 30.27, 28.82, 25.79, 25.62, 24.79, 24.70, 23.62, 22.56, 19.58, 19.29, 18.92, 18.67, 16.61, 16.19, 15.94, 15.66, 15.40, 14.41, 10.98, and 10.72. LC-MS: <i>m</i>/<i>z</i> 881.3 [M + H]<sup>+</sup>, 903.3 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Synthesis of <i>N</i>-[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-Methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide (<b>18</b>)</h3><div class="NLM_p">Tetramer <b>17</b> (5.00 g, 5.68 mmol) was dissolved in THF (10 mL) and diethylamine (3 mL), and the reaction mixture was stirred for 3 h at rt. The solvent was removed, and the crude material was purified by silica gel chromatography (0–10% MeOH in DCM) to give the desired compound (2.952 g, 79%) as a solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub> presumed to be a mixture of <i>cis</i>/<i>trans</i> rotamers): δ [8.82 (d, <i>J</i> = 8.7 Hz) and 8.60 (d, <i>J</i> = 8.4 Hz),1H], [7.79 (d, <i>J</i> = 3.3 Hz) and 7.76 (d, <i>J</i> = 3.2 Hz), 1H], [7.64 (d, <i>J</i> = 3.3 Hz) and 7.61 (d, <i>J</i> = 3.3 Hz), 1H], 7.31–7.11 (m, 5H), [5.53 (ddd, <i>J</i> = 12.5, 8.7, and 4.2 Hz) and 5.39 (ddd, <i>J</i> = 11.0, 8.4, and 4.3 Hz), 1H], 4.02–3.93 (m, 1H), 3.83–2.95 (m, 11H), [3.25 (s) and 3.19 (s), 3H], [3.19 (s) and 3.15 (s), 3H], [2.94 (s) and 2.84 (s), 3H], 2.42–0.74 (m, 23H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 177.50, 177.36, 176.54, 176.50, 173.84, 173.73, 173.60, 173.58, 173.55, 173.27, 173.00, 170.76, 169.55, 169.30, 169.13, 168.95, 143.08, 143.00, 142.84, 138.32, 138.17, 138.03, 129.44, 129.39, 129.02, 128.61, 128.54, 128.51, 126.79, 126.74, 126.67, 126.60, 120.43, 120.37, 120.29, 85.63, 85.55, 81.74, 81.65, 79.20, 78.17, 77.87, 63.04, 62.99, 61.45, 61.42, 60.73, 60.70, 60.20, 58.95, 58.69, 57.96, 57.82, 57.70, 57.53, 56.21, 56.09, 55.82, 55.64, 55.36, 52.14, 51.80, 51.00, 47.54, 47.44, 46.70, 46.59, 43.88, 43.77, 43.58, 43.53, 37.85, 37.18, 35.74, 35.59, 34.67, 34.37, 33.25, 32.43, 31.83, 31.67, 31.40, 30.35, 30.15, 26.62, 26.41, 25.99, 25.78, 25.58, 24.79, 24.70, 23.63, 22.56, 21.22, 20.76, 20.74, 20.60, 20.33, 17.90, 17.70, 17.23, 16.82, 16.38, 16.30, 16.26, 16.03, 15.66, 15.64, 15.40, 15.29, 14.56, 14.40, 12.30, 12.28, 11.36, and 10.99. LC-MS: <i>m</i>/<i>z</i> 658.5 [M + H]<sup>+</sup>, 680.5 [M + Na]<sup>+</sup>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Synthesis of 2-Methylalanyl-<i>N</i>-[(3<i>R,</i>4<i>S,</i>5<i>S</i>)-3-methoxy-1-{(2<i>S</i>)-2-[(1<i>R,</i>2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N-</i>methyl-<span class="smallcaps smallerCapital">l</span>-valinamide (<b>20a</b>)</h3><div class="NLM_p last">Step 1: To the solution of Fmoc aminoisobutyric acid <b>19a</b> (39.7 mg, 0.122 mmol) and tetramer <b>18</b> (80.3 mg, 0.122 mmol) in DCM (4 mL) was added HATU (71.7 mg, 0.183 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (64 μL, 0.366 mmol), and the solution was stirred at rt overnight. The solvent was removed and the crude residue dissolved in EtOAc (6 mL), washed with 1 N HCl (2 × 2 mL) and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed in vacuo and the crude material purified by flash chromatography (0–50% EtOAc in heptane) to provide the protected pentamer intermediate (85 mg, 48%). Step 2: The protected pentamer (85 mg, 0.088 mmol) was taken up in THF (1 mL), and diethylamine (0.5 mL) was added. After stirring for 2 h at rt, the solvent was evaporated and the crude residue taken up in DCM (2 mL) and the solution loaded directly onto silica column and purified by flash chromatography (0–20% MeOH in DCM) to give the desired product (33 mg, 58%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz at 32 °C, presumed to be a mixture of <i>cis</i>/<i>trans</i> rotamers): δ [8.86 (d, <i>J</i> = 8.7 Hz) and 8.63 (d, <i>J</i> = 8.2 Hz), 1H], [8.15 (d, <i>J</i> = 9.2 Hz) and 8.12 (d, <i>J</i> = 9.1 Hz), 1H], [7.80 (d, <i>J</i> = 3.1 Hz) and 7.77 (d, <i>J</i> = 3.2 Hz), 1H], [7.66 (d, <i>J</i> = 3.2 Hz) and 7.63 (d, <i>J</i> = 3.2 Hz), 1H], 7.32–7.12 (5H, m), [5.52 (ddd, <i>J</i> = 12.2, 8.7, and 4.2 Hz) and 5.39 (ddd, <i>J</i> = 11.8, 8.2, and 4.3 Hz), 1H], 4.73–4.58 (m, 1H), [4.61 (t, <i>J</i> = 8.3 Hz) and 4.51 (t, <i>J</i> = 8.5 Hz), 1H], 3.99 (m, 1H), 3.82–2.95 (m, 7H), [3.26 (s) and 3.20 (s), 3H], [3.21 (s) and 3.17 (s), 3H], [3.03 (s) and 2.94 (s), 3H], 2.41–0.83 (m, 28H), 0.78 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 126 MHz at 60 °C): δ 175.6, 175.4, 173.2, 172.9, 172.7, 172.4, 172.2, 172.1, 168.8, 168.4, 142.3, 142.0, 137.6, 137.5, 128.7, 128.5, 127.8, 127.8, 126.1, 125.9, 119.6, 119.5, 85.0, 81.2, 77.4, 77.4, 60.7, 59.9, 58.4, 58.1, 57.0, 56.9, 54.6, 54.6, 53.6, 53.5, 51.5, 50.7, 46.9, 45.9, 43.2, 42.9, 37.3, 35.2, 32.4, 31.7, 31.1, 30.1, 30.1, 27.6, 27.6, 27.1, 27.0, 25.1, 25.0, 24.1, 24.0, 22.9, 19.1, 18.8, 17.6, 17.4, 15.6, 15.3, 14.9, 14.5, 13.6, 10.3, and 10.0. HRMS <i>m</i>/<i>z</i> 743.4524 [M + H]<sup>+</sup>. Calcd for C<sub>39</sub>H<sub>63</sub>N<sub>6</sub>O<sub>6</sub>S, 743.4452.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Synthesis of <i>N</i>,2-Dimethylalanyl-<i>N</i>-[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide (<b>20b</b>)</h3><div class="NLM_p last">Step 1<i>:</i> To a solution of Fmoc-<i>N</i>-methyl aminoisobutyric acid <b>19b</b> (25 mg, 0.076 mmol) and tetramer <b>18</b> (50 mg, 0.076 mmol) in DCM (2 mL) was added HATU (33 mg, 0.084 mmol), followed by <i>N</i>,<i>N</i>-diisopropylethylamine (0.04 mL, 0.228 mmol). The reaction was allowed to stir at rt for 4 h, then the solvent was removed and the crude residue partitioned between EtOAc (3 mL) and 1 N HCl (1 mL). The layers were separated and the organic solution washed with 1 N HCl (1 mL) and brine (1 mL) and dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. Step 2: The residue was taken up in THF (2 mL), and diethylamine (0.5 mL) was added. The reaction was stirred for 2h at rt, then the solvent was evaporated and the crude residue was dissolved in EtOAc (2 mL). The solution was loaded directly onto a silica gel column and purified by flash chromatography (0–30% MeOH in EtOAc) to give the desired product (33 mg, 58%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, presumed to be a mixture of <i>cis</i>/<i>trans</i> rotamers): δ [8.87 (d, <i>J</i> = 8.7 Hz) and 8.64 (d, <i>J</i> = 8.4 Hz), 1H], 7.83 (d, <i>J</i> = 8.9 Hz) and 7.79 (d, <i>J</i> = 3.3 Hz) 1H], [7.77 (d, <i>J</i> = 3.3 Hz) and 7.66 (d, <i>J</i> = 3.3 Hz) 1H], [7.62 (d, <i>J</i> = 3.3 Hz) and 7.60 (d, 3.3 Hz) 1H], 7.31–7.11 (m, 5H), [5.52 (ddd, <i>J</i> = 12.3, 8.6, and 4.1 Hz) and 5.38 (ddd, <i>J</i> = 11.4, 8.4, and 4.2 Hz) 1H], [4.71 (m) and 4.60 (m), 1H], [4.60 (dd, <i>J</i> = 9.3 and 7.3 Hz) and 4.50 (dd, <i>J</i> = 9.3 and 8.0 Hz), 1H], 4.01–3.94 (m, 1H), 3.80–2.90 (m, 5H), [3.25 (s) and 3.20 (s), 3H], [3.19 (s) and 3.15 (s), 3H], 3.03 (s) and 2.94 (s), 3H], 2.45–1.92 (m, 6H), 2.10 (s) and 2.09 (s), 3H], 1.85–1.20 (m, 10H), [1.15 (s) and 1.08 (s), 3H], [1.10 (d, <i>J</i> = 6.7 Hz,) and 1.05 (d, <i>J</i> = 6.8 Hz), 3H], 0.93–0.83 (m, 6H), 0.75 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 176.21, 176.14, 173.86, 173.58, 173.56, 173.21, 173.16, 173.13, 169.43, 169.06, 143.05, 142.85, 138.31, 138.11, 129.44, 129.11, 128.53, 126.79, 126.64, 120.40, 120.29, 85.53, 81.61, 77.91, 61.43, 60.69, 59.00, 58.96, 58.67, 57.68, 57.56, 55.54, 54.03, 53.83, 47.57, 46.61, 43.89, 43.60, 37.70, 35.55, 32.59, 31.97, 31.69, 30.93, 30.88, 30.11, 25.80, 25.75, 25.70, 25.60, 24.87, 24.79, 24.77, 24.71, 23.63, 19.77, 19.46, 18.51, 18.25, 16.12, 15.88, 15.66, 15.41, 10.83, and 10.53. HRMS <i>m</i>/<i>z</i> 757.4698 [M + H]<sup>+</sup>. Calcd for C<sub>40</sub>H<sub>66</sub>N<sub>6</sub>O<sub>6</sub>S, 757.4681.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Synthesis of <i>N</i>∼2∼[(1-Aminocyclopropyl)carbonyl]-<i>N</i>-[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide (<b>20c</b>)</h3><div class="NLM_p last">Step 1: To a solution 1-Fmoc-amino cyclopropane carboxylic acid <b>19c</b> (98.3 mg, 0.304 mmol) in DCM (15 mL) at 0 °C was added HATU (120 mg, 0.334 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.1 mL, 0.608 mmol). The solution was stirred for 15 min, and tetramer <b>18</b> (0.2 g, 0.304 mmol) was added. The reaction was stirred at rt for 1 h, then the solution was concentrated in vacuo. The residue was purified by flash column chromatography (10–90% DCM in EtOAc) to give the protected pentamer (155 mg, 52.9%) as a white solid. Step 2: The protected pentamer (40 mg, 0.042 mmol) was dissolved in THF (1 mL), diethylamine (0.5 mL) was added, and the reaction was stirred at rt overnight. The solvent was removed and the crude residue redissolved in EtOAc (2 mL), loaded directly onto a silica gel column, and purified by flash chromatography (0–30% MeOH in EtOAc) to afford the desired compound (26.7 mg, 86%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ [8.85 (d, <i>J</i> = 8.7 Hz) and 8.62 (d, <i>J</i> = 8.4 Hz), 1H], [8.21 (d, <i>J</i> = 9.2 Hz) and 8.15 (d, <i>J</i> = 9.2 Hz), 1H], [7.78 (dd, <i>J</i> = 8.3 and 3.3 Hz) and 7.63 (dd, <i>J</i> = 10.5 and 3.2 Hz), 1H], 7.32–7.12 (m, 5H), [5.53 (ddd, <i>J</i> = 12.4, 8.6, and 4.1 Hz) and 5.39 (ddd, <i>J</i> = 12.1, 8.3, and 4.1 Hz), 1H], 4.70 (m, 1H), [4.66 (dd, <i>J</i> = 9.2 and 5.8 Hz) and 4.55 (dd, <i>J</i> = 9.1 and 6.8 Hz), 1H], 3.98 (d, <i>J</i> = 7.0 Hz, 1H), 3.83–2.87 (m, 6H), [3.25 (s) and 3.19 (s), 3H], [3.21 (s) and 3.16 (s), 3H], [3.03 (s) and 2.92 (s), 3H], 2.45–0.64 (m, 29H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 175.13, 175.08, 173.89, 173.58, 173.55, 173.19, 173.03, 172.94, 169.46, 169.07, 143.05, 142.84, 138.30, 138.08, 129.44, 129.04, 128.53, 126.80, 126.64, 120.39, 120.29, 85.51, 81.80, 81.63, 78.05, 77.95, 61.42, 61.40, 60.68, 58.96, 58.71, 58.12, 57.73, 57.57, 55.86, 54.33, 54.09, 53.47, 52.20, 52.15, 51.01, 47.57, 46.61, 43.89, 43.79, 43.69, 43.61, 35.76, 35.72, 35.69, 35.52, 32.73, 32.07, 31.65, 31.42, 31.02, 30.99, 30.38, 29.75, 25.94, 25.89, 25.57, 24.79, 24.74, 24.71, 23.63, 20.54, 20.08, 19.66, 18.42, 18.31, 18.08, 18.04, 17.97, 17.64, 17.33, 16.38, 16.21, 15.96, 15.68, 15.61, 15.41, 15.17, 12.50, 12.24, 11.07, 10.83. HRMS <i>m</i>/<i>z</i> 763.4182 [M + Na]<sup>+</sup>. Calcd for C<sub>39</sub>H<sub>60</sub>N<sub>6</sub>NaO<sub>6</sub>S, 763.4187.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Synthesis of <i>N</i>∼2∼[(1-Aminocyclopentyl)carbonyl]-<i>N</i>-[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-methoxy-1-{(2<i>S</i>)-2-[(1<i>R,</i>2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N-</i>methyl-<span class="smallcaps smallerCapital">l</span>-valinamide (<b>20d</b>)</h3><div class="NLM_p last">Step 1: To a solution of Fmoc-amino cyclopentane amino acid <b>19d</b> (106.7 mg, 0.304 mmol) in DCM (15 mL) at 0 °C was added HATU (120 mg, 0.334 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.1 mL, 0.608 mmol). The solution was stirred for 15 min, and tetramer <b>18</b> (0.2 g, 0.304 mmol) was added. The reaction mixture was stirred at rt for 1 h then concentrated in vacuo. The residue was purified by flash column chromatography (10–90% DCM in EtOAc) to give the desired product (165 mg, 54.8%) as a white solid. Step 2: The Fmoc-pentamer (40 mg, 0.40 mmol) was taken up in THF (2 mL), diethylamine (0.5 mL) was added, and the reaction was stirred at rt overnight. The solvent was removed and the crude residue dissolved in EtOAc (2 mL), loaded directly onto a silica gel column, and purified by flash chromatography (0–30% MeOH in EtOAc) to afford the desired compound (31 mg, 97%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6,</sub> presumed to be a mixture of <i>cis</i>/<i>trans</i> rotamers): δ [8.85 (d, <i>J</i> = 8.7 Hz) and 8.62 (d, <i>J</i> = 8.4 Hz), 1H], [8.24 (d, <i>J</i> = 9.3 Hz) and 8.20 (d, <i>J</i> = 9.4 Hz), 1H], [7.79 (d, <i>J</i> = 3.3 Hz) and 7.77 (d, <i>J</i> = 3.3 H), 1H], [7.65 (d, <i>J</i> = 3.2 Hz, 1H) and 7.62 (d, <i>J</i> = 3.3 Hz), 1H], 7.33–7.10 (m, 5H), [5.53 (ddd, <i>J</i> = 12.5, 8.6, and 4.2 Hz) and 5.39 (ddd, <i>J</i> = 12.1, 8.4, and 4.1 Hz), 1H], 4.72–4.50 (m, 1H), [4.63 (dd, <i>J</i> = 9.3 and 6.6 Hz) and 4.53 (dd, <i>J</i> = 9.3 and 7.5 Hz), 1H], 3.80–2.90 (m, 7H), [3.25 (s) and 3.19 (s), 3H], [3.21 (s) and 3.16 (s), 3H], [3.03 (s) and 2.93 (s), 3H], 2.45–0.08 (m, 28H), [1.10 (d, <i>J</i> = 6.7 Hz) and 1.05 (d, <i>J</i> = 6.8 Hz), 3H], 0.77 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 177.27, 177.23, 173.87, 173.58, 173.55, 173.17, 173.08, 173.02, 169.45, 169.07, 143.05, 142.84, 138.31, 138.10, 129.44, 129.08, 128.53, 126.79, 126.64, 120.39, 120.29, 85.53, 81.63, 77.99, 65.21, 65.15, 63.34, 61.42, 60.69, 60.20, 58.96, 58.69, 58.18, 57.71, 57.56, 55.73, 55.36, 54.13, 53.92, 52.20, 52.15, 51.10, 47.57, 46.61, 43.89, 43.60, 35.55, 32.79, 32.11, 31.69, 31.00, 30.93, 30.36, 29.75, 25.87, 25.83, 25.59, 24.79, 24.72, 24.70, 24.65, 23.63, 21.22, 20.55, 19.96, 19.60, 18.26, 17.92, 17.15, 17.09, 16.32, 16.28, 16.20, 15.96, 15.67, 15.40, 15.14, 14.56, 12.49, 12.25, 11.00, 10.74. HRMS <i>m</i>/<i>z</i> 791.451 [M + Na]<sup>+</sup>. Calcd for C<sub>41</sub>H<sub>64</sub>N<sub>6</sub>NaO<sub>6</sub>S, 791.450.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Synthesis of <i>N</i>∼2∼(3-Amino-2,2-dimethylpropanoyl)-<i>N</i>-[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide, Trifluoroacetic Acid Salt (<b>20e</b>)</h3><div class="NLM_p last">Step 1: To a solution of tetramer <b>18</b> (100 mg, 0.152 mmol) in DCM (4 mL) and DMF (0.5 mL) was added 3-{[(9<i>H</i>-fluoren-9-ylmethoxy)carbonyl]amino}-2,2-dimethylpropanoic acid <b>19e</b> (51.6 mg, 0.152 mmol), followed by <i>N</i>,<i>N</i>-diisopropylethylamine (80.0 μL, 0.457 mmol) and HATU (89.8 mg, 0.229 mmol). The reaction was stirred for 18 h then concentrated in vacuo. The residue was dissolved in EtOAc (6 mL) and washed with 1 N HCl and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (0–50% acetone in heptane) to provide the desired product (90 mg, 60%) as a white solid. Step 2: To this resulting Fmoc-protected pentamer (86 mg, 0.088 mmol) in THF (2 mL) was added diethylamine (10 mL). After stirring overnight, the reaction was concentrated in vacuo and the residue was purified by HPLC (method A, 10% CH<sub>3</sub>CN/90% H<sub>2</sub>O to 100% CH<sub>3</sub>CN/0% H<sub>2</sub>O, both solvents containing 0.02% TFA) to give the desired product (55 mg, 72%) a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ [8.91 (d, <i>J</i> = 8.7 Hz) and 8.66 (d, <i>J</i> = 8.4 Hz), 1H], [7.96 (d, <i>J</i> = 8.4 Hz) and 7.89 (d, <i>J</i> = 8.5 Hz), 1H], 7.80 (d, <i>J</i> = 3.3 Hz) and 7.77 (d, <i>J</i> = 3.2 Hz), 1H], [7.67 (d, <i>J</i> = 3.2 Hz) and 7.63 (d, <i>J</i> = 3.2 Hz), 1H], 7.31–7.12 (m, 5H), [5.48 (ddd, <i>J</i> = 12.5, 8.7, and 4.2 Hz) and 5.38 (ddd, <i>J</i> = 11.3, 8.4, and 4.2 Hz), 1H], 4.79–4.58 (m, 1H), [4.54 (dd, <i>J</i> = 8.6 Hz) and 4.44 (dd, <i>J</i> = 8.9 Hz), 1H], 4.00–2.75 (m, 9H), [3.24 (s) and 3.19 (s), 3H], [3.21 (s) and 3.16 (s), 3H], [3.04 (s) and 2.95 (s), 3H], 2.45–1.15 (m, 17H), 1.16–0.83 (m, 12H), 0.76 (t, <i>J</i> = 7.8 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 175.89, 175.87, 173.90, 173.58, 173.55, 173.33, 173.02, 169.32, 169.04, 158.70, 158.44, 158.19, 157.93, 143.14, 142.85, 138.32, 138.08, 129.44, 129.11, 128.57, 128.52, 126.83, 126.62, 120.41, 120.30, 118.52, 116.14, 85.53, 81.62, 77.91, 77.77, 61.45, 60.70, 58.97, 58.64, 57.65, 57.53, 55.24, 55.12, 52.15, 51.34, 47.57, 47.32, 47.27, 46.63, 43.88, 43.60, 37.82, 35.58, 32.05, 31.72, 30.13, 30.07, 25.67, 25.62, 24.80, 24.68, 23.62, 23.47, 22.83, 22.74, 19.55, 19.29, 19.16, 18.99, 16.19, 15.88, 15.67, 15.45, 10.85, 10.53. HRMS <i>m</i>/<i>z</i> 757.4696 [M + H]<sup>+</sup>. Calcd for C<sub>40</sub>H<sub>65</sub>N<sub>6</sub>O<sub>6</sub>S, 757.4681.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Synthesis of <i>N</i>∼2∼[2,2-Dimethyl-3-(methylamino)propanoyl]-<i>N</i>-{(1<i>S</i>,2<i>R</i>)-2-methoxy-4-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-1-[(1<i>S</i>)-1-methylpropyl]-4-oxobutyl}-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide, Trifluoroacetic Acid Salt (<b>20f</b>)</h3><div class="NLM_p last">Step 1: To a vial containing tetramer <b>18</b> (100 mg, 0.152 mmol) in DCM (1 mL) was added Boc-2,2-dimethyl-3-(methylamino)propanoic acid <b>19f</b> (36 mg, 0.152 mmol), followed by <i>N</i>,<i>N</i>-diisopropylethylamine (0.080 mL, 0.456 mmol) and HATU (66 mg, 0.17 mmol). The reaction was stirred at rt for 1 h, then concentrated in vacuo. The residue was dissolved in EtOAc and washed with 1 N HCl (2×) and brine (1×). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, decanted, and concentrated in vacuo. Step 2: Dioxane (1 mL) was added, followed by a solution of 4 N HCl (dioxane, 1.0 mL, 4.0 mmol). The reaction was stirred at rt for 12 h and concentrated in vacuo. The crude material was purified by HPLC (method A, 10% CH<sub>3</sub>CN/90% H<sub>2</sub>O to 100% CH<sub>3</sub>CN/0% H<sub>2</sub>O, both solvents containing 0.02% TFA) to yield the desired product (55.8 mg, 41%) as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ [8.92 (d, <i>J</i> = 8.8 Hz) and 8.65 (d, <i>J</i> = 8.5 Hz), 1H], 8.22 (m, 1H), [8.00 (d, <i>J</i> = 8.6 Hz) and 7.96 (d, <i>J</i> = 8.6 Hz), 1H], [7.80 (d, <i>J</i> = 3.3 Hz) and 7.77 (d, <i>J</i> = 3.3 Hz), 1H], [7.66 (d, <i>J</i> = 3.3 Hz) and 7.62 (d, <i>J</i> = 3.3 Hz), 1H], 7.33–7.10 (m, 5H), [5.48 (ddd, <i>J</i> = 12.4, 8.6, and 4.1 Hz) and 5.38 (ddd, <i>J</i> = 12.2, 8.4, and 4.2 Hz), 1H], 4.80–4.65 (m, 1H), [4.57 (dd, <i>J</i> = 8.6 Hz) and 4.47 (dd, <i>J</i> = 8.9 Hz), 1H], 4.00 (m, 1H), 3.81–2.85 (m, 11H), [3.24 (s) and 3.20 (s), 3H], [3.21 (s) and 3.17 (s), 3H], [3.04 (s) and 2.95 (s), 3H], 2.45–0.07 (m, 32H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 175.90, 175.84, 173.92, 173.60, 173.58, 173.39, 172.87, 169.27, 169.02, 158.95, 158.67, 158.39, 158.12, 143.21, 142.89, 138.33, 138.06, 129.68, 129.45, 129.10, 128.58, 128.52, 126.86, 126.62, 120.45, 120.33, 120.13, 117.79, 115.44, 113.10, 85.48, 81.54, 77.86, 77.63, 61.46, 60.72, 58.94, 58.60, 57.65, 57.53, 57.11, 57.06, 55.44, 55.19, 55.08, 52.14, 51.31, 47.57, 46.63, 43.88, 43.60, 37.78, 35.46, 34.81, 34.79, 32.61, 32.00, 31.74, 30.17, 30.12, 25.66, 25.60, 24.80, 24.67, 23.73, 23.69, 23.63, 22.94, 22.88, 21.53, 19.53, 19.29, 19.16, 18.99, 16.14, 15.82, 15.67, 15.50, 10.83, 10.48. HRMS <i>m</i>/<i>z</i> 771.4857 [M + H]<sup>+</sup>. Calcd for C<sub>41</sub>H<sub>67</sub>N<sub>6</sub>O<sub>6</sub>S, 771.4837.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Synthesis of 2-Methyl-<span class="smallcaps smallerCapital">l</span>-prolyl-<i>N</i>-[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide (<b>20g</b>)</h3><div class="NLM_p last">Step 1: To a solution of (<i>S</i>)-<i>N</i>-Boc-α-methylproline <b>19g</b> (17 mg, 0.076 mmol) and tetramer <b>18</b> (50 mg, 0.076 mmol) in DCM (2 mL) was added HATU (33 mg, 0.084 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.04 mL, 0.228 mmol). The reaction was stirred at rt for 4 h. The solvent was removed, and the crude residue was partitioned between EtOAc (3 mL) and 1 N HCl (1 mL) and the layers were separated. The organic layer was washed with 1 N HCl (1 mL) and brine (1 mL), then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. Step 2: The residue was dissolved in DCM (2 mL), TFA (0.5 mL) was added, and the reaction mixture was stirred at rt for 15 min. The solvent was evaporated, and the crude residue was partitioned between EtOAc (4 mL) and saturated aq NaHCO<sub>3</sub> (2 mL), then the layers were separated. The organic solution was dried over Na<sub>2</sub>SO<sub>4</sub> and loaded directly onto silica column and purified by flash chromatography (0–30% MeOH in EtOAc) to give the desired product (39 mg, 67%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ [8.87 (d, <i>J</i> = 8.8 Hz) and 8.64 (d, <i>J</i> = 8.4 Hz), 1H], [8.29 (d, <i>J</i> = 9.5 Hz) and 8.24 (d, <i>J</i> = 9.6 Hz) 1H], [7.79 (d, <i>J</i> = 3.3 Hz) and 7.77 (d, <i>J</i> = 3.3 Hz), 1H], [7.66 (d, <i>J</i> = 3.2 Hz) and 7.62 (d, <i>J</i> = 3.2 Hz), 1H], 7.31–7.10 (m, 5H), [5.53 (ddd, <i>J</i> = 12.5, 8.7, and 4.2 Hz) and 5.38 (ddd, <i>J</i> = 11.3, 8.5, and 4.2 Hz), 1H], 4.72–4.55 (m, 1H), [4.58 (dd, <i>J</i> = 9.5 and 6.6 Hz) and 4.48 (dd, <i>J</i> = 9.5 and 7.4 Hz), 1H], 3.97 (m, 1H), 3.80–2.62 (m, 8H), [3.25 (s) and 3.19 (s), 3H], [3.20 (s) and 3.15 (s), 3H],[3.02 (s) and 2.92 (s), 3H], 2.42–0.70 (m, 27H), [1.10 (d, <i>J</i> = 6.7 Hz) and 1.05 (d, <i>J</i> = 6.8 Hz), 3H], 0.77 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz,DMSO-<i>d</i><sub>6</sub>): δ 176.32, 173.88, 173.63, 173.58, 173.55, 173.19, 172.93, 172.86, 169.43, 169.04, 143.06, 142.85, 138.31, 138.10, 129.44, 129.24, 129.08, 128.84, 128.53, 126.79, 126.64, 120.40, 120.29, 85.52, 81.61, 77.94, 66.82, 61.43, 61.40, 60.69, 58.96, 58.76, 58.68, 57.71, 57.57, 55.70, 55.37, 53.85, 53.67, 52.15, 51.11, 47.57, 46.91, 46.61, 43.89, 43.60, 37.83, 37.71, 37.68, 35.52, 32.71, 32.05, 31.69, 30.98, 30.93, 30.41, 26.30, 25.84, 25.80, 25.59, 25.05, 24.79, 24.70, 23.63, 21.51, 20.75, 20.68, 19.94, 19.60, 18.11, 17.82, 16.87, 16.75, 16.20, 16.17, 15.93, 15.67, 15.59, 15.41, 12.44, 12.26, 10.93, 10.65. HRMS <i>m</i>/<i>z</i> 769.4703 [M + H]<sup>+</sup>. Calcd for C<sub>41</sub>H<sub>65</sub>N<sub>6</sub>O<sub>6</sub>S, 769.4681.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Synthesis of 2-Methyl-<span class="smallcaps smallerCapital">d</span>-prolyl-<i>N</i>-[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide (<b>20h</b>)</h3><div class="NLM_p last">Step 1: To a solution of (<i>R</i>)-<i>N</i>-Boc-α-methylproline <b>19h</b> (17 mg, 0.076 mmol) and tetramer <b>18</b> (50 mg, 0.076 mmol) in DCM (2 mL) was added HATU (33 mg, 0.084 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.04 mL, 0.228 mmol). The reaction was stirred at rt for 4 h. The solvent was removed, and the crude residue was partitioned between EtOAc (3 mL) and 1 N HCl (1 mL) and the layers were separated. The organic layer was washed with 1 N HCl (1 mL) and brine (1 mL), then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. Step 2: The residue was taken up in DCM (2 mL), TFA (0.5 mL) was added, and the reaction was stirred at rt for 15 min. The solvent was evaporated and the crude residue partitioned between EtOAc (4 mL) and saturated aq NaHCO<sub>3</sub> (2 mL), and the layers separated. The organic solution was dried over Na<sub>2</sub>SO<sub>4</sub>, loaded directly onto a silica column, and purified by flash chromatography (0–30% MeOH in EtOAc) to give the desired product (33 mg, 57%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ [8.86 (d, <i>J</i> = 8.7 Hz) and 8.64 (d, <i>J</i> = 8.5 Hz), 1H], [8.24 (d, <i>J</i> = 9.7 Hz) and 8.20 (d, <i>J</i> = 9.9 Hz), 1H], [7.79 (d, <i>J</i> = 3.2 Hz) and 7.77 (d, <i>J</i> = 3.3 Hz), 1H], [7.66 (d, <i>J</i> = 3.2 Hz) and 7.62 (d, <i>J</i> = 3.2 Hz), 1H], 7.32–7.10 (m, 5H), [5.52 (ddd, <i>J</i> = 12.3, 8.6, and 4.2 Hz) and 5.38 (ddd, <i>J</i> = 11.4, 8.4, and 4.2 Hz), 1H], 4.69 (d, <i>J</i> = 10.6 Hz, 1H), [4.55 (dd, <i>J</i> = 9.7 and 7.4 Hz) and 4.46 (dd, <i>J</i> = 9.7 and 8.0 Hz), 1H], 3.97 (m, 1H), 3.80–2.62 (m, 8), [3.24 (s) and 3.19 (s), 3H], [3.20 (s) and 3.15 (s), 3H], [3.00 (s) and 2.91 (s), 3H], 2.42–0.70 (m, 27H), [1.09 (d, <i>J</i> = 6.7 Hz) and 1.05 (d, <i>J</i> = 6.8 Hz), 3H], 0.75 (t, <i>J</i> = 7.4, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 176.58, 173.86, 173.58, 173.56, 173.15, 173.03, 170.77, 169.41, 169.05, 143.05, 142.85, 138.31, 138.11, 129.44, 129.11, 128.83, 128.54, 126.79, 126.64, 120.40, 120.29, 85.53, 81.61, 77.87, 66.84, 66.79, 61.42, 60.69, 60.21, 58.96, 58.67, 57.68, 57.54, 55.55, 53.83, 53.68, 52.15, 51.16, 47.57, 46.61, 46.57, 43.89, 43.60, 37.67, 37.42, 37.27, 35.53, 34.85, 32.63, 32.03, 31.69, 31.08, 31.05, 26.07, 25.74, 25.59, 24.79, 24.71, 23.63, 21.23, 19.67, 19.40, 18.29, 18.09, 16.86, 16.08, 15.86, 15.66, 15.56, 15.41, 14.56, 12.48, 10.82, 10.53. HRMS <i>m</i>/<i>z</i> 769.4685 [M + H]<sup>+</sup>. Calcd for C<sub>41</sub>H<sub>65</sub>N<sub>6</sub>O<sub>6</sub>S, 769.4681.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Synthesis of <i>N</i>∼2∼{[(3<i>S</i>)-3-Fluoropyrrolidin-3-yl]carbonyl}-<i>N</i>-[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide, Trifluoroacetic Acid Salt (<b>20i</b>)</h3><div class="NLM_p last">Step 1: To a solution of tetramer <b>18</b> (300 mg, 0.45 mmol) and (3<i>S</i>)-1-(<i>tert</i>-butoxycarbonyl)-3-fluoropyrrolidine-3-carboxylic acid (<b>19i</b>, see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) (106 mg, 0.45 mmol) in DCM (10 mL) was added HATU (194 mg, 0.54 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (117 mg, 0.9 mmol), and the reaction was stirred at rt for 3 h. The solvent was removed and the crude residue was purified by preparative HPLC (method B, 55% H<sub>2</sub>O/45% CH<sub>3</sub>CN to 15% H<sub>2</sub>O/85% CH<sub>3</sub>CN, both solvents containing 0.225% NH<sub>4</sub>OH) to afford the desired product (149 mg, 37%) as a white solid. Step 2: The resulting Boc-protected pentamer (20 mg, 0.02 mmol) was dissolved in DCM (0.3 mL) and CH<sub>3</sub>CN (0.3 mL), and a solution of 4 N HCl (dioxane, 0.26 mL) was added. The reaction was stirred at rt for 2.5 h, the solvent was removed, and the crude material was purified by HPLC (method C, 85% H<sub>2</sub>O/15% CH<sub>3</sub>CN to 50% H<sub>2</sub>O/50% CH<sub>3</sub>CN, both solvents containing 0.05% TFA) to obtain the desired product (18.6 mg, 91%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, presumed to be a mixture of <i>cis</i>/<i>trans</i> isomers): δ [9.40 (br s) and 9.23 (br s), 1H)], [8.89 (d, <i>J</i> = 8.8 Hz) and 8.65 (d, <i>J</i> = 8.4 Hz), 1H], [8.48- 8.29 (m, 1H)], [7.81 (d, <i>J</i> = 3.2 Hz) and 7.79 (d, <i>J</i> = 3.2 Hz), 1H], [7.68 (d, <i>J</i> = 3.2 Hz) and 7.65 (d, <i>J</i> = 3.6 Hz), 1H], 7.81–7.17 (m, 5H), [5.53 (ddd, <i>J</i> = 12.8, 9.2, and 4.8 Hz) and 5.41 (ddd, <i>J</i> = 12.4, 8.0, and 4.0 Hz), 1H], 4.70 (bs, 1H), [4.61 (t, <i>J</i> = 8.0 Hz) and 4.51 (t, <i>J</i> = 8.5 Hz), 1H], 3.97 (m, 1H), 3.82–2.85 (m, 10H), [3.25 (s) and 3.20 (s) 3H], [3.21 (s) and 3.16 (s), 3H], [3.05 (s) and 2.97 (s), 3H)], 2.40–0.83 (m, 25H), 0.76 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.91, 173.58, 173.55, 173.27, 172.42, 172.29, 169.35, 169.01, 166.94, 166.91, 166.75, 166.72, 159.02, 158.74, 158.45, 158.17, 143.07, 142.85, 138.31, 138.10, 129.44, 129.12, 128.54, 128.52, 126.81, 126.63, 120.41, 120.30, 119.82, 117.49, 115.16, 112.83, 102.09, 102.02, 100.53, 85.53, 81.61, 77.89, 61.44, 60.68, 58.96, 58.66, 57.68, 57.55, 55.46, 55.27, 53.64, 53.43, 53.37, 52.14, 51.23, 47.57, 46.62, 44.89, 44.87, 43.88, 43.60, 37.69, 35.54, 35.52, 35.34, 30.16, 30.04, 25.70, 25.59, 24.80, 24.68, 23.62, 19.56, 19.16, 18.87, 18.53, 16.16, 15.91, 15.67, 15.44, 10.76, 10.52. HRMS <i>m</i>/<i>z</i> 773.4444 [M + H]<sup>+</sup>. Calcd for C<sub>40</sub>H<sub>62</sub>FN<sub>6</sub>O<sub>6</sub>S, 773.4430.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Synthesis of <i>N</i>∼2∼{[(3<i>R</i>)-3-Fluoropyrrolidin-3-yl]carbonyl}-<i>N</i>-[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide, Trifluoroacetic Acid Salt (<b>20j</b>)</h3><div class="NLM_p last">Step 1: To a solution of tetramer <b>18</b> (300 mg, 0.45 mmol) and (3<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)-3-fluoropyrrolidine-3-carboxylic acid (<b>19j</b>, see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) (106 mg, 0.45 mmol) in DCM (10 mL) was added HATU (194 mg, 0.54 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (117 mg, 0.9 mmol), and the reaction was stirred at rt for 3 h. The solvent was removed, and the crude residue was purified by HPLC (method B, 55% H<sub>2</sub>O/45% CH<sub>3</sub>CN to 15% H<sub>2</sub>O/85% CH<sub>3</sub>CN, both solvents containing 0.225% NH<sub>4</sub>OH) to afford the desired product (159 mg, 40%) as a white solid. Step 2: The resulting pentamer (25 mg, 0.03 mmol) was dissolved in CH<sub>3</sub>CN (0.5 mL), and a solution of 4 N HCl (dioxane, 0.34 mL) was added. The reaction was stirred at rt for 2.5 h. The solvent was removed, and the crude material was purified by HPLC (method C, 95% H<sub>2</sub>O/5% CH<sub>3</sub>CN to 40% H<sub>2</sub>O/60% CH<sub>3</sub>CN, both solvents containing 0.05% TFA) to provide the desired product (17.7 mg, 69%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, presumed to be a mixture of <i>cis</i>/<i>trans</i> isomers): δ [9.33 (br s) and 9.22 (br s), 1H)], [8.88 (d, <i>J</i> = 8.7 Hz) and 8.63 (d, <i>J</i> = 8.3 Hz), 1H], [8.38 (d, <i>J</i> = 8.2 Hz and 8.22 (d, <i>J</i> = 8.2 Hz), 1H)], [7.79 (d, <i>J</i> = 3.3 Hz) and 7.77 (d, <i>J</i> = 3.3 Hz), 1H], [7.65 (d, <i>J</i> = 3.3 Hz) and 7.62 (d, <i>J</i> = 3.3 Hz), 1H], 7.30–7.12 (m, 5H), [5.51 (ddd, <i>J</i> = 12.8, 9.2, and 4.8 Hz) and 5.38 (ddd, <i>J</i> = 12.4, 8.0, and 4.0 Hz), 1H], 4.70 (bs, 1H), [4.65 (t, <i>J</i> = 7.8 Hz) and 4.54 (t, <i>J</i> = 8.3 Hz), 1H], 3.99 (m, 1H), 3.82–2.85 (m, 10H), [3.25 (s) and 3.20 (s) 3H], [3.21 (s) and 3.16 (s), 3H], [3.05 (s) and 2.96 (s), 3H)], 2.40–0.83 (m, 25H), 0.76 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.92, 173.61, 173.58, 173.55, 173.27, 172.20, 169.36, 169.01, 166.88, 166.69, 143.08, 142.85, 138.31, 138.10, 129.44, 129.10, 128.54, 126.81, 126.63, 120.40, 120.30, 102.19, 102.10, 100.64, 100.55, 85.52, 81.61, 77.93, 61.44, 60.69, 58.97, 58.67, 57.70, 57.56, 55.30, 55.06, 53.53, 53.31, 52.15, 51.19, 47.58, 46.63, 44.96, 43.88, 43.61, 37.65, 35.75, 35.63, 35.56, 35.45, 30.32, 30.19, 25.78, 25.59, 24.79, 24.68, 23.62, 19.69, 19.27, 18.62, 18.22, 16.18, 15.92, 15.68, 15.45, 10.84, 10.62. HRMS <i>m</i>/<i>z</i> 773.4428 [M + H]<sup>+</sup>. Calcd for C<sub>40</sub>H<sub>62</sub>FN<sub>6</sub>O<sub>6</sub>S, 773.4430.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Synthesis of (2<i>S</i>)-<i>N</i>-[(2<i>S</i>)-1-{[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-Methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide, Trifluoroacetic Acid Salt (<b>20k</b>)</h3><div class="NLM_p last">Step 1: To a solution of tetramer <b>18</b> (400 mg, 0.6 mmol) and (2<i>S</i>)-1-(<i>tert</i>-butoxycarbonyl)-2-methylpiperidine-2-carboxylic acid (<b>19k</b>, see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) (146 mg, 0.6 mmol) in DCM (10 mL) was added HATU (259 mg, 0.72 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (158 mg, 1.2 mmol), and the reaction was stirred at rt for 3 h. The solvent was removed, and the crude residue was purified by flash silica gel chromatography (1–5% MeOH in DCM) to afford the desired product (200 mg, 38%) as a white solid. Step 2: The resulting pentamer (20 mg, 0.022 mmol) was dissolved in DCM (0.1 mL) and CH<sub>3</sub>CN (0.1 mL), and to this solution was added a solution of 4 N HCl (dioxane 0.26 mL). The reaction was stirred for 2.5 h at rt. The solvent was removed, and the crude material was purified by HPLC (method C, 90% H<sub>2</sub>O/10% CH<sub>3</sub>CN to 40% H<sub>2</sub>O/60% CH<sub>3</sub>CN, both solvents containing 0.05% TFA) to obtain the desired product (13.2 mg, 73%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, presumed to be a mixture of <i>cis</i>/<i>trans</i> isomers): δ [8.90 (d, <i>J</i> = 8.7 Hz) and 8.64 (d, <i>J</i> = 8.3 Hz), 1H], [8.85–8.65 (m), 1H)], [8.56 (d, <i>J</i> = 8.2 Hz and 8.53 (d, <i>J</i> = 8.2 Hz), 1H)], [7.80 (d, <i>J</i> = 3.3 Hz) and 7.77 (d, <i>J</i> = 3.3 Hz), 1H], [7.66 (d, <i>J</i> = 3.3 Hz) and 7.62 (d, <i>J</i> = 3.3 Hz), 1H], 7.33–7.12 (m, 5H), [5.48 (ddd, <i>J</i> = 12.8, 9.2, and 4.8 Hz) and 5.38 (ddd, <i>J</i> = 12.4, 8.0, and 4.0 Hz), 1H], 4.75 (m, 1H), [4.60 (t, <i>J</i> = 7.8 Hz) and 4.52 (t, <i>J</i> = 8.3 Hz), 1H], 3.99 (m, 1H), 3.82–2.90 (m, 8H), [3.25 (s) and 3.20 (s) 3H], [3.22 (s) and 3.17 (s), 3H], [3.07 (s) and 3.00 (s), 3H)], 2.45–0.83 (m, 29H), 0.76 (m, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.92, 173.58, 173.55, 173.31, 172.64, 170.73, 169.29, 169.00, 158.61, 158.33, 143.13, 142.86, 138.33, 138.12, 129.45, 129.17, 128.57, 128.52, 126.83, 126.62, 120.44, 120.30, 117.82, 115.48, 85.59, 81.63, 77.71, 61.46, 61.19, 61.16, 60.70, 58.97, 58.61, 57.63, 57.56, 55.59, 55.55, 52.15, 51.44, 47.58, 46.64, 43.88, 43.61, 37.79, 35.58, 32.51, 31.91, 31.74, 31.36, 30.16, 25.67, 25.62, 24.80, 24.68, 23.62, 22.36, 21.62, 19.39, 19.33, 19.25, 19.23, 18.97, 16.12, 15.80, 15.67, 15.45, 10.69, 10.35. HRMS <i>m</i>/<i>z</i> 783.4834 [M + H]<sup>+</sup>. Calcd for C<sub>42</sub>H<sub>67</sub>N<sub>6</sub>O<sub>6</sub>S, 783.4837.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Synthesis of (2<i>R</i>)-<i>N</i>-[(2<i>S</i>)-1-{[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-Methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide, Trifluoroacetic Acid Salt (<b>20l</b>)</h3><div class="NLM_p last">Step 1: To a solution of tetramer <b>18</b> (280 mg, 0.4 mmol) and (2<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)-2-methylpiperidine-2-carboxylic acid (<b>19l</b>, see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) (100 mg, 0.4 mmol) in DCM (5 mL) was added HATU (182 mg, 0.48 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (100 mg, 0.8 mmol), and the reaction was stirred at rt for 3 h. The solvent was removed, and the crude residue was purified by flash silica gel chromatography (1–5% MeOH in DCM) to afford the desired product (220 mg, 62%) as a white solid. Step 2: The resulting pentamer (20 mg, 0.022 mmol) was dissolved in DCM (0.1 mL) and CH<sub>3</sub>CN (0.1 mL), and to this solution was added a solution of 4 N HCl (dioxane, 0.26 mL). The reaction was stirred for 2.5 h at rt. The solvent was removed, and the crude material was purified by preparative HPLC (method C, 85% H<sub>2</sub>O/15% CH<sub>3</sub>CN to 45% H<sub>2</sub>O/55% CH<sub>3</sub>CN, both solvents containing 0.05% TFA) to obtain the desired product (11.6 mg, 61%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, presumed to be a mixture of <i>cis</i>/<i>trans</i> isomers): δ [8.90 (d, <i>J</i> = 8.8 Hz) and 8.64 (d, <i>J</i> = 8.3 Hz), 1H], [8.75–8.65 (m), 1H)], [8.45 (d, <i>J</i> = 8.2 Hz and 8.43 (d, <i>J</i> = 8.2 Hz), 1H)], [7.80 (d, <i>J</i> = 3.3 Hz) and 7.77 (d, <i>J</i> = 3.3 Hz), 1H], [7.66 (d, <i>J</i> = 3.3 Hz) and 7.62 (d, <i>J</i> = 3.3 Hz), 1H], 7.33–7.10 (m, 5H), [5.47 (ddd, <i>J</i> = 12.4, 8.5, and 4.2 Hz) and 5.38 (ddd, <i>J</i> = 12.1, 8.4, and 4.2 Hz), 1H], 4.73 (m, 1H), [4.58 (t, <i>J</i> = 8.8 Hz) and 4.51 (t, <i>J</i> = 8.9 Hz), 1H], 3.98 (m, 1H), 3.82–2.85 (m, 8H), [3.25 (s) and 3.20 (s) 3H], [3.21 (s) and 3.16 (s), 3H], [3.05 (s) and 2.99 (s), 3H)], 2.45–0.83 (m, 29H), 0.80–0.72 (m, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.92, 173.58, 173.55, 173.25, 172.64, 170.58, 170.55, 169.29, 169.02, 158.90, 158.62, 158.35, 158.07, 143.09, 142.85, 138.32, 138.12, 129.44, 129.18, 128.56, 128.52, 126.83, 126.62, 120.42, 120.30, 117.80, 115.45, 113.11, 85.61, 81.61, 77.99, 77.73, 61.47, 61.34, 61.33, 60.69, 58.97, 58.64, 57.63, 57.53, 55.67, 55.62, 52.15, 51.46, 47.58, 46.62, 43.89, 43.58, 41.33, 37.72, 35.56, 32.56, 32.08, 31.68, 30.21, 25.78, 25.74, 25.62, 24.80, 24.68, 23.62, 23.33, 21.68, 19.31, 19.24, 19.21, 19.18, 18.91, 16.08, 15.78, 15.66, 15.46, 10.90, 10.67. HRMS <i>m</i>/<i>z</i> 783.4836 [M + H]<sup>+</sup>. Calcd for C<sub>42</sub>H<sub>67</sub>N<sub>6</sub>O<sub>6</sub>S, 783.4837.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Synthesis of <i>N</i>,2-Dimethylalanyl-<i>N</i>-{(1<i>S</i>,2<i>R</i>)-4-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-3-{[(1<i>S</i>)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-2-methoxy-1-[(1<i>S</i>)-1-methylpropyl]-4-oxobutyl}-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide, Trifluoroacetic Acid Salt (<b>22a</b>)</h3><div class="NLM_p last">Step 1: To a solution of compound <b>19a</b> (500 mg, 1.56 mmol) in DMF (25 mL) were added HATU (648 mg, 1.7 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (550 mg, 4.26 mmol). A solution of compound <b>21</b> (0.9 g, 1.42 mmol) in DMF (10 mL) was added, and the reaction mixture was stirred at rt overnight. The reaction solution was concentrated in vacuo, and the residue was purified by silica gel chromatography (0–10% EtOAc in DCM) to give the protected pentamer (0.8 g, 73%) as a white solid. Step 2: The protected pentamer (440 mg, 0.47 mmol) was taken up in THF (4 mL), and a solution of LiOH (28 mg, 1.17 mmol) in water (2 mL) was added. The reaction was stirred overnight at rt. The solvent was evaporated, and the residue was azeotroped with heptane (3×). The resulting crude residue was purified by HPLC (method A, 10% CH<sub>3</sub>CN/90% H<sub>2</sub>O to 100% CH<sub>3</sub>CN/0% H<sub>2</sub>O, each solvent containing 0.02% TFA) to provide the desired product (203 mg, 53%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, presumed to be a mixture of <i>cis</i>/<i>trans</i> isomers): δ 8.45–8.07 (m, 4H), 7.26–7.13 (m, 5H), 4.78–4.39 (m, 3H), 3.98 (q, <i>J</i> = 7.8 Hz, 1H), 3.76–2.75 (m, 5H), [3.24 (s) and 3.20 (s), 3H], [3.20 (s) and 3.18 (s), 3H], [3.04 (s) and 2.95 (s), 3H], 2.44–2.04 (m, 5H), 1.87–1.19 (m, 7H), [1.53 (s) and1.52 (s), 3H], [1.41 (s) and 1.39 (s), 3H], 1.08–0.83 (m, 12H), 0.77 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.98, 173.83, 173.65, 173.58, 172.44, 171.75, 171.72, 169.39, 169.07, 158.29, 158.05, 148.81, 139.89, 138.22, 137.95, 129.39, 129.10, 128.76, 128.53, 128.50, 127.70, 126.80, 126.65, 125.06, 120.17, 85.87, 81.92, 81.88, 77.90, 68.19, 61.43, 60.67, 59.00, 58.68, 57.64, 57.59, 57.06, 57.03, 55.60, 55.33, 53.46, 52.41, 47.54, 46.63, 43.56, 43.39, 41.83, 35.65, 32.74, 32.06, 31.71, 30.34, 30.31, 28.81, 25.75, 25.68, 24.77, 24.73, 23.79, 23.60, 23.58, 22.55, 19.35, 19.18, 18.92, 18.87, 16.19, 15.91, 15.68, 15.33, 14.40, 11.47, 10.81, 10.47. HRMS <i>m</i>/<i>z</i> 704.4591 [M + H]<sup>+</sup>. Calcd for C<sub>38</sub>H<sub>61</sub>N<sub>5</sub>O<sub>8</sub>, 704.4593.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Synthesis of <i>N</i>,2-dimethylalanyl-<i>N</i>-{(1<i>S</i>,2<i>R</i>)-4-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-3-{[(1<i>S</i>)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-2-methoxy-1-[(1<i>S</i>)-1-methylpropyl]-4-oxobutyl}-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide, Trifluoroacetic Acid Salt (<b>22b</b>)</h3><div class="NLM_p last">Step 1: To a solution of Fmoc-<i>N</i>-methyl aminoisobutyric acid <b>19b</b> (36 mg, 0.106 mmol) and tetramer <b>21</b> (60.8 mg, 0.096 mmol) in DCM (2 mL) was added HATU (45 mg, 0.115 mmol), followed by <i>N</i>,<i>N</i>-diisopropylethylamine (0.05 mL, 0.288 mmol). The reaction was stirred at rt for 4 h, then the solvent was removed and the crude residue partitioned between EtOAc (3 mL) and 1 N HCl (1 mL). The layers were separated and the organic layer washed with 1 N HCl (1 mL) and brine (1 mL). The resulting solution was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. Step 2: The residue was taken up in THF (1 mL), and aq 1 M LiOH (0.2 mL) was added. The reaction was stirred for 4 h at rt, then the solvent was evaporated and the crude residue was dissolved in DMSO (1 mL). The solution was loaded directly onto an Isco C18 silica column and purified by reverse phase chromatography (0% CH<sub>3</sub>CN/100% H<sub>2</sub>O to 100% CH<sub>3</sub>CN/0% H<sub>2</sub>O, each solvent containing 0.02% TFA) to give the desired product (23 mg, 33%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, presumed to be a mixture of <i>cis</i>/<i>trans</i> isomers): δ 8.87 (d, <i>J</i> = 9.0 Hz, 2H), [8.46 (d, <i>J</i> = 5.7 Hz) and 8.44 (d, <i>J</i> = 5.7 Hz), 1H], [8.39 (d, <i>J</i> = 8.6 Hz) and 8.13 (d, <i>J</i> = 8.2 Hz), 1H], 7.28–7.11 (m, 5H), 4.78–4.37 (m, 3H), 3.98 (m, 1H), 3.76–2.75 (m, 5H), [3.24 (s) and 3.19 (s), 3H], [3.19 (s) and 3.17 (s), 3H], [3.05 (s) and 2.96 (s), 3H], [2.46 (s) and 2.45 (s), 3H], 2.47–2.05 (m, 5H), 1.87–1.19 (m, 7H), [1.53 (s) and 1.51 (s), 3H], [1.42 (s) and 1.40 (s), 3H], 1.08–0.82 (m, 12H), 0.77 (d, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.98, 173.83, 173.65, 173.59, 172.51, 171.10, 171.08, 169.37, 169.07, 138.21, 137.96, 129.39, 129.12, 128.53, 128.51, 126.80, 126.65, 85.87, 81.90, 77.92, 61.73, 61.70, 61.43, 60.66, 59.00, 58.68, 57.63, 57.57, 55.57, 53.46, 52.44, 47.55, 46.62, 43.56, 43.39, 37.75, 36.96, 36.87, 35.63, 32.61, 32.00, 31.74, 30.18, 27.71, 25.71, 24.77, 24.73, 23.58, 21.41, 21.34, 19.25, 19.08, 19.04, 19.01, 16.16, 15.90, 15.68, 15.34, 10.78, 10.48. HRMS <i>m</i>/<i>z</i> 718.4748 [M + H]<sup>+</sup>. Calcd for C38H<sub>63</sub>N<sub>5</sub>O<sub>8</sub>, 718.4749.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Synthesis of 2-Methyl-<span class="smallcaps smallerCapital">l</span>-prolyl-<i>N</i>-[(3<i>R</i>,4<i>S</i>,5<i>S</i>)-3-methoxy-1-{(2<i>S</i>)-2-[(1<i>R</i>,2<i>R</i>)-1-methoxy-2-methyl-3-oxo-3-{[(1<i>S</i>)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-<i>N</i>-methyl-<span class="smallcaps smallerCapital">l</span>-valinamide (<b>22g</b>)</h3><div class="NLM_p last">Step 1: To a solution of (<i>S</i>)-<i>N</i>-Boc-α-methylproline <b>19g</b> (443 mg, 1.93 mmol) and tetramer <b>21</b> (1.02 mg, 1.61 mmol) in DCM (12 mL) was added HATU (735 mg, 1.93 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (1.12 mL, 6.45 mmol). The reaction was stirred at rt for 2 h. The solvent was removed in vacuo, and the crude residue was partitioned between EtOAc (30 mL) and 0.5 N HCl (10 mL) and the layers were separated. The organic layer was washed with brine (1 mL), then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The crude residue was purified by flash chromatography (0–50% acetone in heptane) provided the protected pentamer (1.02 g, 75%). Step 2: The protected pentamer (493 mg, 0.515 mmol) was dissolved in THF (4 mL), and a solution of LiOH (24.7 mg, 1.03 mmol) in water (2 mL) was added. The reaction was stirred for 1 h, then the solvent was removed in vacuo. The crude residue was dissolved in DCM (7 mL), TFA (3 mL) was added, the reaction mixture was stirred at rt for 0.5 h. The solvent was evaporated and the crude residue purified by C18 flash chromatography (0% CH<sub>3</sub>CN/100% H<sub>2</sub>O to 100% CH<sub>3</sub>CN/0% H<sub>2</sub>O, each solvent containing 0.02% TFA) to yield the desired product (325 mg, 75%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, presumed to be a mixture of <i>cis</i>/<i>trans</i> isomers): δ 9.15–8.68 (m, 2H), [8.39 (d, <i>J</i> = 8.6 Hz) and 8.13 (d, <i>J</i> = 8.2 Hz, 1H], 7.28–7.11 (m, 5H), 4.76–4.36 (m, 2H), 3.97 (m, 1H), 3.75–2.95 (m, 8H), [3.24 (s) and 3.19 (s), 3H], [3.19 (s) and 3.16 (s), 3H], [3.05 (s) and 2.97 (s), 3H], [2.83 (dd, <i>J</i> = 11.0 and 2.7 Hz,), 2.79 (dd, <i>J</i> = 10.7 and 3.9 Hz, 1H], 2.45–0.80 (m, 26H), [1.63 (s) and 1.61 (s), 3H], [0.77 (t, <i>J</i> = 7.4) and 0.76 (t, <i>J</i> = 7.4 Hz, 3H]. <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.98, 173.84, 173.65, 173.58, 172.69, 172.61, 171.18, 171.15, 169.35, 169.07, 158.80, 158.55, 158.29, 158.03, 138.21, 137.99, 129.39, 129.14, 128.51, 126.79, 126.66, 118.46, 116.09, 113.72, 85.89, 81.90, 77.98, 77.84, 69.44, 69.39, 61.43, 60.65, 59.00, 58.66, 57.60, 57.55, 56.61, 55.98, 55.76, 53.47, 52.49, 47.56, 46.61, 44.70, 43.56, 43.38, 40.63, 40.53, 40.46, 40.37, 40.29, 40.20, 40.12, 40.04, 39.95, 39.87, 39.70, 39.53, 37.70, 36.95, 36.87, 35.87, 35.61, 32.53, 32.05, 31.73, 30.24, 30.22, 28.81, 25.71, 25.68, 24.76, 24.73, 23.58, 22.95, 22.55, 21.39, 21.37, 19.21, 19.16, 19.13, 18.91, 16.08, 15.82, 15.67, 15.61, 15.33, 14.40, 10.85, 10.63. HRMS <i>m</i>/<i>z</i> 730.4755 [M + H]<sup>+</sup>. Calcd for C<sub>39</sub>H<sub>63</sub>N<sub>5</sub>O<sub>8</sub>, 730.4749.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Experimental Procedure for Cytotoxicity Assays</h3><div class="NLM_p last">N87 cells were obtained from ATCC (Manassas, VA) and were originally derived from a liver metastasis of gastric carcinoma. BT474 cells (ATCC) were derived from a breast carcinoma. MDA-MB-361-DYT2 cells were derived from breast carcinoma and were generously provided by Dr. Dajun Yang of Georgetown University. Cells were seeded in 96-well plates at low density, then treated the following day with compounds in 3-fold serial dilutions at 10 concentrations in duplicate. Cells were incubated for 4 days in a humidified 37 °C/5% CO<sub>2</sub> incubator. The plates were harvested by incubating with CellTiter 96 AQueous One MTS solution (Promega, Madison, WI) for 1.5 h and absorbance measured on a Victor plate reader (PerkinElmer, Waltham, MA) at wavelength 490 nm. IC<sub>50</sub> values were calculated using a four-parameter logistic model with XLfit (IDBS, Bridgewater, NJ).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41"><a href="/doi/suppl/10.1021/jm501649k">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03170" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03170" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Crystallography materials and methods, determination of the absolute configuration for amino acids <b>19i</b>, <b>19j</b>, <b>19k</b>, and <b>19l</b>, and NMR spectra for all new analogues. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501649k/suppl_file/jm501649k_si_001.pdf">jm501649k_si_001.pdf (1.34 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm501649k" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Maderna</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#61000f05130400124f0c000504130f00211107081b04134f020e0c"><span class="__cf_email__" data-cfemail="6c0d02081e090d1f42010d08091e020d2c1c0a0516091e420f0301">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Doroski</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chakrapani Subramanyam</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander Porte</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carolyn A. Leverett</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beth C. Vetelino</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zecheng Chen</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hud Risley</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Parris</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jayvardhan Pandit</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alison H. Varghese</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suman Shanker</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cynthia Song</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sai Chetan K. Sukuru</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen A. Farley</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa M. Wagenaar</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Shapiro</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sylvia Musto</span> - <span class="hlFld-Affiliation affiliation">Oncology
Research Unit, Pfizer Worldwide Research
and Development, 401
North Middletown Road, Pearl River, New York 10965, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">My-Hanh Lam</span> - <span class="hlFld-Affiliation affiliation">Oncology
Research Unit, Pfizer Worldwide Research
and Development, 401
North Middletown Road, Pearl River, New York 10965, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank Loganzo</span> - <span class="hlFld-Affiliation affiliation">Oncology
Research Unit, Pfizer Worldwide Research
and Development, 401
North Middletown Road, Pearl River, New York 10965, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. O’Donnell</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Oncology, Pfizer Worldwide
Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">All animal experiments were performed in accordance with institutional guidelines as defined by institutional Animal Care and Use Committee for U.S. institutions.<br /></br>The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i42" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i42"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i43" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i43"> Abbreviations Used</h2><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption distribution metabolism excretion</p></td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody drug conjugate</p></td></tr><tr><td class="NLM_term">MMAD</td><td class="NLM_def"><p class="first last">monomethyl auristatin-D</p></td></tr><tr><td class="NLM_term">MMAE</td><td class="NLM_def"><p class="first last">monomethyl auristatin-E</p></td></tr><tr><td class="NLM_term">MMAF</td><td class="NLM_def"><p class="first last">monomethyl auristatin-F</p></td></tr><tr><td class="NLM_term">Dov</td><td class="NLM_def"><p class="first last">dolavaline</p></td></tr><tr><td class="NLM_term">Dil</td><td class="NLM_def"><p class="first last">dolaisoleuine</p></td></tr><tr><td class="NLM_term">Dap</td><td class="NLM_def"><p class="first last">dolaproine</p></td></tr><tr><td class="NLM_term">Doe</td><td class="NLM_def"><p class="first last">dolaphenine</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate</p></td></tr><tr><td class="NLM_term">N-Pg</td><td class="NLM_def"><p class="first last">protected amine</p></td></tr><tr><td class="NLM_term">Aib</td><td class="NLM_def"><p class="first last">2-aminoisobutyric acid</p></td></tr><tr><td class="NLM_term">GI<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration for 50% of maximal inhibition of cell proliferation</p></td></tr><tr><td class="NLM_term">RRCK</td><td class="NLM_def"><p class="first last">Ralph Russ canine kidney</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">HHEP</td><td class="NLM_def"><p class="first last">human liver hepatocytes</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the concentration time curve</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">apparent volume of distribution</p></td></tr><tr><td class="NLM_term">rCYP</td><td class="NLM_def"><p class="first last">human recombinant cytochrome P450</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08414" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08414" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuinman, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boettner, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kizu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baczynskyj, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomer, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontems, R. J.</span><span> </span><span class="NLM_article-title">The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">6883</span><span class="NLM_x">–</span> <span class="NLM_lpage">6885</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00256a070" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1987&pages=6883-6885&author=G.+R.+Pettitauthor=Y.+Kamanoauthor=C.+L.+Heraldauthor=A.+A.+Tuinmanauthor=F.+E.+Boettnerauthor=H.+Kizuauthor=J.+M.+Schmidtauthor=L.+Baczynskyjauthor=K.+B.+Tomerauthor=R.+J.+Bontems&title=The+isolation+and+structure+of+a+remarkable+marine+animal+antineoplastic+constituent%3A+dolastatin+10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fja00256a070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00256a070%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DKamano%26aufirst%3DY.%26aulast%3DHerald%26aufirst%3DC.%2BL.%26aulast%3DTuinman%26aufirst%3DA.%2BA.%26aulast%3DBoettner%26aufirst%3DF.%2BE.%26aulast%3DKizu%26aufirst%3DH.%26aulast%3DSchmidt%26aufirst%3DJ.%2BM.%26aulast%3DBaczynskyj%26aufirst%3DL.%26aulast%3DTomer%26aufirst%3DK.%2BB.%26aulast%3DBontems%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520isolation%2520and%2520structure%2520of%2520a%2520remarkable%2520marine%2520animal%2520antineoplastic%2520constituent%253A%2520dolastatin%252010%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1987%26volume%3D109%26spage%3D6883%26epage%3D6885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1941</span><span class="NLM_x">–</span> <span class="NLM_lpage">1949</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1990&pages=1941-1949&author=R.+Baiauthor=G.+R.+Pettitauthor=E.+Hamel&title=Dolastatin+10%2C+a+powerful+cytostatic+peptide+derived+from+a+marine+animal.+Inhibition+of+tubulin+polymerization+mediated+through+the+vinca+alkaloid+binding+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DR.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DDolastatin%252010%252C%2520a%2520powerful%2520cytostatic%2520peptide%2520derived%2520from%2520a%2520marine%2520animal.%2520Inhibition%2520of%2520tubulin%2520polymerization%2520mediated%2520through%2520the%2520vinca%2520alkaloid%2520binding%2520domain%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1990%26volume%3D39%26spage%3D1941%26epage%3D1949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Luesch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, T. H.</span><span> </span><span class="NLM_article-title">Isolation of dolastatin-10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1</span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">–</span> <span class="NLM_lpage">910</span></span><div class="citationLinks">[<a href="/doi/10.1021/np010049y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2001&pages=907-910&author=H.+Lueschauthor=R.+E.+Mooreauthor=V.+J.+Paulauthor=S.+L.+Mooberryauthor=T.+H.+Corbett&title=Isolation+of+dolastatin-10+from+the+marine+cyanobacterium+Symploca+species+VP642+and+total+stereochemistry+and+biological+evaluation+of+its+analogue+symplostatin+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fnp010049y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp010049y%26sid%3Dliteratum%253Aachs%26aulast%3DLuesch%26aufirst%3DH.%26aulast%3DMoore%26aufirst%3DR.%2BE.%26aulast%3DPaul%26aufirst%3DV.%2BJ.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DCorbett%26aufirst%3DT.%2BH.%26atitle%3DIsolation%2520of%2520dolastatin-10%2520from%2520the%2520marine%2520cyanobacterium%2520Symploca%2520species%2520VP642%2520and%2520total%2520stereochemistry%2520and%2520biological%2520evaluation%2520of%2520its%2520analogue%2520symplostatin%25201%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2001%26volume%3D64%26spage%3D907%26epage%3D910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Harrigan, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G.</span><span> </span><span class="NLM_article-title">Symbiotic and dietary marine microalgae as a source of bioactive molecules—experience from natural products research</span> <span class="citation_source-journal">J. Appl. Phycol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1023%2FA%3A1019570122349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2002&pages=103-108&author=G.+G.+Harriganauthor=G.+Goetz&title=Symbiotic+and+dietary+marine+microalgae+as+a+source+of+bioactive+molecules%E2%80%94experience+from+natural+products+research"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Symbiotic and dietary marine microalgae as a source of bioactive molecules-experience from natural products research</span></div><div class="casAuthors">Harrigan, George G.; Goetz, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Phycology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-108</span>CODEN:
                <span class="NLM_cas:coden">JAPPEL</span>;
        ISSN:<span class="NLM_cas:issn">0921-8971</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Cyanobacterial metabolites have proven to be invaluable as tools in the dissection of signal transduction pathways in mammalian cells and some are currently under clin. evaluation as drug candidates.  It is now also realized that cyanobacteria are the true biosynthetic origin of many bioactive mols. isolated from marine invertebrates; marine invertebrates may sequester cyanobacteria through diet or by symbiosis.  This review discusses the dietary-derived cyanobacterial origin of the dolastatins, potent cytotoxic compds., originally isolated from the Indian Ocean sea hare, Dolabella auricularia.  A discussion on the dietary dissemination of cyanobacterial metabolites through the marine food chain is also presented.  Ref. to the metabolites isolated from Dysidea sponges is given to illustrate their origin from symbiotic cyanobacteria assocd. with this organism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokca8ZMSzoY7Vg90H21EOLACvtfcHk0lgJx67nWrWDKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKqtb8%253D&md5=47644f526f7667b9dbd7d2cc902e0b8d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1023%2FA%3A1019570122349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1019570122349%26sid%3Dliteratum%253Aachs%26aulast%3DHarrigan%26aufirst%3DG.%2BG.%26aulast%3DGoetz%26aufirst%3DG.%26atitle%3DSymbiotic%2520and%2520dietary%2520marine%2520microalgae%2520as%2520a%2520source%2520of%2520bioactive%2520molecules%25E2%2580%2594experience%2520from%2520natural%2520products%2520research%26jtitle%3DJ.%2520Appl.%2520Phycol.%26date%3D2002%26volume%3D14%26spage%3D103%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd-Williams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkett, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clewlow, P. J.</span><span> </span><span class="NLM_article-title">Antineoplastic agents. Part 189. The absolute configuration and synthesis of natural (−)-dolastatin-10</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5463</span><span class="NLM_x">–</span> <span class="NLM_lpage">5465</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00196a061" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1989&pages=5463-5465&author=G.+R.+Pettitauthor=S.+B.+Singhauthor=F.+Hoganauthor=P.+Lloyd-Williamsauthor=D.+L.+Heraldauthor=D.+D.+Burkettauthor=P.+J.+Clewlow&title=Antineoplastic+agents.+Part+189.+The+absolute+configuration+and+synthesis+of+natural+%28%E2%88%92%29-dolastatin-10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fja00196a061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00196a061%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26aulast%3DHogan%26aufirst%3DF.%26aulast%3DLloyd-Williams%26aufirst%3DP.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DBurkett%26aufirst%3DD.%2BD.%26aulast%3DClewlow%26aufirst%3DP.%2BJ.%26atitle%3DAntineoplastic%2520agents.%2520Part%2520189.%2520The%2520absolute%2520configuration%2520and%2520synthesis%2520of%2520natural%2520%2528%25E2%2588%2592%2529-dolastatin-10%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1989%26volume%3D111%26spage%3D5463%26epage%3D5465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Cormier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravelli, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span> </span><span class="NLM_article-title">Structural insight into the inhibition of tubulin by vinca domain peptide ligands</span> <span class="citation_source-journal">EMBO Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1101</span><span class="NLM_x">–</span> <span class="NLM_lpage">1106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=1101-1106&author=A.+Cormierauthor=M.+Marchandauthor=R.+B.+Ravelliauthor=M.+Knossowauthor=B.+Gigant&title=Structural+insight+into+the+inhibition+of+tubulin+by+vinca+domain+peptide+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCormier%26aufirst%3DA.%26aulast%3DMarchand%26aufirst%3DM.%26aulast%3DRavelli%26aufirst%3DR.%2BB.%26aulast%3DKnossow%26aufirst%3DM.%26aulast%3DGigant%26aufirst%3DB.%26atitle%3DStructural%2520insight%2520into%2520the%2520inhibition%2520of%2520tubulin%2520by%2520vinca%2520domain%2520peptide%2520ligands%26jtitle%3DEMBO%2520Rep.%26date%3D2008%26volume%3D9%26spage%3D1101%26epage%3D1106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Newman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covey, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benvenuto, J. A.</span><span> </span><span class="NLM_article-title">Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128)</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1994&pages=428-432&author=R.+A.+Newmanauthor=A.+Fuentesauthor=J.+M.+Coveyauthor=J.+A.+Benvenuto&title=Preclinical+pharmacology+of+the+natural+marine+product+dolastatin+10+%28NSC+376128%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DR.%2BA.%26aulast%3DFuentes%26aufirst%3DA.%26aulast%3DCovey%26aufirst%3DJ.%2BM.%26aulast%3DBenvenuto%26aufirst%3DJ.%2BA.%26atitle%3DPreclinical%2520pharmacology%2520of%2520the%2520natural%2520marine%2520product%2520dolastatin%252010%2520%2528NSC%2520376128%2529%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1994%26volume%3D22%26spage%3D428%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Mirsalis, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler-Horvat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaszewski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyson, C. A.</span><span> </span><span class="NLM_article-title">Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1007%2Fs002800050995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=10501913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVWlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1999&pages=395-402&author=J.+C.+Mirsalisauthor=J.+Schindler-Horvatauthor=J.+R.+Hillauthor=J.+E.+Tomaszewskiauthor=S.+J.+Donohueauthor=C.+A.+Tyson&title=Toxicity+of+dolastatin+10+in+mice%2C+rats+and+dogs+and+its+clinical+relevance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicity of dolastatin 10 in mice, rats, and dogs and its clinical relevance</span></div><div class="casAuthors">Mirsalis, Jon C.; Schindler-Horvat, Janice; Hill, James R.; Tomaszewski, Joseph E.; Donohue, Susan J.; Tyson, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">395-402</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Dolastatin 10 (DOL10), an oligopeptide isolated from the sea hare Dolabella auricularia, was shown to be a highly potent cytotoxic agent in a variety of human tumor cell lines.  The purpose of this study was to conduct preclin. toxicity evaluations to det. the target organ(s) of toxicity and its reversibility, the dose-limiting toxicity and the max. tolerated dose (MTD), and to use this information for arriving at a safe starting dose and dose schedule for phase I clin. trails.  DOL10 was administered as a single i.v. bolus dose to CD2F1 mice, Fischer-344 rats, and beagle dogs.  Endpoints evaluated included clin. observations, body wts., hematol., blood serum clin. chem., and microscopic pathol. of tissues.  The MTD (i.e. the highest dose that did not cause lethality but produced substantial toxicity) was approx. 1350 μg/m2 body surface area (450 μg/kg) in mice, 450 μg/m2 (75 μg/kg) in rats, and ≤400 μg/m2 (≤20 μg/kg) in dogs.  Adverse signs were obsd. at doses ≥1350 μg/m2 in mice, ≥150 μg/m2 in rats, and ≥400 μg/m2 in dogs.  Decreased wt. gain or actual wt. loss was obsd. at doses ≥1350 μg/m2 in mice, ≥600 μg/m2 in rats, and ≥450 μg/m2 in dogs.  In all 3 species, the primary target organ of toxicity was the bone marrow, as indicated by decreases in the nos. of erythroid cells, myeloid cells, and megakaryocytes in the femoral bone marrow and by decreased white blood cell (WBC) and reticulocyte counts in peripheral blood.  Marked neutropenia (i.e. >50% decrease compared to control animal or baseline values) was the principal effect on WBCs and occurred within a week of dosing.  A mild anemia was evident 1 wk after administering the drug to rats and dogs.  The hematol. effects were transient and reversed by study termination.  Other lesions at the MTD levels were cellular depletion and necrosis in lymphoid organs (rats and dogs), marked depletion of extramedullary hematopoietic cellular elements in the spleen (rats), thymic atrophy (mice and dogs), and minimal cellular necrosis in the ileum (rats).  More extensive and severe pathol. was obsd. in animals sacrificed in a moribund condition or found dead.  Myelotoxicity was dose-limiting in all 3 species with mice being the least sensitive.  In a phase I clin. trial, granulocytopenia was dose-limiting.  Moreover, the MTD of DOL10 for rats and dogs is comparable to the human MTD.  Therefore, the results from the preclin. toxicol. studies correctly predicted a safe starting dose, the dose-limiting toxicity, and the MTD in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaNjIErA4qtbVg90H21EOLACvtfcHk0lhcZDkoHXpU-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVWlu7Y%253D&md5=cd3eb75208a2e0f97ade4332bfa5ed77</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs002800050995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800050995%26sid%3Dliteratum%253Aachs%26aulast%3DMirsalis%26aufirst%3DJ.%2BC.%26aulast%3DSchindler-Horvat%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DJ.%2BR.%26aulast%3DTomaszewski%26aufirst%3DJ.%2BE.%26aulast%3DDonohue%26aufirst%3DS.%2BJ.%26aulast%3DTyson%26aufirst%3DC.%2BA.%26atitle%3DToxicity%2520of%2520dolastatin%252010%2520in%2520mice%252C%2520rats%2520and%2520dogs%2520and%2520its%2520clinical%2520relevance%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1999%26volume%3D44%26spage%3D395%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Pitot, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, E. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windebank, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagniewski, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, M. M.</span><span> </span><span class="NLM_article-title">Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=10100703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK1MXitVyisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=525-531&author=H.+C.+Pitotauthor=E.+A.+McElroyauthor=J.+M.+Reidauthor=A.+J.+Windebankauthor=J.+A.+Sloanauthor=C.+Erlichmanauthor=P.+G.+Bagniewskiauthor=D.+L.+Walkerauthor=J.+Rubinauthor=R.+M.+Goldbergauthor=A.+A.+Adjeiauthor=M.+M.+Ames&title=Phase+I+trial+of+dolastatin-10+%28NSC+376128%29+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors</span></div><div class="casAuthors">Pitot, Henry C.; McElroy, Edwin A., Jr.; Reid, Joel M.; Windebank, Anthony J.; Sloan, Jeff A.; Erlichman, Charles; Bagniewski, Pamela G.; Walker, Denise L.; Rubin, Joseph; Goldberg, Richard M.; Adjei, Alex A.; Ames, Matthew M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Dolastatin-10 (dola-10) is a potent antimitotic peptide, isolated from the marine mollusk Dolabela auricularia, that inhibits tubulin polymn.  Preclin. studies of dola-10 have demonstrated activity against a variety of murine and human tumors in cell cultures and mice models.  The purpose of this Phase I clin. trial was to characterize the max. tolerated dose, pharmacokinetics, and biol. effects of dola-10 in patients with advanced solid tumors.  Escalating doses of dola-10 were administered as an i.v. bolus every 21 days, using a modified Fibonacci dose escalation schema.  Pharmacokinetic studies were performed with the first treatment cycle.  Neurol. testing was performed on each patient prior to treatment with dola-10, at 6 wk and at study termination.  Thirty eligible patients received a total of 94 cycles (median, 2 cycles; max., 14 cycles) of dola-10 at doses ranging from 65 to 455 μg/m2.  Dose-limiting toxicity of granulocytopenia was seen at 455 μg/m2 for minimally pretreated patients (two or fewer prior chemotherapy regimens) and 325 μg/m2 for heavily pretreated patients (more than two prior chemotherapy regimens).  Nonhematol. toxicity was generally mild.  Local irritation at the drug injection site was mild and not dose dependent.  Nine patients developed new or increased symptoms of mild peripheral sensory neuropathy that was not dose limiting.  This toxicity was more frequent in patients with preexisting peripheral neuropathies.  Pharmacokinetic studies demonstrated a rapid drug distribution with a prolonged plasma elimination phase (t1/2z = 320 min).  The area under the concn.-time curve increased in proportion to administered dose, whereas the clearance remained const. over the doses studied.  Correlation anal. demonstrated a strong relationship between dola-10 area under the concn.-time curve values and decrease from baseline for leukocyte counts.  In conclusion, dola-10 administered every 3 wk as a peripheral i.v. bolus is well tolerated with dose-limiting toxicity of granulocytopenia.  The max. tolerated dose (and recommended Phase II starting dose) is 400 μg/m2 for patients with minimal prior treatment (two or fewer prior chemotherapy regimens) and 325 μg/m2 for patients who are heavily pretreated (more than two prior chemotherapy regimens).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTh_xvULk4irVg90H21EOLACvtfcHk0lhcZDkoHXpU-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitVyisLY%253D&md5=7f6f8059458c8aabd86b9c13a408ceae</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPitot%26aufirst%3DH.%2BC.%26aulast%3DMcElroy%26aufirst%3DE.%2BA.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DWindebank%26aufirst%3DA.%2BJ.%26aulast%3DSloan%26aufirst%3DJ.%2BA.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DBagniewski%26aufirst%3DP.%2BG.%26aulast%3DWalker%26aufirst%3DD.%2BL.%26aulast%3DRubin%26aufirst%3DJ.%26aulast%3DGoldberg%26aufirst%3DR.%2BM.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26atitle%3DPhase%2520I%2520trial%2520of%2520dolastatin-10%2520%2528NSC%2520376128%2529%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1999%26volume%3D5%26spage%3D525%26epage%3D531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Madden, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusztai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbruzzese, J. L.</span><span> </span><span class="NLM_article-title">Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1293</span><span class="NLM_x">–</span> <span class="NLM_lpage">1301</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=10778954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtVOqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=1293-1301&author=T.+Maddenauthor=H.+T.+Tranauthor=D.+Beckauthor=R.+Huieauthor=R.+A.+Newmanauthor=L.+Pusztaiauthor=J.+J.+Wrightauthor=J.+L.+Abbruzzese&title=Novel+marine-derived+anticancer+agents%3A+a+phase+I+clinical%2C+pharmacological%2C+and+pharmacodynamic+study+of+dolastatin+10+%28NSC+376128%29+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors</span></div><div class="casAuthors">Madden, Timothy; Tran, Hai T.; Beck, Debrah; Huie, Reeves; Newman, Robert A.; Pusztai, Lajos; Wright, John J.; Abbruzzese, James L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1293-1301</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Dolastatin (DOLA)-10 is a pentapeptide isolated from the mollusk Dolabella auricularia with clin. promising antitumor activity documented in various in vitro and in vivo tumor models.  The objectives of this Phase I study were to det. the max. tolerated dose, evaluate toxic effects, and document any antitumor activity of this novel agent.  Using an electrospray ionization mass spectroscopy system, we also characterized the clin. pharmacokinetics, pharmacodynamics, and metab. of DOLA-10.  The max. tolerated dose was reached at 300 μg/m2.  Granulocytopenia, the dose-limiting toxicity, was documented in 33% of the patients treated at that dose level.  There were no episodes of thrombocytopenia or severe anemia (Hgb < 8), and no major non-hematol. toxicity was obsd.  Stabilization of tumor growth was obsd. in four patients, but no objective responses were seen.  Whereas a two-compartment model described the DOLA-10 plasma concn.-time data reasonably well, a three-compartment model consistently performed better.  After a rapid distribution phase, DOLA-10 plasma levels declined with mean β and γ half-lives of 0.99 and 18.9 h, resp.  Significant interpatient and intrapatient variability in DOLA-10 plasma clearances was obsd.  The mean area under the concn.-time curve increased proportionally as the dose was escalated, but there was significant overlap between dose levels.  The area under the concn.-time curve and the percentage of decline in neutrophils were correlated.  A single DOLA-10 metabolite was detected in five patients.  Unlike the in vitro studies of DOLA-10, the principal metabolite detected was an N-demethyl deriv., confirmed by mass spectroscopy.  In all five subjects, the concn. of this metabolite never exceeded 2% of the simultaneously measured parent drug concn.  The available preclin., pharmacol., and clin. data suggest that further study of escalated DOLA-10 dosing with cytokine support is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqplGzd64izWbVg90H21EOLACvtfcHk0lheUQrBTbKP_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtVOqtrk%253D&md5=1537dce83d891134bbb6b8b8e3b0e1a7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMadden%26aufirst%3DT.%26aulast%3DTran%26aufirst%3DH.%2BT.%26aulast%3DBeck%26aufirst%3DD.%26aulast%3DHuie%26aufirst%3DR.%26aulast%3DNewman%26aufirst%3DR.%2BA.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26atitle%3DNovel%2520marine-derived%2520anticancer%2520agents%253A%2520a%2520phase%2520I%2520clinical%252C%2520pharmacological%252C%2520and%2520pharmacodynamic%2520study%2520of%2520dolastatin%252010%2520%2528NSC%2520376128%2529%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2000%26volume%3D6%26spage%3D1293%26epage%3D1301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Margolin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longmate, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Synold, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandara, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baratta, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span> </span><span class="NLM_article-title">Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=335-340&author=K.+Margolinauthor=J.+Longmateauthor=T.+W.+Synoldauthor=D.+R.+Gandaraauthor=J.+Weberauthor=R.+Gonzalezauthor=M.+J.+Johansenauthor=R.+Newmanauthor=T.+Barattaauthor=J.+H.+Doroshow&title=Dolastatin-10+in+metastatic+melanoma%3A+a+phase+II+and+pharmokinetic+trial+of+the+California+Cancer+Consortium"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMargolin%26aufirst%3DK.%26aulast%3DLongmate%26aufirst%3DJ.%26aulast%3DSynold%26aufirst%3DT.%2BW.%26aulast%3DGandara%26aufirst%3DD.%2BR.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DJohansen%26aufirst%3DM.%2BJ.%26aulast%3DNewman%26aufirst%3DR.%26aulast%3DBaratta%26aufirst%3DT.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26atitle%3DDolastatin-10%2520in%2520metastatic%2520melanoma%253A%2520a%2520phase%2520II%2520and%2520pharmokinetic%2520trial%2520of%2520the%2520California%2520Cancer%2520Consortium%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2001%26volume%3D19%26spage%3D335%26epage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balcerzak, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmonson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuno, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beard, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogatko, A.</span><span> </span><span class="NLM_article-title">Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas</span> <span class="citation_source-journal">Sarcoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2004&pages=107-111&author=M.+von+Mehrenauthor=S.+P.+Balcerzakauthor=A.+S.+Kraftauthor=J.+H.+Edmonsonauthor=S.+H.+Okunoauthor=M.+Daveyauthor=S.+McLaughlinauthor=M.+T.+Beardauthor=A.+Rogatko&title=Phase+II+trial+of+dolastatin-10%2C+a+novel+anti-tubulin+agent%2C+in+metastatic+soft+tissue+sarcomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBalcerzak%26aufirst%3DS.%2BP.%26aulast%3DKraft%26aufirst%3DA.%2BS.%26aulast%3DEdmonson%26aufirst%3DJ.%2BH.%26aulast%3DOkuno%26aufirst%3DS.%2BH.%26aulast%3DDavey%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DS.%26aulast%3DBeard%26aufirst%3DM.%2BT.%26aulast%3DRogatko%26aufirst%3DA.%26atitle%3DPhase%2520II%2520trial%2520of%2520dolastatin-10%252C%2520a%2520novel%2520anti-tubulin%2520agent%252C%2520in%2520metastatic%2520soft%2520tissue%2520sarcomas%26jtitle%3DSarcoma%26date%3D2004%26volume%3D8%26spage%3D107%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Perez, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillman, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishkin, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krook, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriakose, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberts, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakhil, S. R.</span><span> </span><span class="NLM_article-title">Phase II trial of dolastatin-10 in patients with advanced breast cancer</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=257-261&author=E.+A.+Perezauthor=D.+W.+Hillmanauthor=P.+A.+Fishkinauthor=J.+E.+Krookauthor=W.+W.+Tanauthor=P.+A.+Kuriakoseauthor=S.+R.+Albertsauthor=S.+R.+Dakhil&title=Phase+II+trial+of+dolastatin-10+in+patients+with+advanced+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DHillman%26aufirst%3DD.%2BW.%26aulast%3DFishkin%26aufirst%3DP.%2BA.%26aulast%3DKrook%26aufirst%3DJ.%2BE.%26aulast%3DTan%26aufirst%3DW.%2BW.%26aulast%3DKuriakose%26aufirst%3DP.%2BA.%26aulast%3DAlberts%26aufirst%3DS.%2BR.%26aulast%3DDakhil%26aufirst%3DS.%2BR.%26atitle%3DPhase%2520II%2520trial%2520of%2520dolastatin-10%2520in%2520patients%2520with%2520advanced%2520breast%2520cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2005%26volume%3D23%26spage%3D257%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Miyazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natsume, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakakibara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukagoshi, S.</span><span> </span><span class="NLM_article-title">Synthesis and antitumor activity of novel dolastatin 10 analogs</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1706</span><span class="NLM_x">–</span> <span class="NLM_lpage">1718</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1248%2Fcpb.43.1706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=8536345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK2MXpsF2nsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1995&pages=1706-1718&author=K.+Miyazakiauthor=M.+Kobayashiauthor=T.+Natsumeauthor=M.+Gondoauthor=T.+Mikamiauthor=K.+Sakakibaraauthor=S.+Tsukagoshi&title=Synthesis+and+antitumor+activity+of+novel+dolastatin+10+analogs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antitumor activity of novel dolastatin 10 analogs</span></div><div class="casAuthors">Miyazaki, Koichi; Kobayashi, Motohiro; Natsume, Tsugitaka; Gondo, Masaaki; Mikami, Takashi; Sakakibara, Kyoichi; Tsukagoshi, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1706-18</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Novel analogs of dolastatin 10, a a potent antineoplastic pentapeptide, each modified at one of the constituent amino acid derivs., were synthesized and their antitumor activity was evaluated against P388 leukemia in mice.  The structural requirements for antitumor activity are discussed.  Some of the analogs showed excellent activity in vivo.  Highly active analog I, which lacks the thiazole group of dolastatin 10, was selected for further development as an antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow5K2LB02S6rVg90H21EOLACvtfcHk0lheUQrBTbKP_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpsF2nsbo%253D&md5=65ec18527a369b245d865a87cc7bb638</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1248%2Fcpb.43.1706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.43.1706%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DNatsume%26aufirst%3DT.%26aulast%3DGondo%26aufirst%3DM.%26aulast%3DMikami%26aufirst%3DT.%26aulast%3DSakakibara%26aufirst%3DK.%26aulast%3DTsukagoshi%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520antitumor%2520activity%2520of%2520novel%2520dolastatin%252010%2520analogs%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1995%26volume%3D43%26spage%3D1706%26epage%3D1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natsume, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamaoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyasaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakakibara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukagoshi, S.</span><span> </span><span class="NLM_article-title">Antitumor activity of TZT-1027, a novel dolastatin 10 derivative</span> <span class="citation_source-journal">Jpn. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1111%2Fj.1349-7006.1997.tb00383.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=9140117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK2sXit1ajs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1997&pages=316-327&author=M.+Kobayashiauthor=T.+Natsumeauthor=S.+Tamaokiauthor=J.+Watanabeauthor=H.+Asanoauthor=T.+Mikamiauthor=K.+Miyasakaauthor=K.+Miyazakiauthor=M.+Gondoauthor=K.+Sakakibaraauthor=S.+Tsukagoshi&title=Antitumor+activity+of+TZT-1027%2C+a+novel+dolastatin+10+derivative"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of TZT-1027, a novel dolastatin 10 derivative</span></div><div class="casAuthors">Kobayashi, Motohiro; Natsume, Tsugitaka; Tamaoki, Satoru; Watanabe, Jun-Ichi; Asano, Hajime; Mikami, Takashi; Miyasaka, Katsuhiko; Miyazaki, Koichi; Gondo, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">316-327</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">Dolastatin 10, a pentapeptide isolated from the marine mollusk Dolabella auricularia, has antitumor activity.  TZT-1027, a dolastatin 10 deriv., is a newly synthesized antitumor compd.  The authors evaluated its antitumor activity against a variety of transplantable tumors in mice.  Intermittent injections of TZT-1027 were more effective than single or repeated injections in mice with P388 leukemia and B16 melanoma.  Consequently, TZT-1027 shows schedule dependency.  TZT-1027 was effective against P388 leukemia not only when administered i.p., but also when given i.v.  However, although TZT-1027 given i.v. was active against murine solid tumors, TZT-1027 administered i.p. was ineffective against all the tumors tested with the exception of colon 26 adenocarcinoma.  The i.v. injection of TZT-1027 at a dose of 2.0 mg/kg remarkably inhibited the growth of three murine solid tumors; colon 26 adenocarcinoma, B16 melanoma and M5076 sarcoma, with T/C values of less than 6%.  The antitumor activities of TZT-1027 against these tumors were superior or comparable to those of the ref. agents; dolastatin 10, cisplatin, vincristine, 5-fluorouracil (5-FU) and E7010.  In expts. with drug-resistant P388 leukemia, TZT-1027 showed good activity against cisplatin-resistant P388 and moderate activity against vincristine- and 5-fluorouracil-resistant P388, but no activity against adriamycin-resistant P388.  TZT-1027 was also effective against human xenografts, i.e., tumor regression was obsd. in mice bearing MX-1 breast and LX-1 lung carcinomas.  TZT-1027 at 10μM almost completely inhibited the assembly of porcine brain microtubules.  Therefore, its mechanism of antitumor action seems to be, at least in part, ascribable to the inhibition of microtubule assembly.  Because of its good preclin. activity, TZT-1027 has been entered into phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVQBYoGhWZvbVg90H21EOLACvtfcHk0liW6iN1n51_RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1ajs7k%253D&md5=9938db363d0b24f2ad41f005190faa44</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.1997.tb00383.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.1997.tb00383.x%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DNatsume%26aufirst%3DT.%26aulast%3DTamaoki%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DAsano%26aufirst%3DH.%26aulast%3DMikami%26aufirst%3DT.%26aulast%3DMiyasaka%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DK.%26aulast%3DGondo%26aufirst%3DM.%26aulast%3DSakakibara%26aufirst%3DK.%26aulast%3DTsukagoshi%26aufirst%3DS.%26atitle%3DAntitumor%2520activity%2520of%2520TZT-1027%252C%2520a%2520novel%2520dolastatin%252010%2520derivative%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D1997%26volume%3D88%26spage%3D316%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srirangam, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barkoczy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkin, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapuis, J. C.</span><span> </span><span class="NLM_article-title">Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=7495477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVSmurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1995&pages=529-544&author=G.+R.+Pettitauthor=J.+K.+Srirangamauthor=J.+Barkoczyauthor=M.+D.+Williamsauthor=K.+P.+Durkinauthor=M.+R.+Boydauthor=R.+Baiauthor=E.+Hamelauthor=J.+M.+Schmidtauthor=J.+C.+Chapuis&title=Antineoplastic+agents+337.+Synthesis+of+dolastatin+10+structural+modifications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Antineoplastic agents. 337. Synthesis of dolastatin 10 structural modifications</span></div><div class="casAuthors">Pettit, George R.; Srirangam, Jayaram K.; Barkoczy, Jozsef; Williams, Michael D.; Durkin, Kieran P. M.; Boyd, Michael R.; Bai, Ruoli; Hamel, Ernest; Schmidt, Jean M.; Chapius, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drug Design</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">529-44</span>CODEN:
                <span class="NLM_cas:coden">ACDDEA</span>;
        ISSN:<span class="NLM_cas:issn">0266-9536</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">New structural modifications of the marine mollusk peptide constituent dolastatin 10 have been synthesized and evaluated against a variety of cancer cell lines and for their ability to inhibit tubulin polymn.  A no. of useful structure-activity relationships were uncovered.  The most important observation was that the dolaphenine unit of dolastatin 10 could be satisfactorily replaced with a phenethylamine.  Peptide I, designated auristatin PE, was found to exhibit inhibition of cancer cell growth and tubulin assembly comparable to that of dolastatin 10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmifKCOnza3bVg90H21EOLACvtfcHk0liW6iN1n51_RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVSmurbL&md5=8414966374d41e9e82c88900b47f4c7c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSrirangam%26aufirst%3DJ.%2BK.%26aulast%3DBarkoczy%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DM.%2BD.%26aulast%3DDurkin%26aufirst%3DK.%2BP.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DSchmidt%26aufirst%3DJ.%2BM.%26aulast%3DChapuis%26aufirst%3DJ.%2BC.%26atitle%3DAntineoplastic%2520agents%2520337.%2520Synthesis%2520of%2520dolastatin%252010%2520structural%2520modifications%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D1995%26volume%3D10%26spage%3D529%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Flahive, E.; Srirangam, J.</span><span> </span><span class="NLM_article-title">The dolastatins</span>. In  <span class="citation_source-book">Anticancer Agents from Natural Products</span>, <span class="NLM_edition">2nd</span> ed.; <span class="NLM_contrib-group">Cragg, D. J.; Kingston, G. M.; Newman, D. G. I.</span>, Eds.; <span class="NLM_publisher-name">CRC Press</span>: <span class="NLM_publisher-loc">Boca Raton, FL</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1201%2Fb11185-12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=263-290&author=E.+Flahive&author=J.+Srirangamauthor=D.+J.+Cragg&author=G.+M.+Kingston&author=D.+G.+I.+Newman&title=Anticancer+Agents+from+Natural+Products"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1201%2Fb11185-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1201%252Fb11185-12%26sid%3Dliteratum%253Aachs%26aulast%3DFlahive%26aufirst%3DE.%26atitle%3DThe%2520dolastatins%26btitle%3DAnticancer%2520Agents%2520from%2520Natural%2520Products%26aulast%3DCragg%26aufirst%3DD.%2BJ.%26pub%3DCRC%2520Press%26date%3D2011%26spage%3D263%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Pettit, G. R.; Srirangam, J. K.</span><span> </span><span class="NLM_article-title">Preparation of pentapeptides as neoplasm inhibitors</span>. Can. Pat. Appl. CA 2114156,<span class="NLM_x"> </span><span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=G.+R.+Pettit&author=J.+K.+Srirangam&title=Preparation+of+pentapeptides+as+neoplasm+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26atitle%3DPreparation%2520of%2520pentapeptides%2520as%2520neoplasm%2520inhibitors%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Pettit, G. R.; Barkoczy, J.</span><span> </span><span class="NLM_article-title">Preparation of tumor inhibiting tetrapeptide phenethylamides</span>. Eur. Pat. Appl. EP 600744,<span class="NLM_x"> </span><span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=G.+R.+Pettit&author=J.+Barkoczy&title=Preparation+of+tumor+inhibiting+tetrapeptide+phenethylamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26atitle%3DPreparation%2520of%2520tumor%2520inhibiting%2520tetrapeptide%2520phenethylamides%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Doronina, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torgov, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chace, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeBlanc, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gearing, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bovee, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegall, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francisco, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Development of potent monoclonal antibody auristatin conjugates for cancer therapy</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">778</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1038%2Fnbt832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=12778055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=778-784&author=S.+O.+Doroninaauthor=B.+E.+Tokiauthor=M.+Y.+Torgovauthor=B.+A.+Mendelsohnauthor=C.+G.+Cervenyauthor=D.+F.+Chaceauthor=R.+L.+DeBlancauthor=R.+P.+Gearingauthor=T.+D.+Boveeauthor=C.+B.+Siegallauthor=J.+A.+Franciscoauthor=A.+F.+Wahlauthor=D.+L.+Meyerauthor=P.+D.+Senter&title=Development+of+potent+monoclonal+antibody+auristatin+conjugates+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Development of potent monoclonal antibody auristatin conjugates for cancer therapy</span></div><div class="casAuthors">Doronina, Svetlana O.; Toki, Brian E.; Torgov, Michael Y.; Mendelsohn, Brian A.; Cerveny, Charles G.; Chace, Dana F.; DeBlanc, Ron L.; Gearing, R. Patrick; Bovee, Tim D.; Siegall, Clay B.; Francisco, Joseph A.; Wahl, Alan F.; Meyer, Damon L.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">778-784</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylauristatin E (MMAE), linked to the chimeric mAbs cBR96 (specific to Lewis Y on carcinomas) and cAC10 (specific to CD30 on hematol. malignancies).  The linkers used for conjugate formation included an acid-labile hydrazone and protease-sensitive dipeptides, leading to uniformly substituted conjugates that efficiently released active drug in the lysosomes of antigen-pos. (Ag+) tumor cells.  The peptide-linked mAb-valine-citrulline-MMAE and mAb-phenylalanine-lysine-MMAE conjugates were much more stable in buffers and plasma than the conjugates of mAb and the hydrazone of 5-benzoylvaleric acid-AE ester (AEVB).  As a result, the mAb-Val-Cit-MMAE conjugates exhibited greater in vitro specificity and lower in vivo toxicity than corresponding hydrazone conjugates.  In vivo studies demonstrated that the peptide-linked conjugates induced regressions and cures of established tumor xenografts with therapeutic indexes as high as 60-fold.  These conjugates illustrate the importance of linker technol., drug potency and conjugation methodol. in developing safe and efficacious mAb-drug conjugates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro97SFKtdQ7rVg90H21EOLACvtfcHk0liW6iN1n51_RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D&md5=d77716ec93de5ac7473c18a597339086</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt832%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DTorgov%26aufirst%3DM.%2BY.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DChace%26aufirst%3DD.%2BF.%26aulast%3DDeBlanc%26aufirst%3DR.%2BL.%26aulast%3DGearing%26aufirst%3DR.%2BP.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DSiegall%26aufirst%3DC.%2BB.%26aulast%3DFrancisco%26aufirst%3DJ.%2BA.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DDevelopment%2520of%2520potent%2520monoclonal%2520antibody%2520auristatin%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DNature%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D778%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievers, E. L.</span><span> </span><span class="NLM_article-title">The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">631</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1038%2Fnbt.2289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=22781692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=631-637&author=P.+D.+Senterauthor=E.+L.+Sievers&title=The+discovery+and+development+of+brentuximab+vedotin+for+use+in+relapsed+Hodgkin+lymphoma+and+systemic+anaplastic+large+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma</span></div><div class="casAuthors">Senter, Peter D.; Sievers, Eric L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-637</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Progress was made recently in developing antibody-drug conjugates (ADCs) that can selectively deliver cancer drugs to tumor cells.  In principle, the idea is simple: by attaching drugs to tumor-seeking antibodies, target cells will be killed and nontarget cells will be spared.  In practice, many parameters needed to be addressed to develop safe and effective ADCs, including the expression profiles of tumor vs. normal tissues, the potency of the drug, the linker attaching the drug and placement of the drug on the antibody, and the pharmacokinetic and stability profiles of the resulting ADC.  All these issues had been taken into account in developing brentuximab vedotin (Adcetris), an ADC that recently received accelerated approval by the US Food and Drug Administration for the treatment of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).  Research is under way to extend the applications of brentuximab vedotin and to advance the field by developing other ADCs with new linker and conjugation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyPib6JxGsSrVg90H21EOLACvtfcHk0limi3Qgn2kpVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D&md5=6940eb8178e8c8c150a7b21361e23234</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2289%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DSievers%26aufirst%3DE.%2BL.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520brentuximab%2520vedotin%2520for%2520use%2520in%2520relapsed%2520Hodgkin%2520lymphoma%2520and%2520systemic%2520anaplastic%2520large%2520cell%2520lymphoma%26jtitle%3DNature%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D631%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span> </span><span class="NLM_article-title">Antibody–drug conjugates: an emerging concept in cancer therapy</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3796</span><span class="NLM_x">–</span> <span class="NLM_lpage">827</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-827&author=R.+V.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody%E2%80%93drug+conjugates%3A+an+emerging+concept+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugates%253A%2520an%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Doronina, S. O.; Mendelsohn, B. A.</span><span> </span><span class="NLM_article-title">Preparation of auristatins having an aminobenzoic acid unit at the N terminus</span>. PCT Int. Appl. WO 2006132670,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=S.+O.+Doronina&author=B.+A.+Mendelsohn&title=Preparation+of+auristatins+having+an+aminobenzoic+acid+unit+at+the+N+terminus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26atitle%3DPreparation%2520of%2520auristatins%2520having%2520an%2520aminobenzoic%2520acid%2520unit%2520at%2520the%2520N%2520terminus%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Pettit, G. R.; Williams, M. D.; Srirangam, J. K.</span><span> </span><span class="NLM_article-title">Preparation of dolastatin analog pentapeptide methyl esters as anticancer agents</span>. Eur. Pat. Appl. EP 695759,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=G.+R.+Pettit&author=M.+D.+Williams&author=J.+K.+Srirangam&title=Preparation+of+dolastatin+analog+pentapeptide+methyl+esters+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26atitle%3DPreparation%2520of%2520dolastatin%2520analog%2520pentapeptide%2520methyl%2520esters%2520as%2520anticancer%2520agents%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Mendelsohn, B. A.; Barnscher, S. D.</span><span> </span><span class="NLM_article-title">Preparation of substituted peptide analogs as tubulin polymerization inhibitors for treating cancers</span>. U.S. Pat. Appl. Publ. US 20130190248,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=B.+A.+Mendelsohn&author=S.+D.+Barnscher&title=Preparation+of+substituted+peptide+analogs+as+tubulin+polymerization+inhibitors+for+treating+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26atitle%3DPreparation%2520of%2520substituted%2520peptide%2520analogs%2520as%2520tubulin%2520polymerization%2520inhibitors%2520for%2520treating%2520cancers%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Miao, Z.; Hong, Y.; Zhu, T.</span><span> </span><span class="NLM_article-title">Preparation of drug-conjugates, particularly peptide derivative–antibody conjugates, and their uses for treating cancers</span>. PCT Int. Appl. WO 2013173393,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Z.+Miao&author=Y.+Hong&author=T.+Zhu&title=Preparation+of+drug-conjugates%2C+particularly+peptide+derivative%E2%80%93antibody+conjugates%2C+and+their+uses+for+treating+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DZ.%26atitle%3DPreparation%2520of%2520drug-conjugates%252C%2520particularly%2520peptide%2520derivative%25E2%2580%2593antibody%2520conjugates%252C%2520and%2520their%2520uses%2520for%2520treating%2520cancers%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Gajula, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asthana, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborty, T. K.</span><span> </span><span class="NLM_article-title">A synthetic dolastatin 10 analogue suppresses microtubule dynamics, inhibits cell proliferation, and induces apoptotic cell death</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2235</span><span class="NLM_x">–</span> <span class="NLM_lpage">2245</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3009629" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2235-2245&author=P.+K.+Gajulaauthor=J.+Asthanaauthor=D.+Pandaauthor=T.+K.+Chakraborty&title=A+synthetic+dolastatin+10+analogue+suppresses+microtubule+dynamics%2C+inhibits+cell+proliferation%2C+and+induces+apoptotic+cell+death"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm3009629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009629%26sid%3Dliteratum%253Aachs%26aulast%3DGajula%26aufirst%3DP.%2BK.%26aulast%3DAsthana%26aufirst%3DJ.%26aulast%3DPanda%26aufirst%3DD.%26aulast%3DChakraborty%26aufirst%3DT.%2BK.%26atitle%3DA%2520synthetic%2520dolastatin%252010%2520analogue%2520suppresses%2520microtubule%2520dynamics%252C%2520inhibits%2520cell%2520proliferation%252C%2520and%2520induces%2520apoptotic%2520cell%2520death%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2235%26epage%3D2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Park, Y. J.; Jeong, J. K.; Choi, Y. M.; Lee, M. S.; Choi, J. H.; Cho, E. J.; Song, H.; Park, S. J.; Lee, J.-H.; Hong, S. S.</span><span> </span><span class="NLM_article-title">Dolastatin-10 derivative as anticancer agent and preparation method thereof</span>. PCT Int. Appl. WO 2014046441,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Y.+J.+Park&author=J.+K.+Jeong&author=Y.+M.+Choi&author=M.+S.+Lee&author=J.+H.+Choi&author=E.+J.+Cho&author=H.+Song&author=S.+J.+Park&author=J.-H.+Lee&author=S.+S.+Hong&title=Dolastatin-10+derivative+as+anticancer+agent+and+preparation+method+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DY.%2BJ.%26atitle%3DDolastatin-10%2520derivative%2520as%2520anticancer%2520agent%2520and%2520preparation%2520method%2520thereof%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Harrigan, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luesch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valeriote, F. A.</span><span> </span><span class="NLM_article-title">Symplostatin 1: a dolastatin 10 analogue from the marine cyanobacterium <i>Symploca hydnoides</i></span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1075</span><span class="NLM_x">–</span> <span class="NLM_lpage">1077</span></span><div class="citationLinks">[<a href="/doi/10.1021/np980321c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1998&pages=1075-1077&author=G.+G.+Harriganauthor=H.+Lueschauthor=W.+Y.+Yoshidaauthor=R.+E.+Mooreauthor=D.+G.+Nagleauthor=V.+J.+Paulauthor=S.+L.+Mooberryauthor=T.+H.+Corbettauthor=F.+A.+Valeriote&title=Symplostatin+1%3A+a+dolastatin+10+analogue+from+the+marine+cyanobacterium+Symploca+hydnoides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fnp980321c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp980321c%26sid%3Dliteratum%253Aachs%26aulast%3DHarrigan%26aufirst%3DG.%2BG.%26aulast%3DLuesch%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DW.%2BY.%26aulast%3DMoore%26aufirst%3DR.%2BE.%26aulast%3DNagle%26aufirst%3DD.%2BG.%26aulast%3DPaul%26aufirst%3DV.%2BJ.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DCorbett%26aufirst%3DT.%2BH.%26aulast%3DValeriote%26aufirst%3DF.%2BA.%26atitle%3DSymplostatin%25201%253A%2520a%2520dolastatin%252010%2520analogue%2520from%2520the%2520marine%2520cyanobacterium%2520Symploca%2520hydnoides%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D1998%26volume%3D61%26spage%3D1075%26epage%3D1077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Hamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioiri, T.</span><span> </span><span class="NLM_article-title">Efficient stereoselective synthesis of dolastatin 10, an antineoplastic peptide from a sea hare</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">931</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1991&pages=931-934&author=Y.+Hamadaauthor=K.+Hayashiauthor=T.+Shioiri&title=Efficient+stereoselective+synthesis+of+dolastatin+10%2C+an+antineoplastic+peptide+from+a+sea+hare"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamada%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DShioiri%26aufirst%3DT.%26atitle%3DEfficient%2520stereoselective%2520synthesis%2520of%2520dolastatin%252010%252C%2520an%2520antineoplastic%2520peptide%2520from%2520a%2520sea%2520hare%26jtitle%3DTetrahedron%2520Lett.%26date%3D1991%26volume%3D32%26spage%3D931%26epage%3D934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Mordant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reymond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tone, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavergne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Touati, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben Hassine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratovelomanana-Vidal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genet, J. P.</span><span> </span><span class="NLM_article-title">Total synthesis of dolastatin 10 through ruthenium-catalyzed asymmetric hydrogenations</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">6115</span><span class="NLM_x">–</span> <span class="NLM_lpage">6123</span><div class="note"><p class="first last">and references therein.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=6115-6123&author=C.+Mordantauthor=S.+Reymondauthor=H.+Toneauthor=D.+Lavergneauthor=R.+Touatiauthor=B.+Ben+Hassineauthor=V.+Ratovelomanana-Vidalauthor=J.+P.+Genet&title=Total+synthesis+of+dolastatin+10+through+ruthenium-catalyzed+asymmetric+hydrogenations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMordant%26aufirst%3DC.%26aulast%3DReymond%26aufirst%3DS.%26aulast%3DTone%26aufirst%3DH.%26aulast%3DLavergne%26aufirst%3DD.%26aulast%3DTouati%26aufirst%3DR.%26aulast%3DBen%2BHassine%26aufirst%3DB.%26aulast%3DRatovelomanana-Vidal%26aufirst%3DV.%26aulast%3DGenet%26aufirst%3DJ.%2BP.%26atitle%3DTotal%2520synthesis%2520of%2520dolastatin%252010%2520through%2520ruthenium-catalyzed%2520asymmetric%2520hydrogenations%26jtitle%3DTetrahedron%26date%3D2007%26volume%3D63%26spage%3D6115%26epage%3D6123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Kline, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torgov, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/doi/10.1021/mp0340183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFWgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=9-22&author=T.+Klineauthor=M.+Y.+Torgovauthor=B.+A.+Mendelsohnauthor=C.+G.+Cervenyauthor=P.+D.+Senter&title=Novel+antitumor+prodrugs+designed+for+activation+by+matrix+metalloproteinases-2+and+-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Antitumor Prodrugs Designed for Activation by Matrix Metalloproteinases-2 and -9</span></div><div class="casAuthors">Kline, Toni; Torgov, Michael Y.; Mendelsohn, Brian A.; Cerveny, Charles G.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Enzyme prodrug monotherapy takes advantage of the selectivity and specificity of enzymes that are differentially active in the immediate environment of tumor cells.  Matrix metalloproteinases-2 and -9 (MMP-2 and -9, resp.) are cell-surface Zn-dependent endoproteases assocd. with diverse processes throughout tumor formation and progression.  These enzymes have demonstrated high ratios of tumor- to nontumor-assocd. activity and may represent candidates for antitumor prodrug activation.  Our MMP targeting strategy was to prep. and evaluate two classes of enzyme prodrugs, peptides and sequence-similar peptidomimetics, and det. which would be substrates for the enzymes and thus suitable for further in vitro and in vivo evaluation.  We selected representatives of three structurally and mechanistically distinct classes of compds. for delivery, doxorubicin, several auristatins (novel synthetic members of the dolastatin class of tubulin polymn. inhibitors), and CBI-TMI (a duocarmycin class minor groove binder).  The drugs were acylated on available amines with the broadly recognized MMP substrate P3-P1' sequence acetyl L-prolyl-L-leucyl-glycyl-L-leucine, or with a peptidomimetic analog.  From a panel of four peptides and four peptidomimetics, two compds., both peptides, were substrates, with specific activities in the range of 1-20 nmol min-1 mg-1.  For MMP-9, complete conversion took place in 4-16 h; proteolysis by MMP-2 was considerably slower.  Cleavage occurred, as predicted, at the Gly-Leu bond to liberate a leucyl drug, and no other intermediates or cleavage products were obsd.  Although the MMP-9 proteolysis products were equipotent with the parent leucyl drugs, the prodrugs were not differentially active against MMP-2 or -9-expressing vs. nonexpressing cell lines during a 4 h exposure.  Our data can be interpreted in light of the current understanding of the structural and mechanistic factors governing MMP-2 and -9 proteolysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEXjORYIieZbVg90H21EOLACvtfcHk0lh0pfSwj3uM-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFWgsQ%253D%253D&md5=280d81ea08a896e112521576a211f0d4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fmp0340183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp0340183%26sid%3Dliteratum%253Aachs%26aulast%3DKline%26aufirst%3DT.%26aulast%3DTorgov%26aufirst%3DM.%2BY.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DNovel%2520antitumor%2520prodrugs%2520designed%2520for%2520activation%2520by%2520matrix%2520metalloproteinases-2%2520and%2520-9%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2004%26volume%3D1%26spage%3D9%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Venkatraman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankaramma, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balaram, P.</span><span> </span><span class="NLM_article-title">Design of Folded Peptides</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">3131</span><span class="NLM_x">–</span> <span class="NLM_lpage">3152</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr000053z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmslOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2001&pages=3131-3152&author=J.+Venkatramanauthor=S.+C.+Shankarammaauthor=P.+Balaram&title=Design+of+Folded+Peptides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Folded Peptides</span></div><div class="casAuthors">Venkatraman, Janani; Shankaramma, Sasalu C.; Balaram, Padmanabhan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3131-3152</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with refs.  The construction of complex protein folds relies on the precise conversion of a linear polypeptide chain into a compact 3-dimensional structure.  The interplay of forces that link sequence and folding is intricate and yet to be firmly elucidated.  Here, we attempt to review the various approaches used to construct isolated secondary structural modules and to assemble them into compact tertiary on structures with defined folds and at times, function.  Approaches that emphasize stereochem. control over polypeptide chain folding are considered in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY3RihGQo88LVg90H21EOLACvtfcHk0ljtmzMYxqL2fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmslOhtbs%253D&md5=7b47943dcb9f16cfe9ca44b8edc87a09</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fcr000053z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr000053z%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DJ.%26aulast%3DShankaramma%26aufirst%3DS.%2BC.%26aulast%3DBalaram%26aufirst%3DP.%26atitle%3DDesign%2520of%2520Folded%2520Peptides%26jtitle%3DChem.%2520Rev.%26date%3D2001%26volume%3D101%26spage%3D3131%26epage%3D3152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Mukhtar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adhami, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhtar, H.</span><span> </span><span class="NLM_article-title">Targeting microtubules by natural agents for cancer therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1158%2F1535-7163.MCT-13-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=24435445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=275-284&author=E.+Mukhtarauthor=V.+M.+Adhamiauthor=H.+Mukhtar&title=Targeting+microtubules+by+natural+agents+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Microtubules by Natural Agents for Cancer Therapy</span></div><div class="casAuthors">Mukhtar, Eiman; Adhami, Vaqar Mustafa; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural compds. that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death.  Our improved understanding of tumor biol. and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer.  The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance.  Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs.  Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer.  This review focuses on the successful cancer chemotherapy from natural compds. in clin. settings and the challenges that may abort their usefulness.  Mol Cancer Ther; 13(2); 275-84. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZOcnk6gaB7Vg90H21EOLACvtfcHk0ljtmzMYxqL2fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D&md5=0a14655cff81c9d3a73c0b4514e45112</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0791%26sid%3Dliteratum%253Aachs%26aulast%3DMukhtar%26aufirst%3DE.%26aulast%3DAdhami%26aufirst%3DV.%2BM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DTargeting%2520microtubules%2520by%2520natural%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D275%26epage%3D284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umland, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebhard, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, J. J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">4974</span><span class="NLM_x">–</span> <span class="NLM_lpage">4985</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-Kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0ljtmzMYxqL2fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curmi, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Barbey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charbaut, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebeau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siavoshian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">The 4A X-ray structure of a tubulin:stathmin-like domain complex</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=809-816&author=B.+Gigantauthor=P.+A.+Curmiauthor=C.+Martin-Barbeyauthor=E.+Charbautauthor=S.+Lachkarauthor=L.+Lebeauauthor=S.+Siavoshianauthor=A.+Sobelauthor=M.+Knossow&title=The+4A+X-ray+structure+of+a+tubulin%3Astathmin-like+domain+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DMartin-Barbey%26aufirst%3DC.%26aulast%3DCharbaut%26aufirst%3DE.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DLebeau%26aufirst%3DL.%26aulast%3DSiavoshian%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DThe%25204A%2520X-ray%2520structure%2520of%2520a%2520tubulin%253Astathmin-like%2520domain%2520complex%26jtitle%3DCell%26date%3D2000%26volume%3D102%26spage%3D809%26epage%3D816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Ranaivoson, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berritt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joullié, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">Structural plasticity of tubulin assembly probed by vinca-domain ligands</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">927</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=927-934&author=F.+M.+Ranaivosonauthor=B.+Gigantauthor=S.+Berrittauthor=M.+Joulli%C3%A9author=M.+Knossow&title=Structural+plasticity+of+tubulin+assembly+probed+by+vinca-domain+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRanaivoson%26aufirst%3DF.%2BM.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DBerritt%26aufirst%3DS.%26aulast%3DJoulli%25C3%25A9%26aufirst%3DM.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DStructural%2520plasticity%2520of%2520tubulin%2520assembly%2520probed%2520by%2520vinca-domain%2520ligands%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2012%26volume%3D8%26spage%3D927%26epage%3D934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Nawrotek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span> </span><span class="NLM_article-title">The determinants that govern microtubule assembly from the atomic structure of GTP-tubulin</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">412</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=412&publication_year=2011&pages=35-42&author=A.+Nawrotekauthor=M.+Knossowauthor=B.+Gigant&title=The+determinants+that+govern+microtubule+assembly+from+the+atomic+structure+of+GTP-tubulin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNawrotek%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26aulast%3DGigant%26aufirst%3DB.%26atitle%3DThe%2520determinants%2520that%2520govern%2520microtubule%2520assembly%2520from%2520the%2520atomic%2520structure%2520of%2520GTP-tubulin%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D412%26spage%3D35%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Kang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, H. S.</span><span> </span><span class="NLM_article-title">Internal rotation about the C–N bond of amides</span> <span class="citation_source-journal">J. Mol. Struct.: THEOCHEM</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">676</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1016%2Fj.theochem.2004.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVCrs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=676&publication_year=2004&pages=171-176&author=Y.+K.+Kangauthor=H.+S.+Park&title=Internal+rotation+about+the+C%E2%80%93N+bond+of+amides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Internal rotation about the C-N bond of amides</span></div><div class="casAuthors">Kang, Young Kee; Park, Hae Sook</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Structure: THEOCHEM</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">676</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">THEODJ</span>;
        ISSN:<span class="NLM_cas:issn">0166-1280</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The internal rotation about the C-N bond of formamide (FA), acetamide (AA), N-methylformamide (NMF), N-methylacetamide (NMA), N,N-dimethylformamide (DMF) and N,N-dimethylacetamide (DMA) in the gas phase, chloroform and water was studied at the HF level of theory with 6-31G(d), 6-31G(d,p) and 6-31+G(d) basis sets to figure out the appropriate level of theory in describing the cis-trans isomerization of the X-noPro and X-Pro peptide bonds.  The conductor-like polarizable continuum model (CPCM) was used to calc. solvation free energies.  The conformational electronic energies calcd. at three levels predicted satisfactorily the exptl. rotational barriers ΔG‡ of FA, DMF and DMA, and the obsd. relative enthalpy changes ΔHcis/trans of cis conformers for NMF and NMA to trans ones in the gas phase.  The CPCM method at the HF/6-31+G(d) level predicted well exptl. solvation free energies of acetamide derivs.  The ΔG‡ for FA, NMF, DMF, NMA and DMA, and ΔHcis/trans for NMF and NMA in chloroform and water were satisfactorily described by the CPCM method at HF/6-31G(d) and HF/6-31+G(d) levels.  These results may indicate that the HF/6-31+G(d) level with the CPCM method appears to be the appropriate method in describing the cis-trans isomerization of the X-noPro and X-Pro peptide bonds in solns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqae2PkymIb9bVg90H21EOLACvtfcHk0ljgjEvp97uTUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVCrs7g%253D&md5=01b0dd7f28314ac58adb7aa5ce5fddea</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.theochem.2004.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.theochem.2004.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DPark%26aufirst%3DH.%2BS.%26atitle%3DInternal%2520rotation%2520about%2520the%2520C%25E2%2580%2593N%2520bond%2520of%2520amides%26jtitle%3DJ.%2520Mol.%2520Struct.%253A%2520THEOCHEM%26date%3D2004%26volume%3D676%26spage%3D171%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Alattia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poncet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cave, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouin, P.</span><span> </span><span class="NLM_article-title">Conformational study of dolastatin 10</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2593</span><span class="NLM_x">–</span> <span class="NLM_lpage">2604</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1995&pages=2593-2604&author=T.+Alattiaauthor=F.+Rouxauthor=J.+Poncetauthor=A.+Caveauthor=P.+Jouin&title=Conformational+study+of+dolastatin+10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlattia%26aufirst%3DT.%26aulast%3DRoux%26aufirst%3DF.%26aulast%3DPoncet%26aufirst%3DJ.%26aulast%3DCave%26aufirst%3DA.%26aulast%3DJouin%26aufirst%3DP.%26atitle%3DConformational%2520study%2520of%2520dolastatin%252010%26jtitle%3DTetrahedron%26date%3D1995%26volume%3D51%26spage%3D2593%26epage%3D2604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Benedetti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraternali, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolillo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioiri, T.</span><span> </span><span class="NLM_article-title">Conformational analysis of dolastatin 10: an NMR and theoretical approach</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1995&pages=525-538&author=E.+Benedettiauthor=T.+Carlomagnoauthor=F.+Fraternaliauthor=Y.+Hamadaauthor=K.+Hayashiauthor=L.+Paolilloauthor=T.+Shioiri&title=Conformational+analysis+of+dolastatin+10%3A+an+NMR+and+theoretical+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenedetti%26aufirst%3DE.%26aulast%3DCarlomagno%26aufirst%3DT.%26aulast%3DFraternali%26aufirst%3DF.%26aulast%3DHamada%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DPaolillo%26aufirst%3DL.%26aulast%3DShioiri%26aufirst%3DT.%26atitle%3DConformational%2520analysis%2520of%2520dolastatin%252010%253A%2520an%2520NMR%2520and%2520theoretical%2520approach%26jtitle%3DBiopolymers%26date%3D1995%26volume%3D35%26spage%3D525%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirangam, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E. J.</span><span> </span><span class="NLM_article-title">The Dolastatins. 21. Synthesis, X-ray crystal structure, and molecular modeling of (6<i>R</i>)-isodolastatin 10</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">6127</span><span class="NLM_x">–</span> <span class="NLM_lpage">6130</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00100a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1994&pages=6127-6130&author=G.+R.+Pettitauthor=J.+K.+Sirangamauthor=D.+L.+Heraldauthor=E.+J.+Hamel&title=The+Dolastatins.+21.+Synthesis%2C+X-ray+crystal+structure%2C+and+molecular+modeling+of+%286R%29-isodolastatin+10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjo00100a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00100a001%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSirangam%26aufirst%3DJ.%2BK.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DHamel%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520Dolastatins.%252021.%2520Synthesis%252C%2520X-ray%2520crystal%2520structure%252C%2520and%2520molecular%2520modeling%2520of%2520%25286R%2529-isodolastatin%252010%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1994%26volume%3D59%26spage%3D6127%26epage%3D6130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Pauletti, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangwar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siahaan, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aube, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borchardt, R. T.</span><span> </span><span class="NLM_article-title">Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=235-256&author=G.+M.+Paulettiauthor=S.+Gangwarauthor=T.+J.+Siahaanauthor=J.+Aubeauthor=R.+T.+Borchardt&title=Improvement+of+oral+peptide+bioavailability%3A+Peptidomimetics+and+prodrug+strategies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPauletti%26aufirst%3DG.%2BM.%26aulast%3DGangwar%26aufirst%3DS.%26aulast%3DSiahaan%26aufirst%3DT.%2BJ.%26aulast%3DAube%26aufirst%3DJ.%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26atitle%3DImprovement%2520of%2520oral%2520peptide%2520bioavailability%253A%2520Peptidomimetics%2520and%2520prodrug%2520strategies%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D27%26spage%3D235%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Obach, S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0ljgjEvp97uTUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Han, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopal, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramchandren, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matous, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grove, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, O. A.</span><span> </span><span class="NLM_article-title">CYP3A-mediated drug–drug interaction potential and excretion of brentuximab vedotin, an antibody–drug conjugate, in patients with CD30-positive hematologic malignancies</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">866</span><span class="NLM_x">–</span> <span class="NLM_lpage">877</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1002%2Fjcph.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=23754575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A280%3ADC%252BC3sjht1eksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=866-877&author=T.+H.+Hanauthor=A.+K.+Gopalauthor=R.+Ramchandrenauthor=A.+Goyauthor=R.+Chenauthor=J.+V.+Matousauthor=M.+Cooperauthor=L.+E.+Groveauthor=S.+C.+Alleyauthor=C.+M.+Lynchauthor=O.+A.+O%E2%80%99Connor&title=CYP3A-mediated+drug%E2%80%93drug+interaction+potential+and+excretion+of+brentuximab+vedotin%2C+an+antibody%E2%80%93drug+conjugate%2C+in+patients+with+CD30-positive+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies</span></div><div class="casAuthors">Han Tae H; Gopal Ajay K; Ramchandren Radhakrishnan; Goy Andre; Chen Robert; Matous Jeffrey V; Cooper Maureen; Grove Laurie E; Alley Stephen C; Lynch Carmel M; O'Connor Owen A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">866-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells.  This study evaluated the CYP3A-mediated drug-drug interaction potential of brentuximab vedotin and the excretion of MMAE.  Two 21-day cycles of brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) were administered to 56 patients with CD30-positive hematologic malignancies.  Each patient also received either a sensitive CYP3A substrate (midazolam), an effective inducer (rifampin), or a strong inhibitor (ketoconazole).  Brentuximab vedotin did not affect midazolam exposures.  ADC exposures were unaffected by concomitant rifampin or ketoconazole; however, MMAE exposures were lower with rifampin and higher with ketoconazole.  The short-term safety profile of brentuximab vedotin in this study was generally consistent with historic clinical observations.  The most common adverse events were nausea, fatigue, diarrhea, headache, pyrexia, and neutropenia.  Over a 1-week period, ∼23.5% of intact MMAE was recovered after administration of brentuximab vedotin; all other species were below the limit of quantitation.  The primary excretion route is via feces (median 72% of the recovered MMAE).  These results suggest that brentuximab vedotin (1.8 mg/kg) and MMAE are neither inhibitors nor inducers of CYP3A; however, MMAE is a substrate of CYP3A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2cCHxNhoKccyail4HZd-ifW6udTcc2eaYutqvwcNYyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjht1eksw%253D%253D&md5=bef9c273df11824115e7f18ea5fd9d7f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fjcph.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.116%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DT.%2BH.%26aulast%3DGopal%26aufirst%3DA.%2BK.%26aulast%3DRamchandren%26aufirst%3DR.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DMatous%26aufirst%3DJ.%2BV.%26aulast%3DCooper%26aufirst%3DM.%26aulast%3DGrove%26aufirst%3DL.%2BE.%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DLynch%26aufirst%3DC.%2BM.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DO.%2BA.%26atitle%3DCYP3A-mediated%2520drug%25E2%2580%2593drug%2520interaction%2520potential%2520and%2520excretion%2520of%2520brentuximab%2520vedotin%252C%2520an%2520antibody%25E2%2580%2593drug%2520conjugate%252C%2520in%2520patients%2520with%2520CD30-positive%2520hematologic%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D53%26spage%3D866%26epage%3D877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Hirth, J.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strawderman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, L. H.</span><span> </span><span class="NLM_article-title">The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1255</span><span class="NLM_x">–</span> <span class="NLM_lpage">1258</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=10778948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtVOqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=1255-1258&author=J.-A.+Hirthauthor=P.+B.+Watkinsauthor=M.+Strawdermanauthor=A.+Schottauthor=R.+Brunoauthor=L.+H.+Baker&title=The+effect+of+an+individual%E2%80%99s+cytochrome+CYP3A4+activity+on+docetaxel+clearance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance</span></div><div class="casAuthors">Hirth, JoAnn; Watkins, Paul B.; Strawderman, Myla; Schott, Anne; Bruno, Rene; Baker, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1255-1258</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Docetaxel is a chemotherapeutic agent effective in the treatment of various solid tumors.  Patients given a std. dose of docetaxel exhibit wide interpatient variation in clearance (CL) and toxic effects.  Docetaxel undergoes metab. by cytochrome CYP3A4.  Thus, interpatient variability in CYP3A4 activity may account in part for differences in toxicity and CL.  Twenty-one heavily pretreated patients with metastatic sarcomas received docetaxel (100 mg/m2).  Hepatic CYP3A4 activity in each patient was measured by the [14C-N-methyl]erythromycin breath test (ERMBT).  Blood samples were taken at selected times over the next 24 h for pharmacokinetic anal.  Phenotypic expression of hepatic CYP3A4 activity measured by the ERMBT varied over 20-fold (administered 14C exhaled in 1 h: mean, 2.53%; range, 0.25-5.35%), which is similar to a normal control population.  CL of docetaxel varied nearly 6-fold (mean, 21.0 L/h/m2; range, 5.4-29.1 L/h/m2).  The ERMBT was the best predictor of CL when compared with serum alanine aminotransferase, albumin, alk. phosphatase, or serum α-1-acidic glycoprotein.  The natural log of ERMBT accounted for 67% of the interpatient variation in CL.  Multivariate anal. showed that the natural log of ERMBT and albumin together accounted for 72% of the interpatient variation in CL.  The greatest toxicity was seen in patients with the lowest ERMBT.  Hepatic CYP3A4 activity is the strongest predictor of docetaxel CL and accounts for the majority of interpatient differences in CL.  Patients with low CYP3A4 activity are at risk for having decreased CL and may thus experience increased toxicity from docetaxel.  Those with high activity may be receiving a suboptimal dose.  By measuring CYP3A4 activity, the ERMBT may be clin. useful in tailoring doses of CYP3A4 substrates, such as docetaxel, in certain individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCaT0kF0BvwbVg90H21EOLACvtfcHk0lhEx0J5QrYOJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtVOqtrw%253D&md5=e17d1f952562d0c9ccb39081dce0e11f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHirth%26aufirst%3DJ.-A.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DStrawderman%26aufirst%3DM.%26aulast%3DSchott%26aufirst%3DA.%26aulast%3DBruno%26aufirst%3DR.%26aulast%3DBaker%26aufirst%3DL.%2BH.%26atitle%3DThe%2520effect%2520of%2520an%2520individual%25E2%2580%2599s%2520cytochrome%2520CYP3A4%2520activity%2520on%2520docetaxel%2520clearance%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2000%26volume%3D6%26spage%3D1255%26epage%3D1258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Doroski, M. D.; Maderna, A.; O’Donnell, C. J.; Subramanyam, C.; Vetelino, B. C.; Dushin, R. G.; Strop, P.; Graziani, E. I.</span><span> </span><span class="NLM_article-title">Preparation of cytotoxic pentapeptides and their antibody drug conjugates for treating cancer</span>. PCT Int. Appl. WO 2013072813,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+D.+Doroski&author=A.+Maderna&author=C.+J.+O%E2%80%99Donnell&author=C.+Subramanyam&author=B.+C.+Vetelino&author=R.+G.+Dushin&author=P.+Strop&author=E.+I.+Graziani&title=Preparation+of+cytotoxic+pentapeptides+and+their+antibody+drug+conjugates+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDoroski%26aufirst%3DM.%2BD.%26atitle%3DPreparation%2520of%2520cytotoxic%2520pentapeptides%2520and%2520their%2520antibody%2520drug%2520conjugates%2520for%2520treating%2520cancer%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barkoczy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srirangam, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantoci, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groy, T. L.</span><span> </span><span class="NLM_article-title">The Dolastatins. 22. Synthesis of Boc-dolaproinyl-dolaphenine and four related chiral isomers</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2935</span><span class="NLM_x">–</span> <span class="NLM_lpage">2938</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00090a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1994&pages=2935-2938&author=G.+R.+Pettitauthor=J.+Barkoczyauthor=J.+K.+Srirangamauthor=S.+B.+Singhauthor=D.+L.+Heraldauthor=M.+D.+Williamsauthor=D.+Kantociauthor=F.+Hoganauthor=T.+L.+Groy&title=The+Dolastatins.+22.+Synthesis+of+Boc-dolaproinyl-dolaphenine+and+four+related+chiral+isomers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjo00090a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00090a009%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DBarkoczy%26aufirst%3DJ.%26aulast%3DSrirangam%26aufirst%3DJ.%2BK.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DWilliams%26aufirst%3DM.%2BD.%26aulast%3DKantoci%26aufirst%3DD.%26aulast%3DHogan%26aufirst%3DF.%26aulast%3DGroy%26aufirst%3DT.%2BL.%26atitle%3DThe%2520Dolastatins.%252022.%2520Synthesis%2520of%2520Boc-dolaproinyl-dolaphenine%2520and%2520four%2520related%2520chiral%2520isomers%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1994%26volume%3D59%26spage%3D2935%26epage%3D2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 84 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Bin Hu, <span class="NLM_string-name hlFld-ContribAuthor">Li Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Catalytic Asymmetric Synthesis of Trifluoromethylated γ-Amino Esters/Lactones via Umpolung Strategy. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (2)
                                     , 994-1005. <a href="https://doi.org/10.1021/acs.joc.8b02893" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02893</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02893%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDirect%252BCatalytic%252BAsymmetric%252BSynthesis%252Bof%252BTrifluoromethylated%252B%2525CE%2525B3-Amino%252BEsters%25252FLactones%252Bvia%252BUmpolung%252BStrategy%26aulast%3DHu%26aufirst%3DBin%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D22112018%26date%3D08012019%26date%3D13122018%26volume%3D84%26issue%3D2%26spage%3D994%26epage%3D1005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anokha
S. Ratnayake, Li-ping Chang, L. Nathan Tumey, Frank Loganzo, Joseph A. Chemler, Melissa Wagenaar, Sylvia Musto, Fengping Li, Jeffrey E. Janso, T. Eric Ballard, Brian Rago, Greg L. Steele, WeiDong Ding, Xidong Feng, Christine Hosselet, Vlad Buklan, Judy Lucas, Frank E. Koehn, Christopher J. O’Donnell, <span class="NLM_string-name hlFld-ContribAuthor">Edmund I. Graziani</span>. </span><span class="cited-content_cbyCitation_article-title">Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (1)
                                     , 200-209. <a href="https://doi.org/10.1021/acs.bioconjchem.8b00843" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.8b00843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.8b00843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.8b00843%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DNatural%252BProduct%252BBis-Intercalator%252BDepsipeptides%252Bas%252Ba%252BNew%252BClass%252Bof%252BPayloads%252Bfor%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DRatnayake%26aufirst%3DAnokha%2BS.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D21112018%26date%3D13122018%26volume%3D30%26issue%3D1%26spage%3D200%26epage%3D209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michinori Akaiwa, Tioga Martin, <span class="NLM_string-name hlFld-ContribAuthor">Brian A. Mendelsohn</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of Linear and Macrocyclic Dolastatin 10 Analogues Containing Pyrrolidine Ring Modifications. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (5)
                                     , 5212-5221. <a href="https://doi.org/10.1021/acsomega.8b00093" title="DOI URL">https://doi.org/10.1021/acsomega.8b00093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b00093%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252BLinear%252Band%252BMacrocyclic%252BDolastatin%252B10%252BAnalogues%252BContaining%252BPyrrolidine%252BRing%252BModifications%26aulast%3DAkaiwa%26aufirst%3DMichinori%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D05022018%26date%3D24042018%26volume%3D3%26issue%3D5%26spage%3D5212%26epage%3D5221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julien  Dugal-Tessier</span>, <span class="hlFld-ContribAuthor ">Stuart D.  Barnscher</span>, <span class="hlFld-ContribAuthor ">Akira  Kanai</span>, and <span class="hlFld-ContribAuthor ">Brian A.  Mendelsohn</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2017,</strong> <em>80 </em>
                                    (9)
                                     , 2484-2491. <a href="https://doi.org/10.1021/acs.jnatprod.7b00359" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.7b00359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.7b00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.7b00359%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252BDolastatin%252B10%252BAnalogues%252BContaining%252BHeteroatoms%252Bon%252Bthe%252BAmino%252BAcid%252BSide%252BChains%26aulast%3DDugal-Tessier%26aufirst%3DJulien%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D24042017%26date%3D08092017%26date%3D22092017%26volume%3D80%26issue%3D9%26spage%3D2484%26epage%3D2491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amar S.  Prashad</span>, <span class="hlFld-ContribAuthor ">Birte  Nolting</span>, <span class="hlFld-ContribAuthor ">Vimalkumar  Patel</span>, <span class="hlFld-ContribAuthor ">April  Xu</span>, <span class="hlFld-ContribAuthor ">Bo  Arve</span>, and <span class="hlFld-ContribAuthor ">Leo  Letendre</span>  . </span><span class="cited-content_cbyCitation_article-title">From R&D to Clinical Supplies. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2017,</strong> <em>21 </em>
                                    (4)
                                     , 590-600. <a href="https://doi.org/10.1021/acs.oprd.7b00020" title="DOI URL">https://doi.org/10.1021/acs.oprd.7b00020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.7b00020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.7b00020%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DFrom%252BR%252526D%252Bto%252BClinical%252BSupplies%26aulast%3DPrashad%26aufirst%3DAmar%2BS.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D19012017%26date%3D31032017%26date%3D21042017%26date%3D28032017%26volume%3D21%26issue%3D4%26spage%3D590%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">George R.  Pettit</span>, <span class="hlFld-ContribAuthor ">Noeleen  Melody</span>, and <span class="hlFld-ContribAuthor ">Jean-Charles  Chapuis</span>  . </span><span class="cited-content_cbyCitation_article-title">Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2017,</strong> <em>80 </em>
                                    (3)
                                     , 692-698. <a href="https://doi.org/10.1021/acs.jnatprod.6b01006" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.6b01006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.6b01006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.6b01006%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DAntineoplastic%252BAgents.%252B603.%252BQuinstatins%25253A%252BExceptional%252BCancer%252BCell%252BGrowth%252BInhibitors%26aulast%3DPettit%26aufirst%3DGeorge%2BR.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D03112016%26date%3D17022017%26date%3D24032017%26volume%3D80%26issue%3D3%26spage%3D692%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian A.  Mendelsohn</span>, <span class="hlFld-ContribAuthor ">Stuart D.  Barnscher</span>, <span class="hlFld-ContribAuthor ">Josh T.  Snyder</span>, <span class="hlFld-ContribAuthor ">Zili  An</span>, <span class="hlFld-ContribAuthor ">Jennifer M.  Dodd</span>, and <span class="hlFld-ContribAuthor ">Julien  Dugal-Tessier</span>  . </span><span class="cited-content_cbyCitation_article-title">Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (2)
                                     , 371-381. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00530" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00530</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00530%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DInvestigation%252Bof%252BHydrophilic%252BAuristatin%252BDerivatives%252Bfor%252BUse%252Bin%252BAntibody%252BDrug%252BConjugates%26aulast%3DMendelsohn%26aufirst%3DBrian%2BA.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D15092016%26date%3D16122016%26date%3D06012017%26date%3D15022017%26volume%3D28%26issue%3D2%26spage%3D371%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian  Rago</span>, <span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Cong  Wei</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Steven  Hansel</span>, and <span class="hlFld-ContribAuthor ">Xiaogang  Han</span>  . </span><span class="cited-content_cbyCitation_article-title">Quantitative Conjugated Payload Measurement Using Enzymatic Release of Antibody–Drug Conjugate with Cleavable Linker. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (2)
                                     , 620-626. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00695" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00695</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00695%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DQuantitative%252BConjugated%252BPayload%252BMeasurement%252BUsing%252BEnzymatic%252BRelease%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252Bwith%252BCleavable%252BLinker%26aulast%3DRago%26aufirst%3DBrian%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D2017%26date%3D04122016%26date%3D06012017%26date%3D31012017%26date%3D15022017%26volume%3D28%26issue%3D2%26spage%3D620%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dorin  Toader</span>, <span class="hlFld-ContribAuthor ">Fengjiang  Wang</span>, <span class="hlFld-ContribAuthor ">Lakshmaiah  Gingipalli</span>, <span class="hlFld-ContribAuthor ">Melissa  Vasbinder</span>, <span class="hlFld-ContribAuthor ">Mark  Roth</span>, <span class="hlFld-ContribAuthor ">Shenlan  Mao</span>, <span class="hlFld-ContribAuthor ">Michael  Block</span>, <span class="hlFld-ContribAuthor ">Jay  Harper</span>, <span class="hlFld-ContribAuthor ">Sambaiah  Thota</span>, <span class="hlFld-ContribAuthor ">Mei  Su</span>, <span class="hlFld-ContribAuthor ">Jianquo  Ma</span>, <span class="hlFld-ContribAuthor ">Vahe  Bedian</span>, and <span class="hlFld-ContribAuthor ">Adeela  Kamal</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure–Cytotoxicity Relationships of Analogues of N14-Desacetoxytubulysin H. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (23)
                                     , 10781-10787. <a href="https://doi.org/10.1021/acs.jmedchem.6b01023" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01023%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593Cytotoxicity%252BRelationships%252Bof%252BAnalogues%252Bof%252BN14-Desacetoxytubulysin%252BH%26aulast%3DToader%26aufirst%3DDorin%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D12072016%26date%3D16112016%26date%3D08122016%26date%3D03112016%26volume%3D59%26issue%3D23%26spage%3D10781%26epage%3D10787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carolyn A.  Leverett</span>, <span class="hlFld-ContribAuthor ">Sai Chetan K.  Sukuru</span>, <span class="hlFld-ContribAuthor ">Beth C.  Vetelino</span>, <span class="hlFld-ContribAuthor ">Sylvia  Musto</span>, <span class="hlFld-ContribAuthor ">Kevin  Parris</span>, <span class="hlFld-ContribAuthor ">Jayvardhan  Pandit</span>, <span class="hlFld-ContribAuthor ">Frank  Loganzo</span>, <span class="hlFld-ContribAuthor ">Alison H.  Varghese</span>, <span class="hlFld-ContribAuthor ">Guoyun  Bai</span>, <span class="hlFld-ContribAuthor ">Bin  Liu</span>, <span class="hlFld-ContribAuthor ">Dingguo  Liu</span>, <span class="hlFld-ContribAuthor ">Sarah  Hudson</span>, <span class="hlFld-ContribAuthor ">Venkata Ramana  Doppalapudi</span>, <span class="hlFld-ContribAuthor ">Joseph  Stock</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O’Donnell</span>, and <span class="hlFld-ContribAuthor ">Chakrapani  Subramanyam</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (11)
                                     , 999-1004. <a href="https://doi.org/10.1021/acsmedchemlett.6b00274" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00274</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00274%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BCytotoxic%252BEvaluation%252Bof%252BNovel%252BTubulysin%252BAnalogues%252Bas%252BADC%252BPayloads%26aulast%3DLeverett%26aufirst%3DCarolyn%2BA.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D14072016%26date%3D26082016%26date%3D07092016%26date%3D10112016%26date%3D26082016%26volume%3D7%26issue%3D11%26spage%3D999%26epage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ravi V. J.  Chari</span>  . </span><span class="cited-content_cbyCitation_article-title">Expanding the Reach of Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (11)
                                     , 974-976. <a href="https://doi.org/10.1021/acsmedchemlett.6b00312" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00312%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DExpanding%252Bthe%252BReach%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DChari%26aufirst%3DRavi%2BV.%2BJ.%26date%3D2016%26date%3D2016%26date%3D14092016%26date%3D15092016%26date%3D10112016%26volume%3D7%26issue%3D11%26spage%3D974%26epage%3D976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cong  Wei</span>, <span class="hlFld-ContribAuthor ">Guodong  Zhang</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>, <span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Brian  Rago</span>, <span class="hlFld-ContribAuthor ">Steven  Hansel</span>, and <span class="hlFld-ContribAuthor ">Xiaogang  Han</span>  . </span><span class="cited-content_cbyCitation_article-title">Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma. </span><span class="cited-content_cbyCitation_journal-name">Analytical Chemistry</span><span> <strong>2016,</strong> <em>88 </em>
                                    (9)
                                     , 4979-4986. <a href="https://doi.org/10.1021/acs.analchem.6b00976" title="DOI URL">https://doi.org/10.1021/acs.analchem.6b00976</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.analchem.6b00976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.analchem.6b00976%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Chemistry%26atitle%3DWhere%252BDid%252Bthe%252BLinker-Payload%252BGo%25253F%252BA%252BQuantitative%252BInvestigation%252Bon%252Bthe%252BDestination%252Bof%252Bthe%252BReleased%252BLinker-Payload%252Bfrom%252Ban%252BAntibody-Drug%252BConjugate%252Bwith%252Ba%252BMaleimide%252BLinker%252Bin%252BPlasma%26aulast%3DWei%26aufirst%3DCong%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D11032016%26date%3D13042016%26date%3D21042016%26date%3D03052016%26date%3D13042016%26volume%3D88%26issue%3D9%26spage%3D4979%26epage%3D4986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sujiet  Puthenveetil</span>, <span class="hlFld-ContribAuthor ">Sylvia  Musto</span>, <span class="hlFld-ContribAuthor ">Frank  Loganzo</span>, <span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O’Donnell</span>, and <span class="hlFld-ContribAuthor ">Edmund  Graziani</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2016,</strong> <em>27 </em>
                                    (4)
                                     , 1030-1039. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00054" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00054%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DDevelopment%252Bof%252BSolid-Phase%252BSite-Specific%252BConjugation%252Band%252BIts%252BApplication%252Btoward%252BGeneration%252Bof%252BDual%252BLabeled%252BAntibody%252Band%252BFab%252BDrug%252BConjugates%26aulast%3DPuthenveetil%26aufirst%3DSujiet%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D28012016%26date%3D29022016%26date%3D22032016%26date%3D20042016%26date%3D04032016%26volume%3D27%26issue%3D4%26spage%3D1030%26epage%3D1039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Maderna</span> and <span class="hlFld-ContribAuthor ">Carolyn A.  Leverett</span>  . </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2015,</strong> <em>12 </em>
                                    (6)
                                     , 1798-1812. <a href="https://doi.org/10.1021/mp500762u" title="DOI URL">https://doi.org/10.1021/mp500762u</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/mp500762u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fmp500762u%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BNew%252BAuristatins%25253A%252BStructural%252BModifications%252Band%252BApplication%252Bin%252BAntibody%252BDrug%252BConjugates%26aulast%3DMaderna%26aufirst%3DAndreas%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D2015%26date%3D16112014%26date%3D16022015%26date%3D07022015%26date%3D05032015%26date%3D01062015%26date%3D19022015%26volume%3D12%26issue%3D6%26spage%3D1798%26epage%3D1812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Magdalena  Dorywalska</span>, <span class="hlFld-ContribAuthor ">Pavel  Strop</span>, <span class="hlFld-ContribAuthor ">Jody A.  Melton-Witt</span>, <span class="hlFld-ContribAuthor ">Adela  Hasa-Moreno</span>, <span class="hlFld-ContribAuthor ">Santiago E.  Farias</span>, <span class="hlFld-ContribAuthor ">Meritxell  Galindo Casas</span>, <span class="hlFld-ContribAuthor ">Kathy  Delaria</span>, <span class="hlFld-ContribAuthor ">Victor  Lui</span>, <span class="hlFld-ContribAuthor ">Kris  Poulsen</span>, <span class="hlFld-ContribAuthor ">Carole  Loo</span>, <span class="hlFld-ContribAuthor ">Stellanie  Krimm</span>, <span class="hlFld-ContribAuthor ">Gary  Bolton</span>, <span class="hlFld-ContribAuthor ">Ludivine  Moine</span>, <span class="hlFld-ContribAuthor ">Russell  Dushin</span>, <span class="hlFld-ContribAuthor ">Thomas-Toan  Tran</span>, <span class="hlFld-ContribAuthor ">Shu-Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Mathias  Rickert</span>, <span class="hlFld-ContribAuthor ">Davide  Foletti</span>, <span class="hlFld-ContribAuthor ">David L.  Shelton</span>, <span class="hlFld-ContribAuthor ">Jaume  Pons</span>, and <span class="hlFld-ContribAuthor ">Arvind  Rajpal</span>  . </span><span class="cited-content_cbyCitation_article-title">Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2015,</strong> <em>26 </em>
                                    (4)
                                     , 650-659. <a href="https://doi.org/10.1021/bc5005747" title="DOI URL">https://doi.org/10.1021/bc5005747</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bc5005747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbc5005747%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DEffect%252Bof%252BAttachment%252BSite%252Bon%252BStability%252Bof%252BCleavable%252BAntibody%252BDrug%252BConjugates%26aulast%3DDorywalska%26aufirst%3DMagdalena%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D2015%26date%3D05122014%26date%3D27012015%26date%3D20022015%26date%3D15042015%26date%3D02022015%26volume%3D26%26issue%3D4%26spage%3D650%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Gao</span>, <span class="hlFld-ContribAuthor ">Yanbing  Wang</span>, <span class="hlFld-ContribAuthor ">Huiming  Hua</span>, <span class="hlFld-ContribAuthor ">Dahong  Li</span>, <span class="hlFld-ContribAuthor ">Chunlan  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Marine Drugs</span><span> <strong>2021,</strong> <em>19 </em>
                                    (7)
                                     , 363. <a href="https://doi.org/10.3390/md19070363" title="DOI URL">https://doi.org/10.3390/md19070363</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/md19070363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmd19070363%26sid%3Dliteratum%253Aachs%26jtitle%3DMarine%2520Drugs%26atitle%3DMarine%252BAntitumor%252BPeptide%252BDolastatin%252B10%25253A%252BBiological%252BActivity%25252C%252BStructural%252BModification%252Band%252BSynthetic%252BChemistry%26aulast%3DGao%26aufirst%3DGang%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D7%26spage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hendris  Wongso</span>. </span><span class="cited-content_cbyCitation_article-title">Natural product-based Radiopharmaceuticals:Focus on curcumin and its analogs, flavonoids, and marine peptides. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Analysis</span><span> <strong>2021,</strong> <em>60 </em><a href="https://doi.org/10.1016/j.jpha.2021.07.006" title="DOI URL">https://doi.org/10.1016/j.jpha.2021.07.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpha.2021.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpha.2021.07.006%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Analysis%26atitle%3DNatural%252Bproduct-based%252BRadiopharmaceuticals%25253AFocus%252Bon%252Bcurcumin%252Band%252Bits%252Banalogs%25252C%252Bflavonoids%25252C%252Band%252Bmarine%252Bpeptides%26aulast%3DWongso%26aufirst%3DHendris%26date%3D2021%26volume%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miganoosh  Simonian</span>, , <span class="hlFld-ContribAuthor ">Mozhan  Haji Ghaffari</span>, , <span class="hlFld-ContribAuthor ">Babak  Negahdari</span>, . </span><span class="cited-content_cbyCitation_article-title">Immunotherapy for Breast Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Iranian Biomedical Journal</span><span> <strong>2021,</strong> <em>25 </em>
                                    (3)
                                     , 140-156. <a href="https://doi.org/10.52547/ibj.25.3.140" title="DOI URL">https://doi.org/10.52547/ibj.25.3.140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.52547/ibj.25.3.140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.52547%2Fibj.25.3.140%26sid%3Dliteratum%253Aachs%26jtitle%3DIranian%2520Biomedical%2520Journal%26atitle%3DImmunotherapy%252Bfor%252BBreast%252BCancer%252BTreatment%26aulast%3DSimonian%26aufirst%3DMiganoosh%26date%3D2021%26date%3D2021%26volume%3D25%26issue%3D3%26spage%3D140%26epage%3D156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenneth G.  Geles</span>, <span class="hlFld-ContribAuthor ">Yijie  Gao</span>, <span class="hlFld-ContribAuthor ">Andreas  Giannakou</span>, <span class="hlFld-ContribAuthor ">Latha  Sridharan</span>, <span class="hlFld-ContribAuthor ">Ting-Ting  Yamin</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Riyez  Karim</span>, <span class="hlFld-ContribAuthor ">Joel  Bard</span>, <span class="hlFld-ContribAuthor ">Nicole  Piche-Nicholas</span>, <span class="hlFld-ContribAuthor ">Manoj  Charati</span>, <span class="hlFld-ContribAuthor ">Andreas  Maderna</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Jonathon  Golas</span>, <span class="hlFld-ContribAuthor ">Magali  Guffroy</span>, <span class="hlFld-ContribAuthor ">Steven  Pirie-Shepherd</span>, <span class="hlFld-ContribAuthor ">Marc  Roy</span>, <span class="hlFld-ContribAuthor ">Jessie  Qian</span>, <span class="hlFld-ContribAuthor ">Tania  Franks</span>, <span class="hlFld-ContribAuthor ">Wenyan  Zhong</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O’Donnell</span>, <span class="hlFld-ContribAuthor ">Lioudmila  Tchistiakova</span>, <span class="hlFld-ContribAuthor ">Hans-Peter  Gerber</span>, <span class="hlFld-ContribAuthor ">Puja  Sapra</span>. </span><span class="cited-content_cbyCitation_article-title">NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells. </span><span class="cited-content_cbyCitation_journal-name">Cell Reports Medicine</span><span> <strong>2021,</strong> <em>2 </em>
                                    (5)
                                     , 100279. <a href="https://doi.org/10.1016/j.xcrm.2021.100279" title="DOI URL">https://doi.org/10.1016/j.xcrm.2021.100279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xcrm.2021.100279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xcrm.2021.100279%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Reports%2520Medicine%26atitle%3DNOTCH3-targeted%252Bantibody%252Bdrug%252Bconjugates%252Bregress%252Btumors%252Bby%252Binducing%252Bapoptosis%252Bin%252Breceptor%252Bcells%252Band%252Bthrough%252Btransendocytosis%252Binto%252Bligand%252Bcells%26aulast%3DGeles%26aufirst%3DKenneth%2BG.%26date%3D2021%26volume%3D2%26issue%3D5%26spage%3D100279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>. </span><span class="cited-content_cbyCitation_article-title">The Design and Development of Antibody–Drug Conjugates (ADC
              s
              ) for the Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-39. <a href="https://doi.org/10.1002/0471266949.bmc283" title="DOI URL">https://doi.org/10.1002/0471266949.bmc283</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc283%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDesign%252Band%252BDevelopment%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252B%252528ADC%252Bs%252B%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BCancer%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D39%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hsuan Ping  Chang</span>, <span class="hlFld-ContribAuthor ">Yuen Kiu  Cheung</span>, <span class="hlFld-ContribAuthor ">Dhaval K.  Shah</span>. </span><span class="cited-content_cbyCitation_article-title">Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE). </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2021,</strong> <em>10 </em>
                                    (6)
                                     , 1332. <a href="https://doi.org/10.3390/jcm10061332" title="DOI URL">https://doi.org/10.3390/jcm10061332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm10061332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm10061332%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DWhole-Body%252BPharmacokinetics%252Band%252BPhysiologically%252BBased%252BPharmacokinetic%252BModel%252Bfor%252BMonomethyl%252BAuristatin%252BE%252B%252528MMAE%252529%26aulast%3DChang%26aufirst%3DHsuan%2BPing%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D6%26spage%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philip N.  Moquist</span>, <span class="hlFld-ContribAuthor ">Tim D.  Bovee</span>, <span class="hlFld-ContribAuthor ">Andrew B.  Waight</span>, <span class="hlFld-ContribAuthor ">Jamie A.  Mitchell</span>, <span class="hlFld-ContribAuthor ">Jamie B.  Miyamoto</span>, <span class="hlFld-ContribAuthor ">Marsha L.  Mason</span>, <span class="hlFld-ContribAuthor ">Kim K.  Emmerton</span>, <span class="hlFld-ContribAuthor ">Nicole  Stevens</span>, <span class="hlFld-ContribAuthor ">Cindy  Balasubramanian</span>, <span class="hlFld-ContribAuthor ">Jessica K.  Simmons</span>, <span class="hlFld-ContribAuthor ">Robert P.  Lyon</span>, <span class="hlFld-ContribAuthor ">Peter D.  Senter</span>, <span class="hlFld-ContribAuthor ">Svetlana O.  Doronina</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2021,</strong> <em>20 </em>
                                    (2)
                                     , 320-328. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0618" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0618%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DNovel%252BAuristatins%252Bwith%252BHigh%252BBystander%252Band%252BCytotoxic%252BActivities%252Bin%252BDrug%252BEfflux%2525E2%252580%252593positive%252BTumor%252BModels%26aulast%3DMoquist%26aufirst%3DPhilip%2BN.%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D2%26spage%3D320%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rafael W.  Hartmann</span>, <span class="hlFld-ContribAuthor ">Raphael  Fahrner</span>, <span class="hlFld-ContribAuthor ">Denys  Shevshenko</span>, <span class="hlFld-ContribAuthor ">Mårten  Fyrknäs</span>, <span class="hlFld-ContribAuthor ">Rolf  Larsson</span>, <span class="hlFld-ContribAuthor ">Fredrik  Lehmann</span>, <span class="hlFld-ContribAuthor ">Luke R.  Odell</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design of Azastatin as a Potential ADC Payload with Reduced Bystander Killing. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (24)
                                     , 2500-2512. <a href="https://doi.org/10.1002/cmdc.202000497" title="DOI URL">https://doi.org/10.1002/cmdc.202000497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000497%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRational%252BDesign%252Bof%252BAzastatin%252Bas%252Ba%252BPotential%252BADC%252BPayload%252Bwith%252BReduced%252BBystander%252BKilling%26aulast%3DHartmann%26aufirst%3DRafael%2BW.%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D24%26spage%3D2500%26epage%3D2512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marilia  Barreca</span>, <span class="hlFld-ContribAuthor ">Virginia  Spanò</span>, <span class="hlFld-ContribAuthor ">Alessandra  Montalbano</span>, <span class="hlFld-ContribAuthor ">Mercedes  Cueto</span>, <span class="hlFld-ContribAuthor ">Ana R.  Díaz Marrero</span>, <span class="hlFld-ContribAuthor ">Irem  Deniz</span>, <span class="hlFld-ContribAuthor ">Ayşegül  Erdoğan</span>, <span class="hlFld-ContribAuthor ">Lada  Lukić Bilela</span>, <span class="hlFld-ContribAuthor ">Corentin  Moulin</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Taffin-de-Givenchy</span>, <span class="hlFld-ContribAuthor ">Filippo  Spriano</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Perale</span>, <span class="hlFld-ContribAuthor ">Mohamed  Mehiri</span>, <span class="hlFld-ContribAuthor ">Ana  Rotter</span>, <span class="hlFld-ContribAuthor ">Olivier  P. Thomas</span>, <span class="hlFld-ContribAuthor ">Paola  Barraja</span>, <span class="hlFld-ContribAuthor ">Susana P.  Gaudêncio</span>, <span class="hlFld-ContribAuthor ">Francesco  Bertoni</span>. </span><span class="cited-content_cbyCitation_article-title">Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. </span><span class="cited-content_cbyCitation_journal-name">Marine Drugs</span><span> <strong>2020,</strong> <em>18 </em>
                                    (12)
                                     , 619. <a href="https://doi.org/10.3390/md18120619" title="DOI URL">https://doi.org/10.3390/md18120619</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/md18120619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmd18120619%26sid%3Dliteratum%253Aachs%26jtitle%3DMarine%2520Drugs%26atitle%3DMarine%252BAnticancer%252BAgents%25253A%252BAn%252BOverview%252Bwith%252Ba%252BParticular%252BFocus%252Bon%252BTheir%252BChemical%252BClasses%26aulast%3DBarreca%26aufirst%3DMarilia%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D12%26spage%3D619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sara M.  Tolaney</span>, <span class="hlFld-ContribAuthor ">Khanh T.  Do</span>, <span class="hlFld-ContribAuthor ">Joseph P.  Eder</span>, <span class="hlFld-ContribAuthor ">Patricia M.  LoRusso</span>, <span class="hlFld-ContribAuthor ">Colin D.  Weekes</span>, <span class="hlFld-ContribAuthor ">Sarat  Chandarlapaty</span>, <span class="hlFld-ContribAuthor ">Ching-Wei  Chang</span>, <span class="hlFld-ContribAuthor ">Shang-Chiung  Chen</span>, <span class="hlFld-ContribAuthor ">Denise  Nazzal</span>, <span class="hlFld-ContribAuthor ">Eva  Schuth</span>, <span class="hlFld-ContribAuthor ">Flavia  Brunstein</span>, <span class="hlFld-ContribAuthor ">Montserrat  Carrasco-Triguero</span>, <span class="hlFld-ContribAuthor ">Walter C.  Darbonne</span>, <span class="hlFld-ContribAuthor ">Jennifer M.  Giltnane</span>, <span class="hlFld-ContribAuthor ">William M.  Flanagan</span>, <span class="hlFld-ContribAuthor ">S. Renee  Commerford</span>, <span class="hlFld-ContribAuthor ">Alexander  Ungewickell</span>, <span class="hlFld-ContribAuthor ">Geoffrey I.  Shapiro</span>, <span class="hlFld-ContribAuthor ">Shanu  Modi</span>. </span><span class="cited-content_cbyCitation_article-title">A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2020,</strong> <em>26 </em>
                                    (21)
                                     , 5588-5597. <a href="https://doi.org/10.1158/1078-0432.CCR-20-1067" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-20-1067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-20-1067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-20-1067%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DA%252BPhase%252BI%252BStudy%252Bof%252BDLYE5953A%25252C%252Ban%252BAnti-LY6E%252BAntibody%252BCovalently%252BLinked%252Bto%252BMonomethyl%252BAuristatin%252BE%25252C%252Bin%252BPatients%252Bwith%252BRefractory%252BSolid%252BTumors%26aulast%3DTolaney%26aufirst%3DSara%2BM.%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D21%26spage%3D5588%26epage%3D5597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edmund I.  Graziani</span>, <span class="hlFld-ContribAuthor ">Matthew  Sung</span>, <span class="hlFld-ContribAuthor ">Dangshe  Ma</span>, <span class="hlFld-ContribAuthor ">Bitha  Narayanan</span>, <span class="hlFld-ContribAuthor ">Kimberly  Marquette</span>, <span class="hlFld-ContribAuthor ">Sujiet  Puthenveetil</span>, <span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Jack  Bikker</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Casavant</span>, <span class="hlFld-ContribAuthor ">Eric M.  Bennett</span>, <span class="hlFld-ContribAuthor ">Manoj B.  Charati</span>, <span class="hlFld-ContribAuthor ">Jonathon  Golas</span>, <span class="hlFld-ContribAuthor ">Christine  Hosselet</span>, <span class="hlFld-ContribAuthor ">Cynthia M.  Rohde</span>, <span class="hlFld-ContribAuthor ">George  Hu</span>, <span class="hlFld-ContribAuthor ">Magali  Guffroy</span>, <span class="hlFld-ContribAuthor ">Hadi  Falahatpisheh</span>, <span class="hlFld-ContribAuthor ">Martin  Finkelstein</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>, <span class="hlFld-ContribAuthor ">Lioudmila  Tchistiakova</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Edward  Rosfjord</span>, <span class="hlFld-ContribAuthor ">Frank  Loganzo</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O'Donnell</span>, <span class="hlFld-ContribAuthor ">Hans-Peter  Gerber</span>, <span class="hlFld-ContribAuthor ">Puja  Sapra</span>. </span><span class="cited-content_cbyCitation_article-title">PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (10)
                                     , 2068-2078. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0237" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0237%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DPF-06804103%25252C%252BA%252BSite-specific%252BAnti-HER2%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252Bfor%252Bthe%252BTreatment%252Bof%252BHER2-expressing%252BBreast%25252C%252BGastric%25252C%252Band%252BLung%252BCancers%26aulast%3DGraziani%26aufirst%3DEdmund%2BI.%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D10%26spage%3D2068%26epage%3D2078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan  Škubník</span>, <span class="hlFld-ContribAuthor ">Michal  Jurášek</span>, <span class="hlFld-ContribAuthor ">Tomáš  Ruml</span>, <span class="hlFld-ContribAuthor ">Silvie  Rimpelová</span>. </span><span class="cited-content_cbyCitation_article-title">Mitotic Poisons in Research and Medicine. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (20)
                                     , 4632. <a href="https://doi.org/10.3390/molecules25204632" title="DOI URL">https://doi.org/10.3390/molecules25204632</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25204632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25204632%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMitotic%252BPoisons%252Bin%252BResearch%252Band%252BMedicine%26aulast%3D%25C5%25A0kubn%25C3%25ADk%26aufirst%3DJan%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D20%26spage%3D4632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alison  Betts</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Paul  Jasper</span>, <span class="hlFld-ContribAuthor ">John  Tolsma</span>, <span class="hlFld-ContribAuthor ">Piet H.  van der Graaf</span>, <span class="hlFld-ContribAuthor ">Edmund I.  Graziani</span>, <span class="hlFld-ContribAuthor ">Edward  Rosfjord</span>, <span class="hlFld-ContribAuthor ">Matthew  Sung</span>, <span class="hlFld-ContribAuthor ">Dangshe  Ma</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>. </span><span class="cited-content_cbyCitation_article-title">Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacokinetics and Pharmacodynamics</span><span> <strong>2020,</strong> <em>47 </em>
                                    (5)
                                     , 513-526. <a href="https://doi.org/10.1007/s10928-020-09702-3" title="DOI URL">https://doi.org/10.1007/s10928-020-09702-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10928-020-09702-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10928-020-09702-3%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacokinetics%2520and%2520Pharmacodynamics%26atitle%3DUse%252Bof%252Btranslational%252Bmodeling%252Band%252Bsimulation%252Bfor%252Bquantitative%252Bcomparison%252Bof%252BPF-06804103%25252C%252Ba%252Bnew%252Bgeneration%252BHER2%252BADC%25252C%252Bwith%252BTrastuzumab-DM1%26aulast%3DBetts%26aufirst%3DAlison%26date%3D2020%26date%3D2020%26volume%3D47%26issue%3D5%26spage%3D513%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianzhou  Xu</span>, <span class="hlFld-ContribAuthor ">Ting  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiaxiao  Yao</span>, <span class="hlFld-ContribAuthor ">Jian  Lu</span>, <span class="hlFld-ContribAuthor ">Zhiwen  Liu</span>, <span class="hlFld-ContribAuthor ">Lijian  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in chemistry and bioactivity of marine cyanobacteria Moorea species. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>201 </em>, 112473. <a href="https://doi.org/10.1016/j.ejmech.2020.112473" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112473%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bchemistry%252Band%252Bbioactivity%252Bof%252Bmarine%252Bcyanobacteria%252BMoorea%252Bspecies%26aulast%3DXu%26aufirst%3DJianzhou%26date%3D2020%26volume%3D201%26spage%3D112473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurence  Gauzy-Lazo</span>, <span class="hlFld-ContribAuthor ">Ingrid  Sassoon</span>, <span class="hlFld-ContribAuthor ">Marie-Priscille  Brun</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2020,</strong> <em>25 </em>
                                    (8)
                                     , 843-868. <a href="https://doi.org/10.1177/2472555220912955" title="DOI URL">https://doi.org/10.1177/2472555220912955</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555220912955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555220912955%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DAdvances%252Bin%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BDesign%25253A%252BCurrent%252BClinical%252BLandscape%252Band%252BFuture%252BInnovations%26aulast%3DGauzy-Lazo%26aufirst%3DLaurence%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D8%26spage%3D843%26epage%3D868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua T.  Burgess</span>, <span class="hlFld-ContribAuthor ">Maddison  Rose</span>, <span class="hlFld-ContribAuthor ">Didier  Boucher</span>, <span class="hlFld-ContribAuthor ">Jennifer  Plowman</span>, <span class="hlFld-ContribAuthor ">Christopher  Molloy</span>, <span class="hlFld-ContribAuthor ">Mark  Fisher</span>, <span class="hlFld-ContribAuthor ">Connor  O'Leary</span>, <span class="hlFld-ContribAuthor ">Derek J.  Richard</span>, <span class="hlFld-ContribAuthor ">Kenneth J.  O'Byrne</span>, <span class="hlFld-ContribAuthor ">Emma  Bolderson</span>. </span><span class="cited-content_cbyCitation_article-title">The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fonc.2020.01256" title="DOI URL">https://doi.org/10.3389/fonc.2020.01256</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2020.01256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2020.01256%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DThe%252BTherapeutic%252BPotential%252Bof%252BDNA%252BDamage%252BRepair%252BPathways%252Band%252BGenomic%252BStability%252Bin%252BLung%252BCancer%26aulast%3DBurgess%26aufirst%3DJoshua%2BT.%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marilia  Barreca</span>, <span class="hlFld-ContribAuthor ">Anastasios  Stathis</span>, <span class="hlFld-ContribAuthor ">Paola  Barraja</span>, <span class="hlFld-ContribAuthor ">Francesco  Bertoni</span>. </span><span class="cited-content_cbyCitation_article-title">An overview on anti-tubulin agents for the treatment of lymphoma patients. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2020,</strong> <em>211 </em>, 107552. <a href="https://doi.org/10.1016/j.pharmthera.2020.107552" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2020.107552</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2020.107552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2020.107552%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DAn%252Boverview%252Bon%252Banti-tubulin%252Bagents%252Bfor%252Bthe%252Btreatment%252Bof%252Blymphoma%252Bpatients%26aulast%3DBarreca%26aufirst%3DMarilia%26date%3D2020%26volume%3D211%26spage%3D107552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra  Ramos-Inza</span>, <span class="hlFld-ContribAuthor ">Carlos  Aydillo</span>, <span class="hlFld-ContribAuthor ">Carmen  Sanmartín</span>, <span class="hlFld-ContribAuthor ">Daniel  Plano</span>. </span><span class="cited-content_cbyCitation_article-title">Thiazole Moiety: An Interesting Scaffold for Developing New Antitumoral Compounds. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.5772/intechopen.82741" title="DOI URL">https://doi.org/10.5772/intechopen.82741</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.82741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.82741%26sid%3Dliteratum%253Aachs%26atitle%3DThiazole%252BMoiety%25253A%252BAn%252BInteresting%252BScaffold%252Bfor%252BDeveloping%252BNew%252BAntitumoral%252BCompounds%26aulast%3DRamos-Inza%26aufirst%3DSandra%26date%3D2020%26date%3D2020%26pub%3DIntechOpen%26atitle%3DHeterocycles%252B-%252BSynthesis%252Band%252BBiological%252BActivities%26aulast%3DP.%2BNandeshwarappa%26aufirst%3DB.%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michinori  Akaiwa</span>, <span class="hlFld-ContribAuthor ">Julien  Dugal-Tessier</span>, <span class="hlFld-ContribAuthor ">Brian A.  Mendelsohn</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugate Payloads; Study of Auristatin Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2020,</strong> <em>68 </em>
                                    (3)
                                     , 201-211. <a href="https://doi.org/10.1248/cpb.c19-00853" title="DOI URL">https://doi.org/10.1248/cpb.c19-00853</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c19-00853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c19-00853%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugate%252BPayloads%25253B%252BStudy%252Bof%252BAuristatin%252BDerivatives%26aulast%3DAkaiwa%26aufirst%3DMichinori%26date%3D2020%26volume%3D68%26issue%3D3%26spage%3D201%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nooshafarin  Amani</span>, <span class="hlFld-ContribAuthor ">Farid Abedin  Dorkoosh</span>, <span class="hlFld-ContribAuthor ">Hamid  Mobedi</span>. </span><span class="cited-content_cbyCitation_article-title">ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Delivery</span><span> <strong>2020,</strong> <em>17 </em>
                                    (1)
                                     , 23-51. <a href="https://doi.org/10.2174/1567201816666191121145109" title="DOI URL">https://doi.org/10.2174/1567201816666191121145109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1567201816666191121145109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1567201816666191121145109%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Delivery%26atitle%3DADCs%25252C%252Bas%252BNovel%252BRevolutionary%252BWeapons%252Bfor%252BProviding%252Ba%252BStep%252BForward%252Bin%252BTargeted%252BTherapy%252Bof%252BMalignancies%26aulast%3DAmani%26aufirst%3DNooshafarin%26date%3D2020%26volume%3D17%26issue%3D1%26spage%3D23%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>. </span><span class="cited-content_cbyCitation_article-title">An Overview of the Current ADC Discovery Landscape. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-22. <a href="https://doi.org/10.1007/978-1-4939-9929-3_1" title="DOI URL">https://doi.org/10.1007/978-1-4939-9929-3_1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-9929-3_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-9929-3_1%26sid%3Dliteratum%253Aachs%26atitle%3DAn%252BOverview%252Bof%252Bthe%252BCurrent%252BADC%252BDiscovery%252BLandscape%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2020%26date%3D2019%26spage%3D1%26epage%3D22%26pub%3DSpringer%2520US%26atitle%3DAntibody-Drug%252BConjugates%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2020%26volume%3D2078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sajad  Yaghoubi</span>, <span class="hlFld-ContribAuthor ">Mohammad Hossein  Karimi</span>, <span class="hlFld-ContribAuthor ">Majid  Lotfinia</span>, <span class="hlFld-ContribAuthor ">Tohid  Gharibi</span>, <span class="hlFld-ContribAuthor ">Motahare  Mahi‐Birjand</span>, <span class="hlFld-ContribAuthor ">Esmaeil  Kavi</span>, <span class="hlFld-ContribAuthor ">Fahimeh  Hosseini</span>, <span class="hlFld-ContribAuthor ">Koushan  Sineh Sepehr</span>, <span class="hlFld-ContribAuthor ">Mehrdad  Khatami</span>, <span class="hlFld-ContribAuthor ">Nader  Bagheri</span>, <span class="hlFld-ContribAuthor ">Meghdad  Abdollahpour‐Alitappeh</span>. </span><span class="cited-content_cbyCitation_article-title">Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2020,</strong> <em>235 </em>
                                    (1)
                                     , 31-64. <a href="https://doi.org/10.1002/jcp.28967" title="DOI URL">https://doi.org/10.1002/jcp.28967</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.28967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.28967%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DPotential%252Bdrugs%252Bused%252Bin%252Bthe%252Bantibody%2525E2%252580%252593drug%252Bconjugate%252B%252528ADC%252529%252Barchitecture%252Bfor%252Bcancer%252Btherapy%26aulast%3DYaghoubi%26aufirst%3DSajad%26date%3D2020%26date%3D2019%26volume%3D235%26issue%3D1%26spage%3D31%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria José  Costa</span>, <span class="hlFld-ContribAuthor ">Jyothirmayee  Kudaravalli</span>, <span class="hlFld-ContribAuthor ">Jing-Tyan  Ma</span>, <span class="hlFld-ContribAuthor ">Wei-Hsien  Ho</span>, <span class="hlFld-ContribAuthor ">Kathy  Delaria</span>, <span class="hlFld-ContribAuthor ">Charles  Holz</span>, <span class="hlFld-ContribAuthor ">Angela  Stauffer</span>, <span class="hlFld-ContribAuthor ">Allison Given  Chunyk</span>, <span class="hlFld-ContribAuthor ">Qing  Zong</span>, <span class="hlFld-ContribAuthor ">Eileen  Blasi</span>, <span class="hlFld-ContribAuthor ">Bernard  Buetow</span>, <span class="hlFld-ContribAuthor ">Thomas-Toan  Tran</span>, <span class="hlFld-ContribAuthor ">Kevin  Lindquist</span>, <span class="hlFld-ContribAuthor ">Magdalena  Dorywalska</span>, <span class="hlFld-ContribAuthor ">Arvind  Rajpal</span>, <span class="hlFld-ContribAuthor ">David L.  Shelton</span>, <span class="hlFld-ContribAuthor ">Pavel  Strop</span>, <span class="hlFld-ContribAuthor ">Shu-Hui  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2019,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-019-38745-x" title="DOI URL">https://doi.org/10.1038/s41598-019-38745-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-019-38745-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-019-38745-x%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DOptimal%252Bdesign%25252C%252Banti-tumour%252Befficacy%252Band%252Btolerability%252Bof%252Banti-CXCR4%252Bantibody%252Bdrug%252Bconjugates%26aulast%3DCosta%26aufirst%3DMaria%2BJos%25C3%25A9%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shams  Aaghaz</span>, <span class="hlFld-ContribAuthor ">Vivek  Gohel</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Peptides as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (17)
                                     , 1491-1511. <a href="https://doi.org/10.2174/1568026619666190125161517" title="DOI URL">https://doi.org/10.2174/1568026619666190125161517</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190125161517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190125161517%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DPeptides%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DAaghaz%26aufirst%3DShams%26date%3D2019%26volume%3D19%26issue%3D17%26spage%3D1491%26epage%3D1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanming  Wang</span>, <span class="hlFld-ContribAuthor ">Shiyong  Fan</span>, <span class="hlFld-ContribAuthor ">Dian  Xiao</span>, <span class="hlFld-ContribAuthor ">Fei  Xie</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Wu  Zhong</span>, <span class="hlFld-ContribAuthor ">Xinbo  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (7)
                                     , 957. <a href="https://doi.org/10.3390/cancers11070957" title="DOI URL">https://doi.org/10.3390/cancers11070957</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11070957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11070957%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DNovel%252BSilyl%252BEther-Based%252BAcid-Cleavable%252BAntibody-MMAE%252BConjugates%252Bwith%252BAppropriate%252BStability%252Band%252BEfficacy%26aulast%3DWang%26aufirst%3DYanming%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D7%26spage%3D957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renato B.  Pereira</span>, <span class="hlFld-ContribAuthor ">Nikolai M.  Evdokimov</span>, <span class="hlFld-ContribAuthor ">Florence  Lefranc</span>, <span class="hlFld-ContribAuthor ">Patrícia  Valentão</span>, <span class="hlFld-ContribAuthor ">Alexander  Kornienko</span>, <span class="hlFld-ContribAuthor ">David M.  Pereira</span>, <span class="hlFld-ContribAuthor ">Paula B.  Andrade</span>, <span class="hlFld-ContribAuthor ">Nelson G. M.  Gomes</span>. </span><span class="cited-content_cbyCitation_article-title">Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets. </span><span class="cited-content_cbyCitation_journal-name">Marine Drugs</span><span> <strong>2019,</strong> <em>17 </em>
                                    (6)
                                     , 329. <a href="https://doi.org/10.3390/md17060329" title="DOI URL">https://doi.org/10.3390/md17060329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/md17060329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmd17060329%26sid%3Dliteratum%253Aachs%26jtitle%3DMarine%2520Drugs%26atitle%3DMarine-Derived%252BAnticancer%252BAgents%25253A%252BClinical%252BBenefits%25252C%252BInnovative%252BMechanisms%25252C%252Band%252BNew%252BTargets%26aulast%3DPereira%26aufirst%3DRenato%2BB.%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D6%26spage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alba  Vicente‐Blázquez</span>, <span class="hlFld-ContribAuthor ">Myriam  González</span>, <span class="hlFld-ContribAuthor ">Raquel  Álvarez</span>, <span class="hlFld-ContribAuthor ">Sara  del Mazo</span>, <span class="hlFld-ContribAuthor ">Manuel  Medarde</span>, <span class="hlFld-ContribAuthor ">Rafael  Peláez</span>. </span><span class="cited-content_cbyCitation_article-title">Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (3)
                                     , 775-830. <a href="https://doi.org/10.1002/med.21541" title="DOI URL">https://doi.org/10.1002/med.21541</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21541%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DAntitubulin%252Bsulfonamides%25253A%252BThe%252Bsuccessful%252Bcombination%252Bof%252Ban%252Bestablished%252Bdrug%252Bclass%252Band%252Ba%252Bmultifaceted%252Btarget%26aulast%3DVicente%25E2%2580%2590Bl%25C3%25A1zquez%26aufirst%3DAlba%26date%3D2019%26date%3D2018%26volume%3D39%26issue%3D3%26spage%3D775%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naresh  Goli</span>, <span class="hlFld-ContribAuthor ">Pradeep Kumar  Bolla</span>, <span class="hlFld-ContribAuthor ">Venu  Talla</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview. </span><span class="cited-content_cbyCitation_journal-name">Journal of Drug Delivery Science and Technology</span><span> <strong>2018,</strong> <em>48 </em>, 106-117. <a href="https://doi.org/10.1016/j.jddst.2018.08.022" title="DOI URL">https://doi.org/10.1016/j.jddst.2018.08.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jddst.2018.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jddst.2018.08.022%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Drug%2520Delivery%2520Science%2520and%2520Technology%26atitle%3DAntibody-drug%252Bconjugates%252B%252528ADCs%252529%25253A%252BPotent%252Bbiopharmaceuticals%252Bto%252Btarget%252Bsolid%252Band%252Bhematological%252Bcancers-%252Ban%252Boverview%26aulast%3DGoli%26aufirst%3DNaresh%26date%3D2018%26volume%3D48%26spage%3D106%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gentry T.  King</span>, <span class="hlFld-ContribAuthor ">Keith D.  Eaton</span>, <span class="hlFld-ContribAuthor ">Brandon R.  Beagle</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Zopf</span>, <span class="hlFld-ContribAuthor ">Gilbert Y.  Wong</span>, <span class="hlFld-ContribAuthor ">Heike I.  Krupka</span>, <span class="hlFld-ContribAuthor ">Steven Y.  Hua</span>, <span class="hlFld-ContribAuthor ">Wells A.  Messersmith</span>, <span class="hlFld-ContribAuthor ">Anthony B.  El-Khoueiry</span>. </span><span class="cited-content_cbyCitation_article-title">A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2018,</strong> <em>36 </em>
                                    (5)
                                     , 836-847. <a href="https://doi.org/10.1007/s10637-018-0560-6" title="DOI URL">https://doi.org/10.1007/s10637-018-0560-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-018-0560-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-018-0560-6%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DA%252Bphase%252B1%25252C%252Bdose-escalation%252Bstudy%252Bof%252BPF-06664178%25252C%252Ban%252Banti-Trop-2%25252FAur0101%252Bantibody-drug%252Bconjugate%252Bin%252Bpatients%252Bwith%252Badvanced%252Bor%252Bmetastatic%252Bsolid%252Btumors%26aulast%3DKing%26aufirst%3DGentry%2BT.%26date%3D2018%26date%3D2018%26volume%3D36%26issue%3D5%26spage%3D836%26epage%3D847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michel O.  Steinmetz</span>, <span class="hlFld-ContribAuthor ">Andrea E.  Prota</span>. </span><span class="cited-content_cbyCitation_article-title">Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton. </span><span class="cited-content_cbyCitation_journal-name">Trends in Cell Biology</span><span> <strong>2018,</strong> <em>28 </em>
                                    (10)
                                     , 776-792. <a href="https://doi.org/10.1016/j.tcb.2018.05.001" title="DOI URL">https://doi.org/10.1016/j.tcb.2018.05.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tcb.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tcb.2018.05.001%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Cell%2520Biology%26atitle%3DMicrotubule-Targeting%252BAgents%25253A%252BStrategies%252BTo%252BHijack%252Bthe%252BCytoskeleton%26aulast%3DSteinmetz%26aufirst%3DMichel%2BO.%26date%3D2018%26volume%3D28%26issue%3D10%26spage%3D776%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deboprosad  Mondal</span>, <span class="hlFld-ContribAuthor ">Jacob  Ford</span>, <span class="hlFld-ContribAuthor ">Kevin G.  Pinney</span>. </span><span class="cited-content_cbyCitation_article-title">Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (40)
                                     , 3594-3599. <a href="https://doi.org/10.1016/j.tetlet.2018.08.021" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.08.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.08.021%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DImproved%252BMethodology%252Bfor%252Bthe%252BSynthesis%252Bof%252Ba%252BCathepsin%252BB%252BCleavable%252BDipeptide%252BLinker%25252C%252BWidely%252BUsed%252Bin%252BAntibody-Drug%252BConjugate%252BResearch%26aulast%3DMondal%26aufirst%3DDeboprosad%26date%3D2018%26volume%3D59%26issue%3D40%26spage%3D3594%26epage%3D3599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oi Kwan  Wong</span>, <span class="hlFld-ContribAuthor ">Thomas-Toan  Tran</span>, <span class="hlFld-ContribAuthor ">Wei-Hsien  Ho</span>, <span class="hlFld-ContribAuthor ">Meritxell Galindo  Casas</span>, <span class="hlFld-ContribAuthor ">Melinda  Au</span>, <span class="hlFld-ContribAuthor ">Marjorie  Bateman</span>, <span class="hlFld-ContribAuthor ">Kevin C.  Lindquist</span>, <span class="hlFld-ContribAuthor ">Arvind  Rajpal</span>, <span class="hlFld-ContribAuthor ">David L.  Shelton</span>, <span class="hlFld-ContribAuthor ">Pavel  Strop</span>, <span class="hlFld-ContribAuthor ">Shu-Hui  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (71)
                                     , 33446-33458. <a href="https://doi.org/10.18632/oncotarget.26002" title="DOI URL">https://doi.org/10.18632/oncotarget.26002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26002%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DRN765C%25252C%252Ba%252Blow%252Baffinity%252BEGFR%252Bantibody%252Bdrug%252Bconjugate%252Bwith%252Bpotent%252Banti-tumor%252Bactivity%252Bin%252Bpreclinical%252Bsolid%252Btumor%252Bmodels%26aulast%3DWong%26aufirst%3DOi%2BKwan%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D71%26spage%3D33446%26epage%3D33458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cédric  Rossi</span>, <span class="hlFld-ContribAuthor ">Marie-Lorraine  Chrétien</span>, <span class="hlFld-ContribAuthor ">René-Olivier  Casasnovas</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review. </span><span class="cited-content_cbyCitation_journal-name">Targeted Oncology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (3)
                                     , 287-308. <a href="https://doi.org/10.1007/s11523-018-0558-1" title="DOI URL">https://doi.org/10.1007/s11523-018-0558-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11523-018-0558-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11523-018-0558-1%26sid%3Dliteratum%253Aachs%26jtitle%3DTargeted%2520Oncology%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugates%252Bfor%252Bthe%252BTreatment%252Bof%252BHematological%252BMalignancies%25253A%252BA%252BComprehensive%252BReview%26aulast%3DRossi%26aufirst%3DC%25C3%25A9dric%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D3%26spage%3D287%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thom  Vreven</span>, <span class="hlFld-ContribAuthor ">Devin K.  Schweppe</span>, <span class="hlFld-ContribAuthor ">Juan D.  Chavez</span>, <span class="hlFld-ContribAuthor ">Chad R.  Weisbrod</span>, <span class="hlFld-ContribAuthor ">Sayaka  Shibata</span>, <span class="hlFld-ContribAuthor ">Chunxiang  Zheng</span>, <span class="hlFld-ContribAuthor ">James E.  Bruce</span>, <span class="hlFld-ContribAuthor ">Zhiping  Weng</span>. </span><span class="cited-content_cbyCitation_article-title">Integrating Cross-Linking Experiments with Ab Initio Protein–Protein Docking. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Biology</span><span> <strong>2018,</strong> <em>430 </em>
                                    (12)
                                     , 1814-1828. <a href="https://doi.org/10.1016/j.jmb.2018.04.010" title="DOI URL">https://doi.org/10.1016/j.jmb.2018.04.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmb.2018.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmb.2018.04.010%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Biology%26atitle%3DIntegrating%252BCross-Linking%252BExperiments%252Bwith%252BAb%252BInitio%252BProtein%2525E2%252580%252593Protein%252BDocking%26aulast%3DVreven%26aufirst%3DThom%26date%3D2018%26volume%3D430%26issue%3D12%26spage%3D1814%26epage%3D1828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinya  Yokosaka</span>, <span class="hlFld-ContribAuthor ">Akiko  Izawa</span>, <span class="hlFld-ContribAuthor ">Chizuka  Sakai</span>, <span class="hlFld-ContribAuthor ">Eri  Sakurada</span>, <span class="hlFld-ContribAuthor ">Yasuhiro  Morita</span>, <span class="hlFld-ContribAuthor ">Yukihiro  Nishio</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (8)
                                     , 1643-1652. <a href="https://doi.org/10.1016/j.bmc.2018.02.011" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.02.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.02.011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252Bdolastatin%252B10%252Bderivatives%252Bfor%252Bversatile%252Bconjugations%26aulast%3DYokosaka%26aufirst%3DShinya%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D1643%26epage%3D1652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Hu</span>, <span class="hlFld-ContribAuthor ">Li  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Asymmetric Synthesis of Trifluoromethylated γ-Amino Acids through the Umpolung Addition of Trifluoromethyl Imines to Carboxylic Acid Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2018,</strong> <em>130 </em>
                                    (8)
                                     , 2255-2259. <a href="https://doi.org/10.1002/ange.201710915" title="DOI URL">https://doi.org/10.1002/ange.201710915</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201710915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201710915%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DCatalytic%252BAsymmetric%252BSynthesis%252Bof%252BTrifluoromethylated%252B%2525CE%2525B3-Amino%252BAcids%252Bthrough%252Bthe%252BUmpolung%252BAddition%252Bof%252BTrifluoromethyl%252BImines%252Bto%252BCarboxylic%252BAcid%252BDerivatives%26aulast%3DHu%26aufirst%3DBin%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D8%26spage%3D2255%26epage%3D2259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Hu</span>, <span class="hlFld-ContribAuthor ">Li  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Asymmetric Synthesis of Trifluoromethylated γ-Amino Acids through the Umpolung Addition of Trifluoromethyl Imines to Carboxylic Acid Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2018,</strong> <em>57 </em>
                                    (8)
                                     , 2233-2237. <a href="https://doi.org/10.1002/anie.201710915" title="DOI URL">https://doi.org/10.1002/anie.201710915</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201710915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201710915%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DCatalytic%252BAsymmetric%252BSynthesis%252Bof%252BTrifluoromethylated%252B%2525CE%2525B3-Amino%252BAcids%252Bthrough%252Bthe%252BUmpolung%252BAddition%252Bof%252BTrifluoromethyl%252BImines%252Bto%252BCarboxylic%252BAcid%252BDerivatives%26aulast%3DHu%26aufirst%3DBin%26date%3D2018%26date%3D2018%26volume%3D57%26issue%3D8%26spage%3D2233%26epage%3D2237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ricardo  Calado</span>, <span class="hlFld-ContribAuthor ">Miguel Costa  Leal</span>, <span class="hlFld-ContribAuthor ">Helena  Gaspar</span>, <span class="hlFld-ContribAuthor ">Susana  Santos</span>, <span class="hlFld-ContribAuthor ">António  Marques</span>, <span class="hlFld-ContribAuthor ">Maria Leonor  Nunes</span>, <span class="hlFld-ContribAuthor ">Helena  Vieira</span>. </span><span class="cited-content_cbyCitation_article-title">How to Succeed in Marketing Marine Natural Products for Nutraceutical, Pharmaceutical and Cosmeceutical Markets. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 317-403. <a href="https://doi.org/10.1007/978-3-319-69075-9_9" title="DOI URL">https://doi.org/10.1007/978-3-319-69075-9_9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-69075-9_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-69075-9_9%26sid%3Dliteratum%253Aachs%26atitle%3DHow%252Bto%252BSucceed%252Bin%252BMarketing%252BMarine%252BNatural%252BProducts%252Bfor%252BNutraceutical%25252C%252BPharmaceutical%252Band%252BCosmeceutical%252BMarkets%26aulast%3DCalado%26aufirst%3DRicardo%26date%3D2018%26date%3D2018%26spage%3D317%26epage%3D403%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DGrand%252BChallenges%252Bin%252BMarine%252BBiotechnology%26aulast%3DRampelotto%26aufirst%3DPabulo%2BH.%26date%3D2018%26volume%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>. </span><span class="cited-content_cbyCitation_article-title">Next Generation Payloads for ADCs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 187-214. <a href="https://doi.org/10.1007/978-3-319-78154-9_8" title="DOI URL">https://doi.org/10.1007/978-3-319-78154-9_8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-78154-9_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-78154-9_8%26sid%3Dliteratum%253Aachs%26atitle%3DNext%252BGeneration%252BPayloads%252Bfor%252BADCs%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2018%26date%3D2018%26spage%3D187%26epage%3D214%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DInnovations%252Bfor%252BNext-Generation%252BAntibody-Drug%252BConjugates%26aulast%3DDamelin%26aufirst%3DMarc%26date%3D2018%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pamela A.  Trail</span>, <span class="hlFld-ContribAuthor ">Gene M.  Dubowchik</span>, <span class="hlFld-ContribAuthor ">Timothy B.  Lowinger</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2018,</strong> <em>181 </em>, 126-142. <a href="https://doi.org/10.1016/j.pharmthera.2017.07.013" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2017.07.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2017.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2017.07.013%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DAntibody%252Bdrug%252Bconjugates%252Bfor%252Btreatment%252Bof%252Bbreast%252Bcancer%25253A%252BNovel%252Btargets%252Band%252Bdiverse%252Bapproaches%252Bin%252BADC%252Bdesign%26aulast%3DTrail%26aufirst%3DPamela%2BA.%26date%3D2018%26volume%3D181%26spage%3D126%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew  Sung</span>, <span class="hlFld-ContribAuthor ">Xingzhi  Tan</span>, <span class="hlFld-ContribAuthor ">Bingwen  Lu</span>, <span class="hlFld-ContribAuthor ">Jonathan  Golas</span>, <span class="hlFld-ContribAuthor ">Christine  Hosselet</span>, <span class="hlFld-ContribAuthor ">Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Laurie  Tylaska</span>, <span class="hlFld-ContribAuthor ">Lindsay  King</span>, <span class="hlFld-ContribAuthor ">Dahui  Zhou</span>, <span class="hlFld-ContribAuthor ">Russell  Dushin</span>, <span class="hlFld-ContribAuthor ">Jeremy S.  Myers</span>, <span class="hlFld-ContribAuthor ">Edward  Rosfjord</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Hans-Peter  Gerber</span>, <span class="hlFld-ContribAuthor ">Frank  Loganzo</span>. </span><span class="cited-content_cbyCitation_article-title">Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1). </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (1)
                                     , 243-253. <a href="https://doi.org/10.1158/1535-7163.MCT-17-0403" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-0403</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-0403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-0403%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DCaveolae-Mediated%252BEndocytosis%252Bas%252Ba%252BNovel%252BMechanism%252Bof%252BResistance%252Bto%252BTrastuzumab%252BEmtansine%252B%252528T-DM1%252529%26aulast%3DSung%26aufirst%3DMatthew%26date%3D2018%26date%3D2017%26volume%3D17%26issue%3D1%26spage%3D243%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mikael P.  Johansson</span>, <span class="hlFld-ContribAuthor ">Hannu  Maaheimo</span>, <span class="hlFld-ContribAuthor ">Filip S.  Ekholm</span>. </span><span class="cited-content_cbyCitation_article-title">New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-017-15674-1" title="DOI URL">https://doi.org/10.1038/s41598-017-15674-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-017-15674-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-017-15674-1%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DNew%252Binsight%252Bon%252Bthe%252Bstructural%252Bfeatures%252Bof%252Bthe%252Bcytotoxic%252Bauristatins%252BMMAE%252Band%252BMMAF%252Brevealed%252Bby%252Bcombined%252BNMR%252Bspectroscopy%252Band%252Bquantum%252Bchemical%252Bmodelling%26aulast%3DJohansson%26aufirst%3DMikael%2BP.%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Fengping  Li</span>, <span class="hlFld-ContribAuthor ">Brian  Rago</span>, <span class="hlFld-ContribAuthor ">Xiaogang  Han</span>, <span class="hlFld-ContribAuthor ">Frank  Loganzo</span>, <span class="hlFld-ContribAuthor ">Sylvia  Musto</span>, <span class="hlFld-ContribAuthor ">Edmund I.  Graziani</span>, <span class="hlFld-ContribAuthor ">Sujiet  Puthenveetil</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Casavant</span>, <span class="hlFld-ContribAuthor ">Kimberly  Marquette</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Jack  Bikker</span>, <span class="hlFld-ContribAuthor ">Eric M.  Bennett</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>, <span class="hlFld-ContribAuthor ">Nicole  Piche-Nicholas</span>, <span class="hlFld-ContribAuthor ">Amy  Tam</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O’Donnell</span>, <span class="hlFld-ContribAuthor ">Hans Peter  Gerber</span>, <span class="hlFld-ContribAuthor ">Lioudmila  Tchistiakova</span>. </span><span class="cited-content_cbyCitation_article-title">Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">The AAPS Journal</span><span> <strong>2017,</strong> <em>19 </em>
                                    (4)
                                     , 1123-1135. <a href="https://doi.org/10.1208/s12248-017-0083-7" title="DOI URL">https://doi.org/10.1208/s12248-017-0083-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12248-017-0083-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12248-017-0083-7%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520AAPS%2520Journal%26atitle%3DSite%252BSelection%25253A%252Ba%252BCase%252BStudy%252Bin%252Bthe%252BIdentification%252Bof%252BOptimal%252BCysteine%252BEngineered%252BAntibody%252BDrug%252BConjugates%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2017%26date%3D2017%26volume%3D19%26issue%3D4%26spage%3D1123%26epage%3D1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alain  Beck</span>, <span class="hlFld-ContribAuthor ">Liliane  Goetsch</span>, <span class="hlFld-ContribAuthor ">Charles  Dumontet</span>, <span class="hlFld-ContribAuthor ">Nathalie  Corvaïa</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies and challenges for the next generation of antibody–drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2017,</strong> <em>16 </em>
                                    (5)
                                     , 315-337. <a href="https://doi.org/10.1038/nrd.2016.268" title="DOI URL">https://doi.org/10.1038/nrd.2016.268</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd.2016.268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd.2016.268%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DStrategies%252Band%252Bchallenges%252Bfor%252Bthe%252Bnext%252Bgeneration%252Bof%252Bantibody%2525E2%252580%252593drug%252Bconjugates%26aulast%3DBeck%26aufirst%3DAlain%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D5%26spage%3D315%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David S.  Huang</span>, <span class="hlFld-ContribAuthor ">Henry L.  Wong</span>, <span class="hlFld-ContribAuthor ">Gunda I.  Georg</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Cytotoxicity Evaluation of C4- and C5-Modified Analogues of the α,β-Unsaturated Lactone of Pironetin. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2017,</strong> <em>12 </em>
                                    (7)
                                     , 520-528. <a href="https://doi.org/10.1002/cmdc.201700084" title="DOI URL">https://doi.org/10.1002/cmdc.201700084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700084%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSynthesis%252Band%252BCytotoxicity%252BEvaluation%252Bof%252BC4-%252Band%252BC5-Modified%252BAnalogues%252Bof%252Bthe%252B%2525CE%2525B1%25252C%2525CE%2525B2-Unsaturated%252BLactone%252Bof%252BPironetin%26aulast%3DHuang%26aufirst%3DDavid%2BS.%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D7%26spage%3D520%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Suzhen  Dong</span>, <span class="hlFld-ContribAuthor ">Dengke  Feng</span>, <span class="hlFld-ContribAuthor ">Yazhou  Chen</span>, <span class="hlFld-ContribAuthor ">Mingliang  Ma</span>, <span class="hlFld-ContribAuthor ">Wenhao  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological activity evaluation of dolastatin 10 analogues with N-terminal modifications. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2017,</strong> <em>73 </em>
                                    (16)
                                     , 2255-2266. <a href="https://doi.org/10.1016/j.tet.2017.03.006" title="DOI URL">https://doi.org/10.1016/j.tet.2017.03.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2017.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2017.03.006%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DSynthesis%252Band%252Bbiological%252Bactivity%252Bevaluation%252Bof%252Bdolastatin%252B10%252Banalogues%252Bwith%252BN-terminal%252Bmodifications%26aulast%3DWang%26aufirst%3DXin%26date%3D2017%26volume%3D73%26issue%3D16%26spage%3D2255%26epage%3D2266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Newman</span>, <span class="hlFld-ContribAuthor ">Gordon  Cragg</span>. </span><span class="cited-content_cbyCitation_article-title">Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates. </span><span class="cited-content_cbyCitation_journal-name">Marine Drugs</span><span> <strong>2017,</strong> <em>15 </em>
                                    (4)
                                     , 99. <a href="https://doi.org/10.3390/md15040099" title="DOI URL">https://doi.org/10.3390/md15040099</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/md15040099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmd15040099%26sid%3Dliteratum%253Aachs%26jtitle%3DMarine%2520Drugs%26atitle%3DCurrent%252BStatus%252Bof%252BMarine-Derived%252BCompounds%252Bas%252BWarheads%252Bin%252BAnti-Tumor%252BDrug%252BCandidates%26aulast%3DNewman%26aufirst%3DDavid%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D4%26spage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linghong  Wang</span>, <span class="hlFld-ContribAuthor ">Chao  Dong</span>, <span class="hlFld-ContribAuthor ">Xian  Li</span>, <span class="hlFld-ContribAuthor ">Wenyan  Han</span>, <span class="hlFld-ContribAuthor ">Xiulan  Su</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer potential of bioactive peptides from animal sources. </span><span class="cited-content_cbyCitation_journal-name">Oncology Reports</span><span> <strong>2017,</strong> <em>38 </em>
                                    (2)
                                     , 637-651. <a href="https://doi.org/10.3892/or.2017.5778" title="DOI URL">https://doi.org/10.3892/or.2017.5778</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/or.2017.5778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2For.2017.5778%26sid%3Dliteratum%253Aachs%26jtitle%3DOncology%2520Reports%26atitle%3DAnticancer%252Bpotential%252Bof%252Bbioactive%252Bpeptides%252Bfrom%252Banimal%252Bsources%26aulast%3DWang%26aufirst%3DLinghong%26date%3D2017%26date%3D2017%26volume%3D38%26issue%3D2%26spage%3D637%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marc  Damelin</span>, <span class="hlFld-ContribAuthor ">Alexander  Bankovich</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Bernstein</span>, <span class="hlFld-ContribAuthor ">Justin  Lucas</span>, <span class="hlFld-ContribAuthor ">Liang  Chen</span>, <span class="hlFld-ContribAuthor ">Samuel  Williams</span>, <span class="hlFld-ContribAuthor ">Albert  Park</span>, <span class="hlFld-ContribAuthor ">Jorge  Aguilar</span>, <span class="hlFld-ContribAuthor ">Elana  Ernstoff</span>, <span class="hlFld-ContribAuthor ">Manoj  Charati</span>, <span class="hlFld-ContribAuthor ">Russell  Dushin</span>, <span class="hlFld-ContribAuthor ">Monette  Aujay</span>, <span class="hlFld-ContribAuthor ">Christina  Lee</span>, <span class="hlFld-ContribAuthor ">Hanna  Ramoth</span>, <span class="hlFld-ContribAuthor ">Milly  Milton</span>, <span class="hlFld-ContribAuthor ">Johannes  Hampl</span>, <span class="hlFld-ContribAuthor ">Sasha  Lazetic</span>, <span class="hlFld-ContribAuthor ">Virginia  Pulito</span>, <span class="hlFld-ContribAuthor ">Edward  Rosfjord</span>, <span class="hlFld-ContribAuthor ">Yongliang  Sun</span>, <span class="hlFld-ContribAuthor ">Lindsay  King</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>, <span class="hlFld-ContribAuthor ">Alison  Betts</span>, <span class="hlFld-ContribAuthor ">Magali  Guffroy</span>, <span class="hlFld-ContribAuthor ">Hadi  Falahatpisheh</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O’Donnell</span>, <span class="hlFld-ContribAuthor ">Robert  Stull</span>, <span class="hlFld-ContribAuthor ">Marybeth  Pysz</span>, <span class="hlFld-ContribAuthor ">Paul  Escarpe</span>, <span class="hlFld-ContribAuthor ">David  Liu</span>, <span class="hlFld-ContribAuthor ">Orit  Foord</span>, <span class="hlFld-ContribAuthor ">Hans Peter  Gerber</span>, <span class="hlFld-ContribAuthor ">Puja  Sapra</span>, <span class="hlFld-ContribAuthor ">Scott J.  Dylla</span>. </span><span class="cited-content_cbyCitation_article-title">A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. </span><span class="cited-content_cbyCitation_journal-name">Science Translational Medicine</span><span> <strong>2017,</strong> <em>9 </em>
                                    (372)
                                     , eaag2611. <a href="https://doi.org/10.1126/scitranslmed.aag2611" title="DOI URL">https://doi.org/10.1126/scitranslmed.aag2611</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scitranslmed.aag2611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscitranslmed.aag2611%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Translational%2520Medicine%26atitle%3DA%252BPTK7-targeted%252Bantibody-drug%252Bconjugate%252Breduces%252Btumor-initiating%252Bcells%252Band%252Binduces%252Bsustained%252Btumor%252Bregressions%26aulast%3DDamelin%26aufirst%3DMarc%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D372%26spage%3Deaag2611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dorin  Toader</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 289-289. <a href="https://doi.org/10.1007/7355_2017_29" title="DOI URL">https://doi.org/10.1007/7355_2017_29</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_29%26sid%3Dliteratum%253Aachs%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DToader%26aufirst%3DDorin%26date%3D2017%26spage%3D289%26epage%3D289%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiao-Di  Nie</span>, <span class="hlFld-ContribAuthor ">Yu  Zhang</span>, <span class="hlFld-ContribAuthor ">Chang-Mei  Si</span>, <span class="hlFld-ContribAuthor ">Zhu  Zhou</span>, <span class="hlFld-ContribAuthor ">Xun  Sun</span>, <span class="hlFld-ContribAuthor ">Bang-Guo  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">A practical approach to asymmetric synthesis of dolastatin 10. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2017,</strong> <em>15 </em>
                                    (29)
                                     , 6119-6131. <a href="https://doi.org/10.1039/C7OB01395G" title="DOI URL">https://doi.org/10.1039/C7OB01395G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB01395G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB01395G%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DA%252Bpractical%252Bapproach%252Bto%252Basymmetric%252Bsynthesis%252Bof%252Bdolastatin%252B10%26aulast%3DZhou%26aufirst%3DWen%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D29%26spage%3D6119%26epage%3D6131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leanna R.  Staben</span>, <span class="hlFld-ContribAuthor ">Stefan G.  Koenig</span>, <span class="hlFld-ContribAuthor ">Sophie M.  Lehar</span>, <span class="hlFld-ContribAuthor ">Richard  Vandlen</span>, <span class="hlFld-ContribAuthor ">Donglu  Zhang</span>, <span class="hlFld-ContribAuthor ">Josefa  Chuh</span>, <span class="hlFld-ContribAuthor ">Shang-Fan  Yu</span>, <span class="hlFld-ContribAuthor ">Carl  Ng</span>, <span class="hlFld-ContribAuthor ">Jun  Guo</span>, <span class="hlFld-ContribAuthor ">Yanzhou  Liu</span>, <span class="hlFld-ContribAuthor ">Aimee  Fourie-O'Donohue</span>, <span class="hlFld-ContribAuthor ">MaryAnn  Go</span>, <span class="hlFld-ContribAuthor ">Xin  Linghu</span>, <span class="hlFld-ContribAuthor ">Nathaniel L.  Segraves</span>, <span class="hlFld-ContribAuthor ">Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Jinhua  Chen</span>, <span class="hlFld-ContribAuthor ">BinQing  Wei</span>, <span class="hlFld-ContribAuthor ">Gail D. Lewis  Phillips</span>, <span class="hlFld-ContribAuthor ">Keyang  Xu</span>, <span class="hlFld-ContribAuthor ">Katherine R.  Kozak</span>, <span class="hlFld-ContribAuthor ">Sanjeev  Mariathasan</span>, <span class="hlFld-ContribAuthor ">John A.  Flygare</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Pillow</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemistry</span><span> <strong>2016,</strong> <em>8 </em>
                                    (12)
                                     , 1112-1119. <a href="https://doi.org/10.1038/nchem.2635" title="DOI URL">https://doi.org/10.1038/nchem.2635</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nchem.2635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnchem.2635%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemistry%26atitle%3DTargeted%252Bdrug%252Bdelivery%252Bthrough%252Bthe%252Btraceless%252Brelease%252Bof%252Btertiary%252Band%252Bheteroaryl%252Bamines%252Bfrom%252Bantibody%2525E2%252580%252593drug%252Bconjugates%26aulast%3DStaben%26aufirst%3DLeanna%2BR.%26date%3D2016%26date%3D2016%26volume%3D8%26issue%3D12%26spage%3D1112%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavel  Strop</span>, <span class="hlFld-ContribAuthor ">Thomas-Toan  Tran</span>, <span class="hlFld-ContribAuthor ">Magdalena  Dorywalska</span>, <span class="hlFld-ContribAuthor ">Kathy  Delaria</span>, <span class="hlFld-ContribAuthor ">Russell  Dushin</span>, <span class="hlFld-ContribAuthor ">Oi Kwan  Wong</span>, <span class="hlFld-ContribAuthor ">Wei-Hsien  Ho</span>, <span class="hlFld-ContribAuthor ">Dahui  Zhou</span>, <span class="hlFld-ContribAuthor ">Aidong  Wu</span>, <span class="hlFld-ContribAuthor ">Eugenia  Kraynov</span>, <span class="hlFld-ContribAuthor ">Laura  Aschenbrenner</span>, <span class="hlFld-ContribAuthor ">Bora  Han</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O'Donnell</span>, <span class="hlFld-ContribAuthor ">Jaume  Pons</span>, <span class="hlFld-ContribAuthor ">Arvind  Rajpal</span>, <span class="hlFld-ContribAuthor ">Dave L.  Shelton</span>, <span class="hlFld-ContribAuthor ">Shu-Hui  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2016,</strong> <em>15 </em>
                                    (11)
                                     , 2698-2708. <a href="https://doi.org/10.1158/1535-7163.MCT-16-0431" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-16-0431</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-16-0431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-16-0431%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DRN927C%25252C%252Ba%252BSite-Specific%252BTrop-2%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252B%252528ADC%252529%252Bwith%252BEnhanced%252BStability%25252C%252BIs%252BHighly%252BEfficacious%252Bin%252BPreclinical%252BSolid%252BTumor%252BModels%26aulast%3DStrop%26aufirst%3DPavel%26date%3D2016%26date%3D2016%26volume%3D15%26issue%3D11%26spage%3D2698%26epage%3D2708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian  Rago</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Lindsay  King</span>, <span class="hlFld-ContribAuthor ">Jenny  Zhang</span>, <span class="hlFld-ContribAuthor ">L Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Fengping  Li</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>, <span class="hlFld-ContribAuthor ">Cong  Wei</span>, <span class="hlFld-ContribAuthor ">Mauricio  Leal</span>, <span class="hlFld-ContribAuthor ">Steve  Hansel</span>, <span class="hlFld-ContribAuthor ">Xiaogang  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Calculated conjugated payload from immunoassay and LC–MS intact protein analysis measurements of antibody-drug conjugate. </span><span class="cited-content_cbyCitation_journal-name">Bioanalysis</span><span> <strong>2016,</strong> <em>8 </em>
                                    (21)
                                     , 2205-2217. <a href="https://doi.org/10.4155/bio-2016-0160" title="DOI URL">https://doi.org/10.4155/bio-2016-0160</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/bio-2016-0160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fbio-2016-0160%26sid%3Dliteratum%253Aachs%26jtitle%3DBioanalysis%26atitle%3DCalculated%252Bconjugated%252Bpayload%252Bfrom%252Bimmunoassay%252Band%252BLC%2525E2%252580%252593MS%252Bintact%252Bprotein%252Banalysis%252Bmeasurements%252Bof%252Bantibody-drug%252Bconjugate%26aulast%3DRago%26aufirst%3DBrian%26date%3D2016%26volume%3D8%26issue%3D21%26spage%3D2205%26epage%3D2217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alison M.  Betts</span>, <span class="hlFld-ContribAuthor ">Nahor  Haddish-Berhane</span>, <span class="hlFld-ContribAuthor ">John  Tolsma</span>, <span class="hlFld-ContribAuthor ">Paul  Jasper</span>, <span class="hlFld-ContribAuthor ">Lindsay E.  King</span>, <span class="hlFld-ContribAuthor ">Yongliang  Sun</span>, <span class="hlFld-ContribAuthor ">Subramanyam  Chakrapani</span>, <span class="hlFld-ContribAuthor ">Boris  Shor</span>, <span class="hlFld-ContribAuthor ">Joseph  Boni</span>, <span class="hlFld-ContribAuthor ">Theodore R.  Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. </span><span class="cited-content_cbyCitation_journal-name">The AAPS Journal</span><span> <strong>2016,</strong> <em>18 </em>
                                    (5)
                                     , 1101-1116. <a href="https://doi.org/10.1208/s12248-016-9929-7" title="DOI URL">https://doi.org/10.1208/s12248-016-9929-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12248-016-9929-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12248-016-9929-7%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520AAPS%2520Journal%26atitle%3DPreclinical%252Bto%252BClinical%252BTranslation%252Bof%252BAntibody-Drug%252BConjugates%252BUsing%252BPK%25252FPD%252BModeling%25253A%252Ba%252BRetrospective%252BAnalysis%252Bof%252BInotuzumab%252BOzogamicin%26aulast%3DBetts%26aufirst%3DAlison%2BM.%26date%3D2016%26date%3D2016%26volume%3D18%26issue%3D5%26spage%3D1101%26epage%3D1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew B.  Waight</span>, <span class="hlFld-ContribAuthor ">Katja  Bargsten</span>, <span class="hlFld-ContribAuthor ">Svetlana  Doronina</span>, <span class="hlFld-ContribAuthor ">Michel O.  Steinmetz</span>, <span class="hlFld-ContribAuthor ">Django  Sussman</span>, <span class="hlFld-ContribAuthor ">Andrea E.  Prota</span>, . </span><span class="cited-content_cbyCitation_article-title">Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2016,</strong> <em>11 </em>
                                    (8)
                                     , e0160890. <a href="https://doi.org/10.1371/journal.pone.0160890" title="DOI URL">https://doi.org/10.1371/journal.pone.0160890</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0160890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0160890%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DStructural%252BBasis%252Bof%252BMicrotubule%252BDestabilization%252Bby%252BPotent%252BAuristatin%252BAnti-Mitotics%26aulast%3DWaight%26aufirst%3DAndrew%2BB.%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D8%26spage%3De0160890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leanne  Grafmuller</span>, <span class="hlFld-ContribAuthor ">Cong  Wei</span>, <span class="hlFld-ContribAuthor ">Ragu  Ramanathan</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>, <span class="hlFld-ContribAuthor ">Rick  Steenwyk</span>, <span class="hlFld-ContribAuthor ">Joseph  Tweed</span>. </span><span class="cited-content_cbyCitation_article-title">Unconjugated payload quantification and DAR characterization of antibody–drug conjugates using high-resolution MS. </span><span class="cited-content_cbyCitation_journal-name">Bioanalysis</span><span> <strong>2016,</strong> <em>8 </em>
                                    (16)
                                     , 1663-1678. <a href="https://doi.org/10.4155/bio-2016-0120" title="DOI URL">https://doi.org/10.4155/bio-2016-0120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/bio-2016-0120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fbio-2016-0120%26sid%3Dliteratum%253Aachs%26jtitle%3DBioanalysis%26atitle%3DUnconjugated%252Bpayload%252Bquantification%252Band%252BDAR%252Bcharacterization%252Bof%252Bantibody%2525E2%252580%252593drug%252Bconjugates%252Busing%252Bhigh-resolution%252BMS%26aulast%3DGrafmuller%26aufirst%3DLeanne%26date%3D2016%26volume%3D8%26issue%3D16%26spage%3D1663%26epage%3D1678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi  Yan</span>, <span class="hlFld-ContribAuthor ">Yujie  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yingxia  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Azetidine-Containing TZT-1027 Analogues as Antitumor Agents. </span><span class="cited-content_cbyCitation_journal-name">Marine Drugs</span><span> <strong>2016,</strong> <em>14 </em>
                                    (5)
                                     , 85. <a href="https://doi.org/10.3390/md14050085" title="DOI URL">https://doi.org/10.3390/md14050085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/md14050085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmd14050085%26sid%3Dliteratum%253Aachs%26jtitle%3DMarine%2520Drugs%26atitle%3DNovel%252BAzetidine-Containing%252BTZT-1027%252BAnalogues%252Bas%252BAntitumor%252BAgents%26aulast%3DYan%26aufirst%3DQi%26date%3D2016%26date%3D2016%26volume%3D14%26issue%3D5%26spage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Boris  Shor</span>, <span class="hlFld-ContribAuthor ">Jennifer  Kahler</span>, <span class="hlFld-ContribAuthor ">Maureen  Dougher</span>, <span class="hlFld-ContribAuthor ">Jane  Xu</span>, <span class="hlFld-ContribAuthor ">Michelle  Mack</span>, <span class="hlFld-ContribAuthor ">Ed  Rosfjord</span>, <span class="hlFld-ContribAuthor ">Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Eugene  Melamud</span>, <span class="hlFld-ContribAuthor ">Puja  Sapra</span>. </span><span class="cited-content_cbyCitation_article-title">Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2016,</strong> <em>22 </em>
                                    (2)
                                     , 383-394. <a href="https://doi.org/10.1158/1078-0432.CCR-15-1166" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-15-1166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-15-1166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-15-1166%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DEnhanced%252BAntitumor%252BActivity%252Bof%252Ban%252BAnti-5T4%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252Bin%252BCombination%252Bwith%252BPI3K%25252FmTOR%252Binhibitors%252Bor%252BTaxanes%26aulast%3DShor%26aufirst%3DBoris%26date%3D2016%26date%3D2015%26volume%3D22%26issue%3D2%26spage%3D383%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John W.  Blunt</span>, <span class="hlFld-ContribAuthor ">Brent R.  Copp</span>, <span class="hlFld-ContribAuthor ">Robert A.  Keyzers</span>, <span class="hlFld-ContribAuthor ">Murray H. G.  Munro</span>, <span class="hlFld-ContribAuthor ">Michèle R.  Prinsep</span>. </span><span class="cited-content_cbyCitation_article-title">Marine natural products. </span><span class="cited-content_cbyCitation_journal-name">Natural Product Reports</span><span> <strong>2016,</strong> <em>33 </em>
                                    (3)
                                     , 382-431. <a href="https://doi.org/10.1039/C5NP00156K" title="DOI URL">https://doi.org/10.1039/C5NP00156K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5NP00156K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5NP00156K%26sid%3Dliteratum%253Aachs%26jtitle%3DNatural%2520Product%2520Reports%26atitle%3DMarine%252Bnatural%252Bproducts%26aulast%3DBlunt%26aufirst%3DJohn%2BW.%26date%3D2016%26date%3D2016%26volume%3D33%26issue%3D3%26spage%3D382%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Polakis</span>, . </span><span class="cited-content_cbyCitation_article-title">Antibody Drug Conjugates for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2016,</strong> <em>68 </em>
                                    (1)
                                     , 3-19. <a href="https://doi.org/10.1124/pr.114.009373" title="DOI URL">https://doi.org/10.1124/pr.114.009373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.114.009373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.114.009373%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DAntibody%252BDrug%252BConjugates%252Bfor%252BCancer%252BTherapy%26aulast%3DPolakis%26aufirst%3DPaul%26date%3D2016%26date%3D2015%26volume%3D68%26issue%3D1%26spage%3D3%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Su  Xu</span>, <span class="hlFld-ContribAuthor ">Bhavitavya  Nijampatnam</span>, <span class="hlFld-ContribAuthor ">Shilpa  Dutta</span>, <span class="hlFld-ContribAuthor ">Sadanandan  Velu</span>. </span><span class="cited-content_cbyCitation_article-title">Cyanobacterial Metabolite Calothrixins: Recent Advances in Synthesis and Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Marine Drugs</span><span> <strong>2016,</strong> <em>14 </em>
                                    (1)
                                     , 17. <a href="https://doi.org/10.3390/md14010017" title="DOI URL">https://doi.org/10.3390/md14010017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/md14010017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmd14010017%26sid%3Dliteratum%253Aachs%26jtitle%3DMarine%2520Drugs%26atitle%3DCyanobacterial%252BMetabolite%252BCalothrixins%25253A%252BRecent%252BAdvances%252Bin%252BSynthesis%252Band%252BBiological%252BEvaluation%26aulast%3DXu%26aufirst%3DSu%26date%3D2016%26date%3D2016%26volume%3D14%26issue%3D1%26spage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alberto  Visintin</span>, <span class="hlFld-ContribAuthor ">Kelly  Knowlton</span>, <span class="hlFld-ContribAuthor ">Edyta  Tyminski</span>, <span class="hlFld-ContribAuthor ">Chi-Iou  Lin</span>, <span class="hlFld-ContribAuthor ">Xiang  Zheng</span>, <span class="hlFld-ContribAuthor ">Kimberly  Marquette</span>, <span class="hlFld-ContribAuthor ">Sadhana  Jain</span>, <span class="hlFld-ContribAuthor ">Lioudmila  Tchistiakova</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O'Donnell</span>, <span class="hlFld-ContribAuthor ">Andreas  Maderna</span>, <span class="hlFld-ContribAuthor ">Xianjun  Cao</span>, <span class="hlFld-ContribAuthor ">Robert  Dunn</span>, <span class="hlFld-ContribAuthor ">William B.  Snyder</span>, <span class="hlFld-ContribAuthor ">Anson K.  Abraham</span>, <span class="hlFld-ContribAuthor ">Mauricio  Leal</span>, <span class="hlFld-ContribAuthor ">Shoba  Shetty</span>, <span class="hlFld-ContribAuthor ">Anthony  Barry</span>, <span class="hlFld-ContribAuthor ">Leigh  Zawel</span>, <span class="hlFld-ContribAuthor ">Anthony J.  Coyle</span>, <span class="hlFld-ContribAuthor ">Harold F.  Dvorak</span>, <span class="hlFld-ContribAuthor ">Shou-Ching  Jaminet</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2015,</strong> <em>14 </em>
                                    (8)
                                     , 1868-1876. <a href="https://doi.org/10.1158/1535-7163.MCT-15-0188" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-15-0188</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-15-0188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-15-0188%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DNovel%252BAnti-TM4SF1%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252Bwith%252BActivity%252Bagainst%252BTumor%252BCells%252Band%252BTumor%252BVasculature%26aulast%3DVisintin%26aufirst%3DAlberto%26date%3D2015%26date%3D2015%26volume%3D14%26issue%3D8%26spage%3D1868%26epage%3D1876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Magdalena  Dorywalska</span>, <span class="hlFld-ContribAuthor ">Pavel  Strop</span>, <span class="hlFld-ContribAuthor ">Jody A.  Melton-Witt</span>, <span class="hlFld-ContribAuthor ">Adela  Hasa-Moreno</span>, <span class="hlFld-ContribAuthor ">Santiago E.  Farias</span>, <span class="hlFld-ContribAuthor ">Meritxell  Galindo Casas</span>, <span class="hlFld-ContribAuthor ">Kathy  Delaria</span>, <span class="hlFld-ContribAuthor ">Victor  Lui</span>, <span class="hlFld-ContribAuthor ">Kris  Poulsen</span>, <span class="hlFld-ContribAuthor ">Janette  Sutton</span>, <span class="hlFld-ContribAuthor ">Gary  Bolton</span>, <span class="hlFld-ContribAuthor ">Dahui  Zhou</span>, <span class="hlFld-ContribAuthor ">Ludivine  Moine</span>, <span class="hlFld-ContribAuthor ">Russell  Dushin</span>, <span class="hlFld-ContribAuthor ">Thomas-Toan  Tran</span>, <span class="hlFld-ContribAuthor ">Shu-Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Mathias  Rickert</span>, <span class="hlFld-ContribAuthor ">Davide  Foletti</span>, <span class="hlFld-ContribAuthor ">David L.  Shelton</span>, <span class="hlFld-ContribAuthor ">Jaume  Pons</span>, <span class="hlFld-ContribAuthor ">Arvind  Rajpal</span>, . </span><span class="cited-content_cbyCitation_article-title">Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2015,</strong> <em>10 </em>
                                    (7)
                                     , e0132282. <a href="https://doi.org/10.1371/journal.pone.0132282" title="DOI URL">https://doi.org/10.1371/journal.pone.0132282</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0132282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0132282%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DSite-Dependent%252BDegradation%252Bof%252Ba%252BNon-Cleavable%252BAuristatin-Based%252BLinker-Payload%252Bin%252BRodent%252BPlasma%252Band%252BIts%252BEffect%252Bon%252BADC%252BEfficacy%26aulast%3DDorywalska%26aufirst%3DMagdalena%26date%3D2015%26date%3D2015%26volume%3D10%26issue%3D7%26spage%3De0132282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Brian  Rago</span>, <span class="hlFld-ContribAuthor ">Xiaogang  Han</span>. </span><span class="cited-content_cbyCitation_article-title">In vivo
              biotransformations of antibody–drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioanalysis</span><span> <strong>2015,</strong> <em>7 </em>
                                    (13)
                                     , 1649-1664. <a href="https://doi.org/10.4155/bio.15.84" title="DOI URL">https://doi.org/10.4155/bio.15.84</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/bio.15.84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fbio.15.84%26sid%3Dliteratum%253Aachs%26jtitle%3DBioanalysis%26atitle%3DIn%252Bvivo%252Bbiotransformations%252Bof%252Bantibody%2525E2%252580%252593drug%252Bconjugates%26aulast%3DTumey%26aufirst%3DL%2BNathan%26date%3D2015%26volume%3D7%26issue%3D13%26spage%3D1649%26epage%3D1664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan E.  McNamara</span>, <span class="hlFld-ContribAuthor ">Silvia  Senese</span>, <span class="hlFld-ContribAuthor ">Todd O.  Yeates</span>, <span class="hlFld-ContribAuthor ">Jorge Z.  Torres</span>. </span><span class="cited-content_cbyCitation_article-title">Structures of potent anticancer compounds bound to tubulin. </span><span class="cited-content_cbyCitation_journal-name">Protein Science</span><span> <strong>2015,</strong> <em>24 </em>
                                    (7)
                                     , 1164-1172. <a href="https://doi.org/10.1002/pro.2704" title="DOI URL">https://doi.org/10.1002/pro.2704</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pro.2704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpro.2704%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Science%26atitle%3DStructures%252Bof%252Bpotent%252Banticancer%252Bcompounds%252Bbound%252Bto%252Btubulin%26aulast%3DMcNamara%26aufirst%3DDan%2BE.%26date%3D2015%26date%3D2015%26volume%3D24%26issue%3D7%26spage%3D1164%26epage%3D1172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Guo</span>, <span class="hlFld-ContribAuthor ">Ying-Chao  Liu</span>, <span class="hlFld-ContribAuthor ">Bo  Li</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Convenient synthesis of α,α-(bisallyl and bispropargyl)-substituted amines via aza-Barbier-type reaction. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2015,</strong> <em>56 </em>
                                    (19)
                                     , 2469-2471. <a href="https://doi.org/10.1016/j.tetlet.2015.03.103" title="DOI URL">https://doi.org/10.1016/j.tetlet.2015.03.103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2015.03.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2015.03.103%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DConvenient%252Bsynthesis%252Bof%252B%2525CE%2525B1%25252C%2525CE%2525B1-%252528bisallyl%252Band%252Bbispropargyl%252529-substituted%252Bamines%252Bvia%252Baza-Barbier-type%252Breaction%26aulast%3DGuo%26aufirst%3DTao%26date%3D2015%26volume%3D56%26issue%3D19%26spage%3D2469%26epage%3D2471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frank  Loganzo</span>, <span class="hlFld-ContribAuthor ">Xingzhi  Tan</span>, <span class="hlFld-ContribAuthor ">Matthew  Sung</span>, <span class="hlFld-ContribAuthor ">Guixian  Jin</span>, <span class="hlFld-ContribAuthor ">Jeremy S.  Myers</span>, <span class="hlFld-ContribAuthor ">Eugene  Melamud</span>, <span class="hlFld-ContribAuthor ">Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Veronica  Diesl</span>, <span class="hlFld-ContribAuthor ">Maximillian T.  Follettie</span>, <span class="hlFld-ContribAuthor ">Sylvia  Musto</span>, <span class="hlFld-ContribAuthor ">My-Hanh  Lam</span>, <span class="hlFld-ContribAuthor ">William  Hu</span>, <span class="hlFld-ContribAuthor ">Manoj B.  Charati</span>, <span class="hlFld-ContribAuthor ">Kiran  Khandke</span>, <span class="hlFld-ContribAuthor ">Kenny Sung Kyoo  Kim</span>, <span class="hlFld-ContribAuthor ">Mike  Cinque</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Edmund  Graziani</span>, <span class="hlFld-ContribAuthor ">Andreas  Maderna</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O'Donnell</span>, <span class="hlFld-ContribAuthor ">Kim T.  Arndt</span>, <span class="hlFld-ContribAuthor ">Hans-Peter  Gerber</span>. </span><span class="cited-content_cbyCitation_article-title">Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2015,</strong> <em>14 </em>
                                    (4)
                                     , 952-963. <a href="https://doi.org/10.1158/1535-7163.MCT-14-0862" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-14-0862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-14-0862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-14-0862%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DTumor%252BCells%252BChronically%252BTreated%252Bwith%252Ba%252BTrastuzumab%2525E2%252580%252593Maytansinoid%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BDevelop%252BVaried%252BResistance%252BMechanisms%252Bbut%252BRespond%252Bto%252BAlternate%252BTreatments%26aulast%3DLoganzo%26aufirst%3DFrank%26date%3D2015%26date%3D2015%26volume%3D14%26issue%3D4%26spage%3D952%26epage%3D963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeffrey Y. W.  Mak</span>, <span class="hlFld-ContribAuthor ">Weijun  Xu</span>, <span class="hlFld-ContribAuthor ">David P.  Fairlie</span>. </span><span class="cited-content_cbyCitation_article-title">Thiazoles in Peptides and Peptidomimetics. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 235-266. <a href="https://doi.org/10.1007/7081_2015_176" title="DOI URL">https://doi.org/10.1007/7081_2015_176</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7081_2015_176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7081_2015_176%26sid%3Dliteratum%253Aachs%26atitle%3DThiazoles%252Bin%252BPeptides%252Band%252BPeptidomimetics%26aulast%3DMak%26aufirst%3DJeffrey%2BY.%2BW.%26date%3D2015%26date%3D2015%26spage%3D235%26epage%3D266%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DPeptidomimetics%252BI%26aulast%3DLubell%26aufirst%3DWilliam%2BD.%26date%3D2017%26volume%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of Dolastatin 10 (<b>1</b>) and key amino acid components.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of key auristatin analogues with three different C-termini. Top: Dolastatin 10 (<b>1</b>) and monomethyl auristatin-D (MMAD, <b>2</b>). Middle: auristatin-E (<b>3</b>) and monomethyl auristatin-E (MMAE, <b>4</b>). Bottom: auristatin-PHE (<b>5</b>) and monomethyl auristatin-F (MMAF, <b>6</b>). Color coding of C-termini: dolaphenine, (orange), (1<i>S</i>,2<i>R</i>)-(+)-norephedrine (yellow), and phenylalanine (green). Red arrow: removal of one <i>N</i>-Me group does not lead to significant potency loss.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Hotspots for structural modifications of auristatin analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of soblidotin (TZT-1027) (<b>7</b>) with the (Tc)2R tubulin construct as described by Cormier, Knossow, et al.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> View of the N-terminus with the arrow indicating the N-terminal secondary carbon atom of interest. The structure of <b>7</b> is depicted with the correct stereochemical assignments as reported for <b>7</b><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> but deviates from that reported in ref <a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">6</a>, see text. A binding void is apparent in the receptor pocket that indicates the potential for further substitutions. Protein residues are displayed with their van der Waals radii and color coded based on atom type (dark-blue, nitrogen; red, oxygen; light-blue, β subunit carbon; green, α subunit carbon). For the overall orientation of auristatin analogues at the α,β-tubulin interface, see Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> and ref <a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">6</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0013.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Convergent Synthesis of Dolalstatin 10 (<b>1</b>) Based on Tripeptide <b>8</b> and Dimer <b>9</b>.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0014.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the Tetramer Val-Dil-Dap-Doe (<b>18</b>) by Using a Modular Approach from Dimers <b>15</b> and <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TFA/DCM for <b>15</b>; (b) HCl dioxane for <b>16</b>; (c) HATU, <i>i</i>-Pr<sub>2</sub>NEt, DCM, 78%; (d) Et<sub>2</sub>NH, THF, rt, 87%. Boc-protected <b>18</b> was previously prepared by an alternative method.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a></p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0015.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of New Auristatin Analogues <b>20a</b>–<b>l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HATU, Et<sub>3</sub>N, DMF; (b) Et<sub>2</sub>NH, THF (<b>a</b>–<b>e</b>) or TFA, DCM (<b>f</b>–<b>l</b>), (yields: 27–67% over two steps). N-Pg: protected amine.</p></p></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0016.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of New Auristatin Analogues <b>22a</b>,<b>b</b>,<b>g</b> Containing a Phenylalanine- Instead of the Dolaphenine C-Terminus Present in <b>20a</b>–<b>l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HATU, Et<sub>3</sub>N, DMF (b) LiOH, MeOH; (c) TFA, DCM (additional step for <b>22g</b>). Yields: 33–56% over two steps.</p></p></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Co-crystal structure of <b>20a</b> with the (Tc)2R tubulin construct. Overview of the binding mode with relative orientation of construct components. <b>20a</b> binds at the α,β-tubulin interface. A second molecule of <b>20a</b> is also associated with the exterior β-subunit. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1I">4X1I</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding mode of <b>20a</b> observed in the 3.1 Å costructure with tubulin with selected key receptor interactions at the N-terminus. Red, β-subunit; blue, α-subunit; GDP in green. For simplicity, the structure of <b>20a</b> is drawn with <i>trans</i>-configuration of the Val-Dil amide bond (indicated with arrow), but in the cocrystal structure the Val-Dil amide bond of <b>20a</b> bound at the tubulin β1/α2 interface has <i>cis</i>-configuration, see text. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1I">4X1I</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding mode of <b>20a</b> observed in the 3.1 Å costructure with tubulin, view on the C-terminus. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1I">4X1I</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Configurational differences between the valine (Val) and dolaisoleuine (Dil) residues of compound <b>20a</b>, as observed at the β1/α2 tubulin interface (cyan) and observed bound to β2 tubulin (orange), is highlighted by the red circle. Only in the <i>cis</i>-configuration the carbonyl of the valine residue is able to make a productive interaction with Asn α329 from the α2 subunit. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1I">4X1I</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Overlayed cocrystal structures of <b>22a</b> and <b>22g</b>. Left: structure complexes in the binding domain superimposed and showing entire peptide structures of <b>22a</b> and <b>22g</b>. Right: close-up view of N-terminus. Visible is the critical hydrogen bond network of both N-termini with Asp β179, Phe α351, and Asn α329, interactions that are preserved in both molecules and believed to be important for binding affinity. The Val-Dil amide bonds are in <i>cis</i>-configuration. RDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1K">4X1K</a> (<b>22a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X20">4X20</a> (<b>22g</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0011.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Overlayed cocrystal structures of <b>22b</b> and <b>22g</b>, view of the N-terminus. Notable is the relative orientation of the pyrrolidine Me-group and the two geminal methyl groups in <b>22b</b>. In both analogues, the Val-Dil amide bonds have <i>cis</i>-configuration and engage with Asn α329 via bifocal interaction. RDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1Y">4X1Y</a> (<b>22b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X20">4X20</a> (<b>22g</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/medium/jm-2014-01649k_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0012.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>X</i>-axis: log scale, human liver microsome (HLM) apparent intrinsic clearance values of selected analogues [μL/min/mg], dose: 1 μM. <i>Y</i>-axis: Compound row number, without dimension. Compounds in the yellow box are compounds with reference N-termini. Significant increase in HLM clearance values for new analogues was recorded and is graphically represented by the green arrow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm501649k/20141218/images/large/jm-2014-01649k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501649k&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11337" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11337" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuinman, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boettner, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kizu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baczynskyj, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomer, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontems, R. J.</span><span> </span><span class="NLM_article-title">The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">6883</span><span class="NLM_x">–</span> <span class="NLM_lpage">6885</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00256a070" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1987&pages=6883-6885&author=G.+R.+Pettitauthor=Y.+Kamanoauthor=C.+L.+Heraldauthor=A.+A.+Tuinmanauthor=F.+E.+Boettnerauthor=H.+Kizuauthor=J.+M.+Schmidtauthor=L.+Baczynskyjauthor=K.+B.+Tomerauthor=R.+J.+Bontems&title=The+isolation+and+structure+of+a+remarkable+marine+animal+antineoplastic+constituent%3A+dolastatin+10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fja00256a070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00256a070%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DKamano%26aufirst%3DY.%26aulast%3DHerald%26aufirst%3DC.%2BL.%26aulast%3DTuinman%26aufirst%3DA.%2BA.%26aulast%3DBoettner%26aufirst%3DF.%2BE.%26aulast%3DKizu%26aufirst%3DH.%26aulast%3DSchmidt%26aufirst%3DJ.%2BM.%26aulast%3DBaczynskyj%26aufirst%3DL.%26aulast%3DTomer%26aufirst%3DK.%2BB.%26aulast%3DBontems%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520isolation%2520and%2520structure%2520of%2520a%2520remarkable%2520marine%2520animal%2520antineoplastic%2520constituent%253A%2520dolastatin%252010%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1987%26volume%3D109%26spage%3D6883%26epage%3D6885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1941</span><span class="NLM_x">–</span> <span class="NLM_lpage">1949</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1990&pages=1941-1949&author=R.+Baiauthor=G.+R.+Pettitauthor=E.+Hamel&title=Dolastatin+10%2C+a+powerful+cytostatic+peptide+derived+from+a+marine+animal.+Inhibition+of+tubulin+polymerization+mediated+through+the+vinca+alkaloid+binding+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DR.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DDolastatin%252010%252C%2520a%2520powerful%2520cytostatic%2520peptide%2520derived%2520from%2520a%2520marine%2520animal.%2520Inhibition%2520of%2520tubulin%2520polymerization%2520mediated%2520through%2520the%2520vinca%2520alkaloid%2520binding%2520domain%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1990%26volume%3D39%26spage%3D1941%26epage%3D1949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Luesch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, T. H.</span><span> </span><span class="NLM_article-title">Isolation of dolastatin-10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1</span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">–</span> <span class="NLM_lpage">910</span></span><div class="citationLinks">[<a href="/doi/10.1021/np010049y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2001&pages=907-910&author=H.+Lueschauthor=R.+E.+Mooreauthor=V.+J.+Paulauthor=S.+L.+Mooberryauthor=T.+H.+Corbett&title=Isolation+of+dolastatin-10+from+the+marine+cyanobacterium+Symploca+species+VP642+and+total+stereochemistry+and+biological+evaluation+of+its+analogue+symplostatin+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fnp010049y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp010049y%26sid%3Dliteratum%253Aachs%26aulast%3DLuesch%26aufirst%3DH.%26aulast%3DMoore%26aufirst%3DR.%2BE.%26aulast%3DPaul%26aufirst%3DV.%2BJ.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DCorbett%26aufirst%3DT.%2BH.%26atitle%3DIsolation%2520of%2520dolastatin-10%2520from%2520the%2520marine%2520cyanobacterium%2520Symploca%2520species%2520VP642%2520and%2520total%2520stereochemistry%2520and%2520biological%2520evaluation%2520of%2520its%2520analogue%2520symplostatin%25201%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2001%26volume%3D64%26spage%3D907%26epage%3D910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Harrigan, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G.</span><span> </span><span class="NLM_article-title">Symbiotic and dietary marine microalgae as a source of bioactive molecules—experience from natural products research</span> <span class="citation_source-journal">J. Appl. Phycol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1023%2FA%3A1019570122349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2002&pages=103-108&author=G.+G.+Harriganauthor=G.+Goetz&title=Symbiotic+and+dietary+marine+microalgae+as+a+source+of+bioactive+molecules%E2%80%94experience+from+natural+products+research"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Symbiotic and dietary marine microalgae as a source of bioactive molecules-experience from natural products research</span></div><div class="casAuthors">Harrigan, George G.; Goetz, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Phycology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-108</span>CODEN:
                <span class="NLM_cas:coden">JAPPEL</span>;
        ISSN:<span class="NLM_cas:issn">0921-8971</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Cyanobacterial metabolites have proven to be invaluable as tools in the dissection of signal transduction pathways in mammalian cells and some are currently under clin. evaluation as drug candidates.  It is now also realized that cyanobacteria are the true biosynthetic origin of many bioactive mols. isolated from marine invertebrates; marine invertebrates may sequester cyanobacteria through diet or by symbiosis.  This review discusses the dietary-derived cyanobacterial origin of the dolastatins, potent cytotoxic compds., originally isolated from the Indian Ocean sea hare, Dolabella auricularia.  A discussion on the dietary dissemination of cyanobacterial metabolites through the marine food chain is also presented.  Ref. to the metabolites isolated from Dysidea sponges is given to illustrate their origin from symbiotic cyanobacteria assocd. with this organism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokca8ZMSzoY7Vg90H21EOLACvtfcHk0lhrtuFFci3Zow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKqtb8%253D&md5=47644f526f7667b9dbd7d2cc902e0b8d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1023%2FA%3A1019570122349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1019570122349%26sid%3Dliteratum%253Aachs%26aulast%3DHarrigan%26aufirst%3DG.%2BG.%26aulast%3DGoetz%26aufirst%3DG.%26atitle%3DSymbiotic%2520and%2520dietary%2520marine%2520microalgae%2520as%2520a%2520source%2520of%2520bioactive%2520molecules%25E2%2580%2594experience%2520from%2520natural%2520products%2520research%26jtitle%3DJ.%2520Appl.%2520Phycol.%26date%3D2002%26volume%3D14%26spage%3D103%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd-Williams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkett, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clewlow, P. J.</span><span> </span><span class="NLM_article-title">Antineoplastic agents. Part 189. The absolute configuration and synthesis of natural (−)-dolastatin-10</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5463</span><span class="NLM_x">–</span> <span class="NLM_lpage">5465</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00196a061" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1989&pages=5463-5465&author=G.+R.+Pettitauthor=S.+B.+Singhauthor=F.+Hoganauthor=P.+Lloyd-Williamsauthor=D.+L.+Heraldauthor=D.+D.+Burkettauthor=P.+J.+Clewlow&title=Antineoplastic+agents.+Part+189.+The+absolute+configuration+and+synthesis+of+natural+%28%E2%88%92%29-dolastatin-10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fja00196a061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00196a061%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26aulast%3DHogan%26aufirst%3DF.%26aulast%3DLloyd-Williams%26aufirst%3DP.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DBurkett%26aufirst%3DD.%2BD.%26aulast%3DClewlow%26aufirst%3DP.%2BJ.%26atitle%3DAntineoplastic%2520agents.%2520Part%2520189.%2520The%2520absolute%2520configuration%2520and%2520synthesis%2520of%2520natural%2520%2528%25E2%2588%2592%2529-dolastatin-10%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1989%26volume%3D111%26spage%3D5463%26epage%3D5465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Cormier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravelli, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span> </span><span class="NLM_article-title">Structural insight into the inhibition of tubulin by vinca domain peptide ligands</span> <span class="citation_source-journal">EMBO Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1101</span><span class="NLM_x">–</span> <span class="NLM_lpage">1106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=1101-1106&author=A.+Cormierauthor=M.+Marchandauthor=R.+B.+Ravelliauthor=M.+Knossowauthor=B.+Gigant&title=Structural+insight+into+the+inhibition+of+tubulin+by+vinca+domain+peptide+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCormier%26aufirst%3DA.%26aulast%3DMarchand%26aufirst%3DM.%26aulast%3DRavelli%26aufirst%3DR.%2BB.%26aulast%3DKnossow%26aufirst%3DM.%26aulast%3DGigant%26aufirst%3DB.%26atitle%3DStructural%2520insight%2520into%2520the%2520inhibition%2520of%2520tubulin%2520by%2520vinca%2520domain%2520peptide%2520ligands%26jtitle%3DEMBO%2520Rep.%26date%3D2008%26volume%3D9%26spage%3D1101%26epage%3D1106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Newman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covey, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benvenuto, J. A.</span><span> </span><span class="NLM_article-title">Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128)</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1994&pages=428-432&author=R.+A.+Newmanauthor=A.+Fuentesauthor=J.+M.+Coveyauthor=J.+A.+Benvenuto&title=Preclinical+pharmacology+of+the+natural+marine+product+dolastatin+10+%28NSC+376128%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DR.%2BA.%26aulast%3DFuentes%26aufirst%3DA.%26aulast%3DCovey%26aufirst%3DJ.%2BM.%26aulast%3DBenvenuto%26aufirst%3DJ.%2BA.%26atitle%3DPreclinical%2520pharmacology%2520of%2520the%2520natural%2520marine%2520product%2520dolastatin%252010%2520%2528NSC%2520376128%2529%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1994%26volume%3D22%26spage%3D428%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Mirsalis, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler-Horvat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaszewski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyson, C. A.</span><span> </span><span class="NLM_article-title">Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1007%2Fs002800050995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=10501913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVWlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1999&pages=395-402&author=J.+C.+Mirsalisauthor=J.+Schindler-Horvatauthor=J.+R.+Hillauthor=J.+E.+Tomaszewskiauthor=S.+J.+Donohueauthor=C.+A.+Tyson&title=Toxicity+of+dolastatin+10+in+mice%2C+rats+and+dogs+and+its+clinical+relevance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicity of dolastatin 10 in mice, rats, and dogs and its clinical relevance</span></div><div class="casAuthors">Mirsalis, Jon C.; Schindler-Horvat, Janice; Hill, James R.; Tomaszewski, Joseph E.; Donohue, Susan J.; Tyson, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">395-402</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Dolastatin 10 (DOL10), an oligopeptide isolated from the sea hare Dolabella auricularia, was shown to be a highly potent cytotoxic agent in a variety of human tumor cell lines.  The purpose of this study was to conduct preclin. toxicity evaluations to det. the target organ(s) of toxicity and its reversibility, the dose-limiting toxicity and the max. tolerated dose (MTD), and to use this information for arriving at a safe starting dose and dose schedule for phase I clin. trails.  DOL10 was administered as a single i.v. bolus dose to CD2F1 mice, Fischer-344 rats, and beagle dogs.  Endpoints evaluated included clin. observations, body wts., hematol., blood serum clin. chem., and microscopic pathol. of tissues.  The MTD (i.e. the highest dose that did not cause lethality but produced substantial toxicity) was approx. 1350 μg/m2 body surface area (450 μg/kg) in mice, 450 μg/m2 (75 μg/kg) in rats, and ≤400 μg/m2 (≤20 μg/kg) in dogs.  Adverse signs were obsd. at doses ≥1350 μg/m2 in mice, ≥150 μg/m2 in rats, and ≥400 μg/m2 in dogs.  Decreased wt. gain or actual wt. loss was obsd. at doses ≥1350 μg/m2 in mice, ≥600 μg/m2 in rats, and ≥450 μg/m2 in dogs.  In all 3 species, the primary target organ of toxicity was the bone marrow, as indicated by decreases in the nos. of erythroid cells, myeloid cells, and megakaryocytes in the femoral bone marrow and by decreased white blood cell (WBC) and reticulocyte counts in peripheral blood.  Marked neutropenia (i.e. >50% decrease compared to control animal or baseline values) was the principal effect on WBCs and occurred within a week of dosing.  A mild anemia was evident 1 wk after administering the drug to rats and dogs.  The hematol. effects were transient and reversed by study termination.  Other lesions at the MTD levels were cellular depletion and necrosis in lymphoid organs (rats and dogs), marked depletion of extramedullary hematopoietic cellular elements in the spleen (rats), thymic atrophy (mice and dogs), and minimal cellular necrosis in the ileum (rats).  More extensive and severe pathol. was obsd. in animals sacrificed in a moribund condition or found dead.  Myelotoxicity was dose-limiting in all 3 species with mice being the least sensitive.  In a phase I clin. trial, granulocytopenia was dose-limiting.  Moreover, the MTD of DOL10 for rats and dogs is comparable to the human MTD.  Therefore, the results from the preclin. toxicol. studies correctly predicted a safe starting dose, the dose-limiting toxicity, and the MTD in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaNjIErA4qtbVg90H21EOLACvtfcHk0lgp4lRXZxFLOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVWlu7Y%253D&md5=cd3eb75208a2e0f97ade4332bfa5ed77</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs002800050995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800050995%26sid%3Dliteratum%253Aachs%26aulast%3DMirsalis%26aufirst%3DJ.%2BC.%26aulast%3DSchindler-Horvat%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DJ.%2BR.%26aulast%3DTomaszewski%26aufirst%3DJ.%2BE.%26aulast%3DDonohue%26aufirst%3DS.%2BJ.%26aulast%3DTyson%26aufirst%3DC.%2BA.%26atitle%3DToxicity%2520of%2520dolastatin%252010%2520in%2520mice%252C%2520rats%2520and%2520dogs%2520and%2520its%2520clinical%2520relevance%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1999%26volume%3D44%26spage%3D395%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Pitot, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, E. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windebank, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagniewski, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, M. M.</span><span> </span><span class="NLM_article-title">Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=10100703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK1MXitVyisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=525-531&author=H.+C.+Pitotauthor=E.+A.+McElroyauthor=J.+M.+Reidauthor=A.+J.+Windebankauthor=J.+A.+Sloanauthor=C.+Erlichmanauthor=P.+G.+Bagniewskiauthor=D.+L.+Walkerauthor=J.+Rubinauthor=R.+M.+Goldbergauthor=A.+A.+Adjeiauthor=M.+M.+Ames&title=Phase+I+trial+of+dolastatin-10+%28NSC+376128%29+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors</span></div><div class="casAuthors">Pitot, Henry C.; McElroy, Edwin A., Jr.; Reid, Joel M.; Windebank, Anthony J.; Sloan, Jeff A.; Erlichman, Charles; Bagniewski, Pamela G.; Walker, Denise L.; Rubin, Joseph; Goldberg, Richard M.; Adjei, Alex A.; Ames, Matthew M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Dolastatin-10 (dola-10) is a potent antimitotic peptide, isolated from the marine mollusk Dolabela auricularia, that inhibits tubulin polymn.  Preclin. studies of dola-10 have demonstrated activity against a variety of murine and human tumors in cell cultures and mice models.  The purpose of this Phase I clin. trial was to characterize the max. tolerated dose, pharmacokinetics, and biol. effects of dola-10 in patients with advanced solid tumors.  Escalating doses of dola-10 were administered as an i.v. bolus every 21 days, using a modified Fibonacci dose escalation schema.  Pharmacokinetic studies were performed with the first treatment cycle.  Neurol. testing was performed on each patient prior to treatment with dola-10, at 6 wk and at study termination.  Thirty eligible patients received a total of 94 cycles (median, 2 cycles; max., 14 cycles) of dola-10 at doses ranging from 65 to 455 μg/m2.  Dose-limiting toxicity of granulocytopenia was seen at 455 μg/m2 for minimally pretreated patients (two or fewer prior chemotherapy regimens) and 325 μg/m2 for heavily pretreated patients (more than two prior chemotherapy regimens).  Nonhematol. toxicity was generally mild.  Local irritation at the drug injection site was mild and not dose dependent.  Nine patients developed new or increased symptoms of mild peripheral sensory neuropathy that was not dose limiting.  This toxicity was more frequent in patients with preexisting peripheral neuropathies.  Pharmacokinetic studies demonstrated a rapid drug distribution with a prolonged plasma elimination phase (t1/2z = 320 min).  The area under the concn.-time curve increased in proportion to administered dose, whereas the clearance remained const. over the doses studied.  Correlation anal. demonstrated a strong relationship between dola-10 area under the concn.-time curve values and decrease from baseline for leukocyte counts.  In conclusion, dola-10 administered every 3 wk as a peripheral i.v. bolus is well tolerated with dose-limiting toxicity of granulocytopenia.  The max. tolerated dose (and recommended Phase II starting dose) is 400 μg/m2 for patients with minimal prior treatment (two or fewer prior chemotherapy regimens) and 325 μg/m2 for patients who are heavily pretreated (more than two prior chemotherapy regimens).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTh_xvULk4irVg90H21EOLACvtfcHk0lgp4lRXZxFLOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitVyisLY%253D&md5=7f6f8059458c8aabd86b9c13a408ceae</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPitot%26aufirst%3DH.%2BC.%26aulast%3DMcElroy%26aufirst%3DE.%2BA.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DWindebank%26aufirst%3DA.%2BJ.%26aulast%3DSloan%26aufirst%3DJ.%2BA.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DBagniewski%26aufirst%3DP.%2BG.%26aulast%3DWalker%26aufirst%3DD.%2BL.%26aulast%3DRubin%26aufirst%3DJ.%26aulast%3DGoldberg%26aufirst%3DR.%2BM.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26atitle%3DPhase%2520I%2520trial%2520of%2520dolastatin-10%2520%2528NSC%2520376128%2529%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1999%26volume%3D5%26spage%3D525%26epage%3D531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Madden, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusztai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbruzzese, J. L.</span><span> </span><span class="NLM_article-title">Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1293</span><span class="NLM_x">–</span> <span class="NLM_lpage">1301</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=10778954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtVOqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=1293-1301&author=T.+Maddenauthor=H.+T.+Tranauthor=D.+Beckauthor=R.+Huieauthor=R.+A.+Newmanauthor=L.+Pusztaiauthor=J.+J.+Wrightauthor=J.+L.+Abbruzzese&title=Novel+marine-derived+anticancer+agents%3A+a+phase+I+clinical%2C+pharmacological%2C+and+pharmacodynamic+study+of+dolastatin+10+%28NSC+376128%29+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors</span></div><div class="casAuthors">Madden, Timothy; Tran, Hai T.; Beck, Debrah; Huie, Reeves; Newman, Robert A.; Pusztai, Lajos; Wright, John J.; Abbruzzese, James L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1293-1301</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Dolastatin (DOLA)-10 is a pentapeptide isolated from the mollusk Dolabella auricularia with clin. promising antitumor activity documented in various in vitro and in vivo tumor models.  The objectives of this Phase I study were to det. the max. tolerated dose, evaluate toxic effects, and document any antitumor activity of this novel agent.  Using an electrospray ionization mass spectroscopy system, we also characterized the clin. pharmacokinetics, pharmacodynamics, and metab. of DOLA-10.  The max. tolerated dose was reached at 300 μg/m2.  Granulocytopenia, the dose-limiting toxicity, was documented in 33% of the patients treated at that dose level.  There were no episodes of thrombocytopenia or severe anemia (Hgb < 8), and no major non-hematol. toxicity was obsd.  Stabilization of tumor growth was obsd. in four patients, but no objective responses were seen.  Whereas a two-compartment model described the DOLA-10 plasma concn.-time data reasonably well, a three-compartment model consistently performed better.  After a rapid distribution phase, DOLA-10 plasma levels declined with mean β and γ half-lives of 0.99 and 18.9 h, resp.  Significant interpatient and intrapatient variability in DOLA-10 plasma clearances was obsd.  The mean area under the concn.-time curve increased proportionally as the dose was escalated, but there was significant overlap between dose levels.  The area under the concn.-time curve and the percentage of decline in neutrophils were correlated.  A single DOLA-10 metabolite was detected in five patients.  Unlike the in vitro studies of DOLA-10, the principal metabolite detected was an N-demethyl deriv., confirmed by mass spectroscopy.  In all five subjects, the concn. of this metabolite never exceeded 2% of the simultaneously measured parent drug concn.  The available preclin., pharmacol., and clin. data suggest that further study of escalated DOLA-10 dosing with cytokine support is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqplGzd64izWbVg90H21EOLACvtfcHk0lhmkzPgtVXEYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtVOqtrk%253D&md5=1537dce83d891134bbb6b8b8e3b0e1a7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMadden%26aufirst%3DT.%26aulast%3DTran%26aufirst%3DH.%2BT.%26aulast%3DBeck%26aufirst%3DD.%26aulast%3DHuie%26aufirst%3DR.%26aulast%3DNewman%26aufirst%3DR.%2BA.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26atitle%3DNovel%2520marine-derived%2520anticancer%2520agents%253A%2520a%2520phase%2520I%2520clinical%252C%2520pharmacological%252C%2520and%2520pharmacodynamic%2520study%2520of%2520dolastatin%252010%2520%2528NSC%2520376128%2529%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2000%26volume%3D6%26spage%3D1293%26epage%3D1301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Margolin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longmate, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Synold, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandara, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baratta, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span> </span><span class="NLM_article-title">Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=335-340&author=K.+Margolinauthor=J.+Longmateauthor=T.+W.+Synoldauthor=D.+R.+Gandaraauthor=J.+Weberauthor=R.+Gonzalezauthor=M.+J.+Johansenauthor=R.+Newmanauthor=T.+Barattaauthor=J.+H.+Doroshow&title=Dolastatin-10+in+metastatic+melanoma%3A+a+phase+II+and+pharmokinetic+trial+of+the+California+Cancer+Consortium"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMargolin%26aufirst%3DK.%26aulast%3DLongmate%26aufirst%3DJ.%26aulast%3DSynold%26aufirst%3DT.%2BW.%26aulast%3DGandara%26aufirst%3DD.%2BR.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DJohansen%26aufirst%3DM.%2BJ.%26aulast%3DNewman%26aufirst%3DR.%26aulast%3DBaratta%26aufirst%3DT.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26atitle%3DDolastatin-10%2520in%2520metastatic%2520melanoma%253A%2520a%2520phase%2520II%2520and%2520pharmokinetic%2520trial%2520of%2520the%2520California%2520Cancer%2520Consortium%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2001%26volume%3D19%26spage%3D335%26epage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balcerzak, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmonson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuno, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beard, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogatko, A.</span><span> </span><span class="NLM_article-title">Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas</span> <span class="citation_source-journal">Sarcoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2004&pages=107-111&author=M.+von+Mehrenauthor=S.+P.+Balcerzakauthor=A.+S.+Kraftauthor=J.+H.+Edmonsonauthor=S.+H.+Okunoauthor=M.+Daveyauthor=S.+McLaughlinauthor=M.+T.+Beardauthor=A.+Rogatko&title=Phase+II+trial+of+dolastatin-10%2C+a+novel+anti-tubulin+agent%2C+in+metastatic+soft+tissue+sarcomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBalcerzak%26aufirst%3DS.%2BP.%26aulast%3DKraft%26aufirst%3DA.%2BS.%26aulast%3DEdmonson%26aufirst%3DJ.%2BH.%26aulast%3DOkuno%26aufirst%3DS.%2BH.%26aulast%3DDavey%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DS.%26aulast%3DBeard%26aufirst%3DM.%2BT.%26aulast%3DRogatko%26aufirst%3DA.%26atitle%3DPhase%2520II%2520trial%2520of%2520dolastatin-10%252C%2520a%2520novel%2520anti-tubulin%2520agent%252C%2520in%2520metastatic%2520soft%2520tissue%2520sarcomas%26jtitle%3DSarcoma%26date%3D2004%26volume%3D8%26spage%3D107%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Perez, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillman, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishkin, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krook, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriakose, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberts, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakhil, S. R.</span><span> </span><span class="NLM_article-title">Phase II trial of dolastatin-10 in patients with advanced breast cancer</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=257-261&author=E.+A.+Perezauthor=D.+W.+Hillmanauthor=P.+A.+Fishkinauthor=J.+E.+Krookauthor=W.+W.+Tanauthor=P.+A.+Kuriakoseauthor=S.+R.+Albertsauthor=S.+R.+Dakhil&title=Phase+II+trial+of+dolastatin-10+in+patients+with+advanced+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DHillman%26aufirst%3DD.%2BW.%26aulast%3DFishkin%26aufirst%3DP.%2BA.%26aulast%3DKrook%26aufirst%3DJ.%2BE.%26aulast%3DTan%26aufirst%3DW.%2BW.%26aulast%3DKuriakose%26aufirst%3DP.%2BA.%26aulast%3DAlberts%26aufirst%3DS.%2BR.%26aulast%3DDakhil%26aufirst%3DS.%2BR.%26atitle%3DPhase%2520II%2520trial%2520of%2520dolastatin-10%2520in%2520patients%2520with%2520advanced%2520breast%2520cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2005%26volume%3D23%26spage%3D257%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Miyazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natsume, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakakibara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukagoshi, S.</span><span> </span><span class="NLM_article-title">Synthesis and antitumor activity of novel dolastatin 10 analogs</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1706</span><span class="NLM_x">–</span> <span class="NLM_lpage">1718</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1248%2Fcpb.43.1706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=8536345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK2MXpsF2nsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1995&pages=1706-1718&author=K.+Miyazakiauthor=M.+Kobayashiauthor=T.+Natsumeauthor=M.+Gondoauthor=T.+Mikamiauthor=K.+Sakakibaraauthor=S.+Tsukagoshi&title=Synthesis+and+antitumor+activity+of+novel+dolastatin+10+analogs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antitumor activity of novel dolastatin 10 analogs</span></div><div class="casAuthors">Miyazaki, Koichi; Kobayashi, Motohiro; Natsume, Tsugitaka; Gondo, Masaaki; Mikami, Takashi; Sakakibara, Kyoichi; Tsukagoshi, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1706-18</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Novel analogs of dolastatin 10, a a potent antineoplastic pentapeptide, each modified at one of the constituent amino acid derivs., were synthesized and their antitumor activity was evaluated against P388 leukemia in mice.  The structural requirements for antitumor activity are discussed.  Some of the analogs showed excellent activity in vivo.  Highly active analog I, which lacks the thiazole group of dolastatin 10, was selected for further development as an antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow5K2LB02S6rVg90H21EOLACvtfcHk0lgi8hjD_BP74A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpsF2nsbo%253D&md5=65ec18527a369b245d865a87cc7bb638</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1248%2Fcpb.43.1706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.43.1706%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DNatsume%26aufirst%3DT.%26aulast%3DGondo%26aufirst%3DM.%26aulast%3DMikami%26aufirst%3DT.%26aulast%3DSakakibara%26aufirst%3DK.%26aulast%3DTsukagoshi%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520antitumor%2520activity%2520of%2520novel%2520dolastatin%252010%2520analogs%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1995%26volume%3D43%26spage%3D1706%26epage%3D1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natsume, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamaoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyasaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakakibara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukagoshi, S.</span><span> </span><span class="NLM_article-title">Antitumor activity of TZT-1027, a novel dolastatin 10 derivative</span> <span class="citation_source-journal">Jpn. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1111%2Fj.1349-7006.1997.tb00383.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=9140117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK2sXit1ajs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1997&pages=316-327&author=M.+Kobayashiauthor=T.+Natsumeauthor=S.+Tamaokiauthor=J.+Watanabeauthor=H.+Asanoauthor=T.+Mikamiauthor=K.+Miyasakaauthor=K.+Miyazakiauthor=M.+Gondoauthor=K.+Sakakibaraauthor=S.+Tsukagoshi&title=Antitumor+activity+of+TZT-1027%2C+a+novel+dolastatin+10+derivative"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of TZT-1027, a novel dolastatin 10 derivative</span></div><div class="casAuthors">Kobayashi, Motohiro; Natsume, Tsugitaka; Tamaoki, Satoru; Watanabe, Jun-Ichi; Asano, Hajime; Mikami, Takashi; Miyasaka, Katsuhiko; Miyazaki, Koichi; Gondo, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">316-327</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">Dolastatin 10, a pentapeptide isolated from the marine mollusk Dolabella auricularia, has antitumor activity.  TZT-1027, a dolastatin 10 deriv., is a newly synthesized antitumor compd.  The authors evaluated its antitumor activity against a variety of transplantable tumors in mice.  Intermittent injections of TZT-1027 were more effective than single or repeated injections in mice with P388 leukemia and B16 melanoma.  Consequently, TZT-1027 shows schedule dependency.  TZT-1027 was effective against P388 leukemia not only when administered i.p., but also when given i.v.  However, although TZT-1027 given i.v. was active against murine solid tumors, TZT-1027 administered i.p. was ineffective against all the tumors tested with the exception of colon 26 adenocarcinoma.  The i.v. injection of TZT-1027 at a dose of 2.0 mg/kg remarkably inhibited the growth of three murine solid tumors; colon 26 adenocarcinoma, B16 melanoma and M5076 sarcoma, with T/C values of less than 6%.  The antitumor activities of TZT-1027 against these tumors were superior or comparable to those of the ref. agents; dolastatin 10, cisplatin, vincristine, 5-fluorouracil (5-FU) and E7010.  In expts. with drug-resistant P388 leukemia, TZT-1027 showed good activity against cisplatin-resistant P388 and moderate activity against vincristine- and 5-fluorouracil-resistant P388, but no activity against adriamycin-resistant P388.  TZT-1027 was also effective against human xenografts, i.e., tumor regression was obsd. in mice bearing MX-1 breast and LX-1 lung carcinomas.  TZT-1027 at 10μM almost completely inhibited the assembly of porcine brain microtubules.  Therefore, its mechanism of antitumor action seems to be, at least in part, ascribable to the inhibition of microtubule assembly.  Because of its good preclin. activity, TZT-1027 has been entered into phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVQBYoGhWZvbVg90H21EOLACvtfcHk0lgi8hjD_BP74A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1ajs7k%253D&md5=9938db363d0b24f2ad41f005190faa44</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.1997.tb00383.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.1997.tb00383.x%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DNatsume%26aufirst%3DT.%26aulast%3DTamaoki%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DAsano%26aufirst%3DH.%26aulast%3DMikami%26aufirst%3DT.%26aulast%3DMiyasaka%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DK.%26aulast%3DGondo%26aufirst%3DM.%26aulast%3DSakakibara%26aufirst%3DK.%26aulast%3DTsukagoshi%26aufirst%3DS.%26atitle%3DAntitumor%2520activity%2520of%2520TZT-1027%252C%2520a%2520novel%2520dolastatin%252010%2520derivative%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D1997%26volume%3D88%26spage%3D316%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srirangam, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barkoczy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkin, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapuis, J. C.</span><span> </span><span class="NLM_article-title">Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=7495477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVSmurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1995&pages=529-544&author=G.+R.+Pettitauthor=J.+K.+Srirangamauthor=J.+Barkoczyauthor=M.+D.+Williamsauthor=K.+P.+Durkinauthor=M.+R.+Boydauthor=R.+Baiauthor=E.+Hamelauthor=J.+M.+Schmidtauthor=J.+C.+Chapuis&title=Antineoplastic+agents+337.+Synthesis+of+dolastatin+10+structural+modifications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Antineoplastic agents. 337. Synthesis of dolastatin 10 structural modifications</span></div><div class="casAuthors">Pettit, George R.; Srirangam, Jayaram K.; Barkoczy, Jozsef; Williams, Michael D.; Durkin, Kieran P. M.; Boyd, Michael R.; Bai, Ruoli; Hamel, Ernest; Schmidt, Jean M.; Chapius, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drug Design</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">529-44</span>CODEN:
                <span class="NLM_cas:coden">ACDDEA</span>;
        ISSN:<span class="NLM_cas:issn">0266-9536</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">New structural modifications of the marine mollusk peptide constituent dolastatin 10 have been synthesized and evaluated against a variety of cancer cell lines and for their ability to inhibit tubulin polymn.  A no. of useful structure-activity relationships were uncovered.  The most important observation was that the dolaphenine unit of dolastatin 10 could be satisfactorily replaced with a phenethylamine.  Peptide I, designated auristatin PE, was found to exhibit inhibition of cancer cell growth and tubulin assembly comparable to that of dolastatin 10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmifKCOnza3bVg90H21EOLACvtfcHk0li7N-osNdia7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVSmurbL&md5=8414966374d41e9e82c88900b47f4c7c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSrirangam%26aufirst%3DJ.%2BK.%26aulast%3DBarkoczy%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DM.%2BD.%26aulast%3DDurkin%26aufirst%3DK.%2BP.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DSchmidt%26aufirst%3DJ.%2BM.%26aulast%3DChapuis%26aufirst%3DJ.%2BC.%26atitle%3DAntineoplastic%2520agents%2520337.%2520Synthesis%2520of%2520dolastatin%252010%2520structural%2520modifications%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D1995%26volume%3D10%26spage%3D529%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Flahive, E.; Srirangam, J.</span><span> </span><span class="NLM_article-title">The dolastatins</span>. In  <span class="citation_source-book">Anticancer Agents from Natural Products</span>, <span class="NLM_edition">2nd</span> ed.; <span class="NLM_contrib-group">Cragg, D. J.; Kingston, G. M.; Newman, D. G. I.</span>, Eds.; <span class="NLM_publisher-name">CRC Press</span>: <span class="NLM_publisher-loc">Boca Raton, FL</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1201%2Fb11185-12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=263-290&author=E.+Flahive&author=J.+Srirangamauthor=D.+J.+Cragg&author=G.+M.+Kingston&author=D.+G.+I.+Newman&title=Anticancer+Agents+from+Natural+Products"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1201%2Fb11185-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1201%252Fb11185-12%26sid%3Dliteratum%253Aachs%26aulast%3DFlahive%26aufirst%3DE.%26atitle%3DThe%2520dolastatins%26btitle%3DAnticancer%2520Agents%2520from%2520Natural%2520Products%26aulast%3DCragg%26aufirst%3DD.%2BJ.%26pub%3DCRC%2520Press%26date%3D2011%26spage%3D263%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Pettit, G. R.; Srirangam, J. K.</span><span> </span><span class="NLM_article-title">Preparation of pentapeptides as neoplasm inhibitors</span>. Can. Pat. Appl. CA 2114156,<span class="NLM_x"> </span><span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=G.+R.+Pettit&author=J.+K.+Srirangam&title=Preparation+of+pentapeptides+as+neoplasm+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26atitle%3DPreparation%2520of%2520pentapeptides%2520as%2520neoplasm%2520inhibitors%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Pettit, G. R.; Barkoczy, J.</span><span> </span><span class="NLM_article-title">Preparation of tumor inhibiting tetrapeptide phenethylamides</span>. Eur. Pat. Appl. EP 600744,<span class="NLM_x"> </span><span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=G.+R.+Pettit&author=J.+Barkoczy&title=Preparation+of+tumor+inhibiting+tetrapeptide+phenethylamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26atitle%3DPreparation%2520of%2520tumor%2520inhibiting%2520tetrapeptide%2520phenethylamides%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Doronina, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torgov, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chace, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeBlanc, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gearing, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bovee, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegall, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francisco, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Development of potent monoclonal antibody auristatin conjugates for cancer therapy</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">778</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1038%2Fnbt832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=12778055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=778-784&author=S.+O.+Doroninaauthor=B.+E.+Tokiauthor=M.+Y.+Torgovauthor=B.+A.+Mendelsohnauthor=C.+G.+Cervenyauthor=D.+F.+Chaceauthor=R.+L.+DeBlancauthor=R.+P.+Gearingauthor=T.+D.+Boveeauthor=C.+B.+Siegallauthor=J.+A.+Franciscoauthor=A.+F.+Wahlauthor=D.+L.+Meyerauthor=P.+D.+Senter&title=Development+of+potent+monoclonal+antibody+auristatin+conjugates+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Development of potent monoclonal antibody auristatin conjugates for cancer therapy</span></div><div class="casAuthors">Doronina, Svetlana O.; Toki, Brian E.; Torgov, Michael Y.; Mendelsohn, Brian A.; Cerveny, Charles G.; Chace, Dana F.; DeBlanc, Ron L.; Gearing, R. Patrick; Bovee, Tim D.; Siegall, Clay B.; Francisco, Joseph A.; Wahl, Alan F.; Meyer, Damon L.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">778-784</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylauristatin E (MMAE), linked to the chimeric mAbs cBR96 (specific to Lewis Y on carcinomas) and cAC10 (specific to CD30 on hematol. malignancies).  The linkers used for conjugate formation included an acid-labile hydrazone and protease-sensitive dipeptides, leading to uniformly substituted conjugates that efficiently released active drug in the lysosomes of antigen-pos. (Ag+) tumor cells.  The peptide-linked mAb-valine-citrulline-MMAE and mAb-phenylalanine-lysine-MMAE conjugates were much more stable in buffers and plasma than the conjugates of mAb and the hydrazone of 5-benzoylvaleric acid-AE ester (AEVB).  As a result, the mAb-Val-Cit-MMAE conjugates exhibited greater in vitro specificity and lower in vivo toxicity than corresponding hydrazone conjugates.  In vivo studies demonstrated that the peptide-linked conjugates induced regressions and cures of established tumor xenografts with therapeutic indexes as high as 60-fold.  These conjugates illustrate the importance of linker technol., drug potency and conjugation methodol. in developing safe and efficacious mAb-drug conjugates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro97SFKtdQ7rVg90H21EOLACvtfcHk0li7N-osNdia7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D&md5=d77716ec93de5ac7473c18a597339086</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt832%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DTorgov%26aufirst%3DM.%2BY.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DChace%26aufirst%3DD.%2BF.%26aulast%3DDeBlanc%26aufirst%3DR.%2BL.%26aulast%3DGearing%26aufirst%3DR.%2BP.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DSiegall%26aufirst%3DC.%2BB.%26aulast%3DFrancisco%26aufirst%3DJ.%2BA.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DDevelopment%2520of%2520potent%2520monoclonal%2520antibody%2520auristatin%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DNature%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D778%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievers, E. L.</span><span> </span><span class="NLM_article-title">The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">631</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1038%2Fnbt.2289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=22781692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=631-637&author=P.+D.+Senterauthor=E.+L.+Sievers&title=The+discovery+and+development+of+brentuximab+vedotin+for+use+in+relapsed+Hodgkin+lymphoma+and+systemic+anaplastic+large+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma</span></div><div class="casAuthors">Senter, Peter D.; Sievers, Eric L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-637</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Progress was made recently in developing antibody-drug conjugates (ADCs) that can selectively deliver cancer drugs to tumor cells.  In principle, the idea is simple: by attaching drugs to tumor-seeking antibodies, target cells will be killed and nontarget cells will be spared.  In practice, many parameters needed to be addressed to develop safe and effective ADCs, including the expression profiles of tumor vs. normal tissues, the potency of the drug, the linker attaching the drug and placement of the drug on the antibody, and the pharmacokinetic and stability profiles of the resulting ADC.  All these issues had been taken into account in developing brentuximab vedotin (Adcetris), an ADC that recently received accelerated approval by the US Food and Drug Administration for the treatment of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).  Research is under way to extend the applications of brentuximab vedotin and to advance the field by developing other ADCs with new linker and conjugation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyPib6JxGsSrVg90H21EOLACvtfcHk0lh140z08M0mHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D&md5=6940eb8178e8c8c150a7b21361e23234</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2289%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DSievers%26aufirst%3DE.%2BL.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520brentuximab%2520vedotin%2520for%2520use%2520in%2520relapsed%2520Hodgkin%2520lymphoma%2520and%2520systemic%2520anaplastic%2520large%2520cell%2520lymphoma%26jtitle%3DNature%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D631%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span> </span><span class="NLM_article-title">Antibody–drug conjugates: an emerging concept in cancer therapy</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3796</span><span class="NLM_x">–</span> <span class="NLM_lpage">827</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-827&author=R.+V.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody%E2%80%93drug+conjugates%3A+an+emerging+concept+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugates%253A%2520an%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Doronina, S. O.; Mendelsohn, B. A.</span><span> </span><span class="NLM_article-title">Preparation of auristatins having an aminobenzoic acid unit at the N terminus</span>. PCT Int. Appl. WO 2006132670,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=S.+O.+Doronina&author=B.+A.+Mendelsohn&title=Preparation+of+auristatins+having+an+aminobenzoic+acid+unit+at+the+N+terminus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26atitle%3DPreparation%2520of%2520auristatins%2520having%2520an%2520aminobenzoic%2520acid%2520unit%2520at%2520the%2520N%2520terminus%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Pettit, G. R.; Williams, M. D.; Srirangam, J. K.</span><span> </span><span class="NLM_article-title">Preparation of dolastatin analog pentapeptide methyl esters as anticancer agents</span>. Eur. Pat. Appl. EP 695759,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=G.+R.+Pettit&author=M.+D.+Williams&author=J.+K.+Srirangam&title=Preparation+of+dolastatin+analog+pentapeptide+methyl+esters+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26atitle%3DPreparation%2520of%2520dolastatin%2520analog%2520pentapeptide%2520methyl%2520esters%2520as%2520anticancer%2520agents%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Mendelsohn, B. A.; Barnscher, S. D.</span><span> </span><span class="NLM_article-title">Preparation of substituted peptide analogs as tubulin polymerization inhibitors for treating cancers</span>. U.S. Pat. Appl. Publ. US 20130190248,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=B.+A.+Mendelsohn&author=S.+D.+Barnscher&title=Preparation+of+substituted+peptide+analogs+as+tubulin+polymerization+inhibitors+for+treating+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26atitle%3DPreparation%2520of%2520substituted%2520peptide%2520analogs%2520as%2520tubulin%2520polymerization%2520inhibitors%2520for%2520treating%2520cancers%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Miao, Z.; Hong, Y.; Zhu, T.</span><span> </span><span class="NLM_article-title">Preparation of drug-conjugates, particularly peptide derivative–antibody conjugates, and their uses for treating cancers</span>. PCT Int. Appl. WO 2013173393,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Z.+Miao&author=Y.+Hong&author=T.+Zhu&title=Preparation+of+drug-conjugates%2C+particularly+peptide+derivative%E2%80%93antibody+conjugates%2C+and+their+uses+for+treating+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DZ.%26atitle%3DPreparation%2520of%2520drug-conjugates%252C%2520particularly%2520peptide%2520derivative%25E2%2580%2593antibody%2520conjugates%252C%2520and%2520their%2520uses%2520for%2520treating%2520cancers%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Gajula, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asthana, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborty, T. K.</span><span> </span><span class="NLM_article-title">A synthetic dolastatin 10 analogue suppresses microtubule dynamics, inhibits cell proliferation, and induces apoptotic cell death</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2235</span><span class="NLM_x">–</span> <span class="NLM_lpage">2245</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3009629" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2235-2245&author=P.+K.+Gajulaauthor=J.+Asthanaauthor=D.+Pandaauthor=T.+K.+Chakraborty&title=A+synthetic+dolastatin+10+analogue+suppresses+microtubule+dynamics%2C+inhibits+cell+proliferation%2C+and+induces+apoptotic+cell+death"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm3009629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009629%26sid%3Dliteratum%253Aachs%26aulast%3DGajula%26aufirst%3DP.%2BK.%26aulast%3DAsthana%26aufirst%3DJ.%26aulast%3DPanda%26aufirst%3DD.%26aulast%3DChakraborty%26aufirst%3DT.%2BK.%26atitle%3DA%2520synthetic%2520dolastatin%252010%2520analogue%2520suppresses%2520microtubule%2520dynamics%252C%2520inhibits%2520cell%2520proliferation%252C%2520and%2520induces%2520apoptotic%2520cell%2520death%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2235%26epage%3D2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Park, Y. J.; Jeong, J. K.; Choi, Y. M.; Lee, M. S.; Choi, J. H.; Cho, E. J.; Song, H.; Park, S. J.; Lee, J.-H.; Hong, S. S.</span><span> </span><span class="NLM_article-title">Dolastatin-10 derivative as anticancer agent and preparation method thereof</span>. PCT Int. Appl. WO 2014046441,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Y.+J.+Park&author=J.+K.+Jeong&author=Y.+M.+Choi&author=M.+S.+Lee&author=J.+H.+Choi&author=E.+J.+Cho&author=H.+Song&author=S.+J.+Park&author=J.-H.+Lee&author=S.+S.+Hong&title=Dolastatin-10+derivative+as+anticancer+agent+and+preparation+method+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DY.%2BJ.%26atitle%3DDolastatin-10%2520derivative%2520as%2520anticancer%2520agent%2520and%2520preparation%2520method%2520thereof%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Harrigan, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luesch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valeriote, F. A.</span><span> </span><span class="NLM_article-title">Symplostatin 1: a dolastatin 10 analogue from the marine cyanobacterium <i>Symploca hydnoides</i></span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1075</span><span class="NLM_x">–</span> <span class="NLM_lpage">1077</span></span><div class="citationLinks">[<a href="/doi/10.1021/np980321c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1998&pages=1075-1077&author=G.+G.+Harriganauthor=H.+Lueschauthor=W.+Y.+Yoshidaauthor=R.+E.+Mooreauthor=D.+G.+Nagleauthor=V.+J.+Paulauthor=S.+L.+Mooberryauthor=T.+H.+Corbettauthor=F.+A.+Valeriote&title=Symplostatin+1%3A+a+dolastatin+10+analogue+from+the+marine+cyanobacterium+Symploca+hydnoides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fnp980321c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp980321c%26sid%3Dliteratum%253Aachs%26aulast%3DHarrigan%26aufirst%3DG.%2BG.%26aulast%3DLuesch%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DW.%2BY.%26aulast%3DMoore%26aufirst%3DR.%2BE.%26aulast%3DNagle%26aufirst%3DD.%2BG.%26aulast%3DPaul%26aufirst%3DV.%2BJ.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DCorbett%26aufirst%3DT.%2BH.%26aulast%3DValeriote%26aufirst%3DF.%2BA.%26atitle%3DSymplostatin%25201%253A%2520a%2520dolastatin%252010%2520analogue%2520from%2520the%2520marine%2520cyanobacterium%2520Symploca%2520hydnoides%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D1998%26volume%3D61%26spage%3D1075%26epage%3D1077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Hamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioiri, T.</span><span> </span><span class="NLM_article-title">Efficient stereoselective synthesis of dolastatin 10, an antineoplastic peptide from a sea hare</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">931</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1991&pages=931-934&author=Y.+Hamadaauthor=K.+Hayashiauthor=T.+Shioiri&title=Efficient+stereoselective+synthesis+of+dolastatin+10%2C+an+antineoplastic+peptide+from+a+sea+hare"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamada%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DShioiri%26aufirst%3DT.%26atitle%3DEfficient%2520stereoselective%2520synthesis%2520of%2520dolastatin%252010%252C%2520an%2520antineoplastic%2520peptide%2520from%2520a%2520sea%2520hare%26jtitle%3DTetrahedron%2520Lett.%26date%3D1991%26volume%3D32%26spage%3D931%26epage%3D934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Mordant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reymond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tone, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavergne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Touati, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben Hassine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratovelomanana-Vidal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genet, J. P.</span><span> </span><span class="NLM_article-title">Total synthesis of dolastatin 10 through ruthenium-catalyzed asymmetric hydrogenations</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">6115</span><span class="NLM_x">–</span> <span class="NLM_lpage">6123</span><div class="note"><p class="first last">and references therein.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=6115-6123&author=C.+Mordantauthor=S.+Reymondauthor=H.+Toneauthor=D.+Lavergneauthor=R.+Touatiauthor=B.+Ben+Hassineauthor=V.+Ratovelomanana-Vidalauthor=J.+P.+Genet&title=Total+synthesis+of+dolastatin+10+through+ruthenium-catalyzed+asymmetric+hydrogenations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMordant%26aufirst%3DC.%26aulast%3DReymond%26aufirst%3DS.%26aulast%3DTone%26aufirst%3DH.%26aulast%3DLavergne%26aufirst%3DD.%26aulast%3DTouati%26aufirst%3DR.%26aulast%3DBen%2BHassine%26aufirst%3DB.%26aulast%3DRatovelomanana-Vidal%26aufirst%3DV.%26aulast%3DGenet%26aufirst%3DJ.%2BP.%26atitle%3DTotal%2520synthesis%2520of%2520dolastatin%252010%2520through%2520ruthenium-catalyzed%2520asymmetric%2520hydrogenations%26jtitle%3DTetrahedron%26date%3D2007%26volume%3D63%26spage%3D6115%26epage%3D6123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Kline, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torgov, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/doi/10.1021/mp0340183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFWgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=9-22&author=T.+Klineauthor=M.+Y.+Torgovauthor=B.+A.+Mendelsohnauthor=C.+G.+Cervenyauthor=P.+D.+Senter&title=Novel+antitumor+prodrugs+designed+for+activation+by+matrix+metalloproteinases-2+and+-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Antitumor Prodrugs Designed for Activation by Matrix Metalloproteinases-2 and -9</span></div><div class="casAuthors">Kline, Toni; Torgov, Michael Y.; Mendelsohn, Brian A.; Cerveny, Charles G.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Enzyme prodrug monotherapy takes advantage of the selectivity and specificity of enzymes that are differentially active in the immediate environment of tumor cells.  Matrix metalloproteinases-2 and -9 (MMP-2 and -9, resp.) are cell-surface Zn-dependent endoproteases assocd. with diverse processes throughout tumor formation and progression.  These enzymes have demonstrated high ratios of tumor- to nontumor-assocd. activity and may represent candidates for antitumor prodrug activation.  Our MMP targeting strategy was to prep. and evaluate two classes of enzyme prodrugs, peptides and sequence-similar peptidomimetics, and det. which would be substrates for the enzymes and thus suitable for further in vitro and in vivo evaluation.  We selected representatives of three structurally and mechanistically distinct classes of compds. for delivery, doxorubicin, several auristatins (novel synthetic members of the dolastatin class of tubulin polymn. inhibitors), and CBI-TMI (a duocarmycin class minor groove binder).  The drugs were acylated on available amines with the broadly recognized MMP substrate P3-P1' sequence acetyl L-prolyl-L-leucyl-glycyl-L-leucine, or with a peptidomimetic analog.  From a panel of four peptides and four peptidomimetics, two compds., both peptides, were substrates, with specific activities in the range of 1-20 nmol min-1 mg-1.  For MMP-9, complete conversion took place in 4-16 h; proteolysis by MMP-2 was considerably slower.  Cleavage occurred, as predicted, at the Gly-Leu bond to liberate a leucyl drug, and no other intermediates or cleavage products were obsd.  Although the MMP-9 proteolysis products were equipotent with the parent leucyl drugs, the prodrugs were not differentially active against MMP-2 or -9-expressing vs. nonexpressing cell lines during a 4 h exposure.  Our data can be interpreted in light of the current understanding of the structural and mechanistic factors governing MMP-2 and -9 proteolysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEXjORYIieZbVg90H21EOLACvtfcHk0ljUoqH1l0UvVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFWgsQ%253D%253D&md5=280d81ea08a896e112521576a211f0d4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fmp0340183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp0340183%26sid%3Dliteratum%253Aachs%26aulast%3DKline%26aufirst%3DT.%26aulast%3DTorgov%26aufirst%3DM.%2BY.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DNovel%2520antitumor%2520prodrugs%2520designed%2520for%2520activation%2520by%2520matrix%2520metalloproteinases-2%2520and%2520-9%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2004%26volume%3D1%26spage%3D9%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Venkatraman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankaramma, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balaram, P.</span><span> </span><span class="NLM_article-title">Design of Folded Peptides</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">3131</span><span class="NLM_x">–</span> <span class="NLM_lpage">3152</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr000053z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmslOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2001&pages=3131-3152&author=J.+Venkatramanauthor=S.+C.+Shankarammaauthor=P.+Balaram&title=Design+of+Folded+Peptides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Folded Peptides</span></div><div class="casAuthors">Venkatraman, Janani; Shankaramma, Sasalu C.; Balaram, Padmanabhan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3131-3152</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with refs.  The construction of complex protein folds relies on the precise conversion of a linear polypeptide chain into a compact 3-dimensional structure.  The interplay of forces that link sequence and folding is intricate and yet to be firmly elucidated.  Here, we attempt to review the various approaches used to construct isolated secondary structural modules and to assemble them into compact tertiary on structures with defined folds and at times, function.  Approaches that emphasize stereochem. control over polypeptide chain folding are considered in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY3RihGQo88LVg90H21EOLACvtfcHk0ljUoqH1l0UvVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmslOhtbs%253D&md5=7b47943dcb9f16cfe9ca44b8edc87a09</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fcr000053z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr000053z%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DJ.%26aulast%3DShankaramma%26aufirst%3DS.%2BC.%26aulast%3DBalaram%26aufirst%3DP.%26atitle%3DDesign%2520of%2520Folded%2520Peptides%26jtitle%3DChem.%2520Rev.%26date%3D2001%26volume%3D101%26spage%3D3131%26epage%3D3152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Mukhtar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adhami, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhtar, H.</span><span> </span><span class="NLM_article-title">Targeting microtubules by natural agents for cancer therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1158%2F1535-7163.MCT-13-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=24435445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=275-284&author=E.+Mukhtarauthor=V.+M.+Adhamiauthor=H.+Mukhtar&title=Targeting+microtubules+by+natural+agents+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Microtubules by Natural Agents for Cancer Therapy</span></div><div class="casAuthors">Mukhtar, Eiman; Adhami, Vaqar Mustafa; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural compds. that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death.  Our improved understanding of tumor biol. and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer.  The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance.  Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs.  Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer.  This review focuses on the successful cancer chemotherapy from natural compds. in clin. settings and the challenges that may abort their usefulness.  Mol Cancer Ther; 13(2); 275-84. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZOcnk6gaB7Vg90H21EOLACvtfcHk0liWKLrp97r7SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D&md5=0a14655cff81c9d3a73c0b4514e45112</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0791%26sid%3Dliteratum%253Aachs%26aulast%3DMukhtar%26aufirst%3DE.%26aulast%3DAdhami%26aufirst%3DV.%2BM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DTargeting%2520microtubules%2520by%2520natural%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D275%26epage%3D284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umland, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebhard, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, J. J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">4974</span><span class="NLM_x">–</span> <span class="NLM_lpage">4985</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-Kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0liWKLrp97r7SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curmi, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Barbey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charbaut, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebeau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siavoshian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">The 4A X-ray structure of a tubulin:stathmin-like domain complex</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=809-816&author=B.+Gigantauthor=P.+A.+Curmiauthor=C.+Martin-Barbeyauthor=E.+Charbautauthor=S.+Lachkarauthor=L.+Lebeauauthor=S.+Siavoshianauthor=A.+Sobelauthor=M.+Knossow&title=The+4A+X-ray+structure+of+a+tubulin%3Astathmin-like+domain+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DMartin-Barbey%26aufirst%3DC.%26aulast%3DCharbaut%26aufirst%3DE.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DLebeau%26aufirst%3DL.%26aulast%3DSiavoshian%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DThe%25204A%2520X-ray%2520structure%2520of%2520a%2520tubulin%253Astathmin-like%2520domain%2520complex%26jtitle%3DCell%26date%3D2000%26volume%3D102%26spage%3D809%26epage%3D816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Ranaivoson, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berritt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joullié, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">Structural plasticity of tubulin assembly probed by vinca-domain ligands</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">927</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=927-934&author=F.+M.+Ranaivosonauthor=B.+Gigantauthor=S.+Berrittauthor=M.+Joulli%C3%A9author=M.+Knossow&title=Structural+plasticity+of+tubulin+assembly+probed+by+vinca-domain+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRanaivoson%26aufirst%3DF.%2BM.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DBerritt%26aufirst%3DS.%26aulast%3DJoulli%25C3%25A9%26aufirst%3DM.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DStructural%2520plasticity%2520of%2520tubulin%2520assembly%2520probed%2520by%2520vinca-domain%2520ligands%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2012%26volume%3D8%26spage%3D927%26epage%3D934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Nawrotek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span> </span><span class="NLM_article-title">The determinants that govern microtubule assembly from the atomic structure of GTP-tubulin</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">412</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=412&publication_year=2011&pages=35-42&author=A.+Nawrotekauthor=M.+Knossowauthor=B.+Gigant&title=The+determinants+that+govern+microtubule+assembly+from+the+atomic+structure+of+GTP-tubulin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNawrotek%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26aulast%3DGigant%26aufirst%3DB.%26atitle%3DThe%2520determinants%2520that%2520govern%2520microtubule%2520assembly%2520from%2520the%2520atomic%2520structure%2520of%2520GTP-tubulin%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D412%26spage%3D35%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Kang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, H. S.</span><span> </span><span class="NLM_article-title">Internal rotation about the C–N bond of amides</span> <span class="citation_source-journal">J. Mol. Struct.: THEOCHEM</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">676</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1016%2Fj.theochem.2004.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVCrs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=676&publication_year=2004&pages=171-176&author=Y.+K.+Kangauthor=H.+S.+Park&title=Internal+rotation+about+the+C%E2%80%93N+bond+of+amides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Internal rotation about the C-N bond of amides</span></div><div class="casAuthors">Kang, Young Kee; Park, Hae Sook</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Structure: THEOCHEM</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">676</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">THEODJ</span>;
        ISSN:<span class="NLM_cas:issn">0166-1280</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The internal rotation about the C-N bond of formamide (FA), acetamide (AA), N-methylformamide (NMF), N-methylacetamide (NMA), N,N-dimethylformamide (DMF) and N,N-dimethylacetamide (DMA) in the gas phase, chloroform and water was studied at the HF level of theory with 6-31G(d), 6-31G(d,p) and 6-31+G(d) basis sets to figure out the appropriate level of theory in describing the cis-trans isomerization of the X-noPro and X-Pro peptide bonds.  The conductor-like polarizable continuum model (CPCM) was used to calc. solvation free energies.  The conformational electronic energies calcd. at three levels predicted satisfactorily the exptl. rotational barriers ΔG‡ of FA, DMF and DMA, and the obsd. relative enthalpy changes ΔHcis/trans of cis conformers for NMF and NMA to trans ones in the gas phase.  The CPCM method at the HF/6-31+G(d) level predicted well exptl. solvation free energies of acetamide derivs.  The ΔG‡ for FA, NMF, DMF, NMA and DMA, and ΔHcis/trans for NMF and NMA in chloroform and water were satisfactorily described by the CPCM method at HF/6-31G(d) and HF/6-31+G(d) levels.  These results may indicate that the HF/6-31+G(d) level with the CPCM method appears to be the appropriate method in describing the cis-trans isomerization of the X-noPro and X-Pro peptide bonds in solns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqae2PkymIb9bVg90H21EOLACvtfcHk0ljvJLVUR4kSOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVCrs7g%253D&md5=01b0dd7f28314ac58adb7aa5ce5fddea</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.theochem.2004.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.theochem.2004.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DPark%26aufirst%3DH.%2BS.%26atitle%3DInternal%2520rotation%2520about%2520the%2520C%25E2%2580%2593N%2520bond%2520of%2520amides%26jtitle%3DJ.%2520Mol.%2520Struct.%253A%2520THEOCHEM%26date%3D2004%26volume%3D676%26spage%3D171%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Alattia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poncet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cave, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouin, P.</span><span> </span><span class="NLM_article-title">Conformational study of dolastatin 10</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2593</span><span class="NLM_x">–</span> <span class="NLM_lpage">2604</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1995&pages=2593-2604&author=T.+Alattiaauthor=F.+Rouxauthor=J.+Poncetauthor=A.+Caveauthor=P.+Jouin&title=Conformational+study+of+dolastatin+10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlattia%26aufirst%3DT.%26aulast%3DRoux%26aufirst%3DF.%26aulast%3DPoncet%26aufirst%3DJ.%26aulast%3DCave%26aufirst%3DA.%26aulast%3DJouin%26aufirst%3DP.%26atitle%3DConformational%2520study%2520of%2520dolastatin%252010%26jtitle%3DTetrahedron%26date%3D1995%26volume%3D51%26spage%3D2593%26epage%3D2604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Benedetti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraternali, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolillo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioiri, T.</span><span> </span><span class="NLM_article-title">Conformational analysis of dolastatin 10: an NMR and theoretical approach</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1995&pages=525-538&author=E.+Benedettiauthor=T.+Carlomagnoauthor=F.+Fraternaliauthor=Y.+Hamadaauthor=K.+Hayashiauthor=L.+Paolilloauthor=T.+Shioiri&title=Conformational+analysis+of+dolastatin+10%3A+an+NMR+and+theoretical+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenedetti%26aufirst%3DE.%26aulast%3DCarlomagno%26aufirst%3DT.%26aulast%3DFraternali%26aufirst%3DF.%26aulast%3DHamada%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DPaolillo%26aufirst%3DL.%26aulast%3DShioiri%26aufirst%3DT.%26atitle%3DConformational%2520analysis%2520of%2520dolastatin%252010%253A%2520an%2520NMR%2520and%2520theoretical%2520approach%26jtitle%3DBiopolymers%26date%3D1995%26volume%3D35%26spage%3D525%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirangam, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E. J.</span><span> </span><span class="NLM_article-title">The Dolastatins. 21. Synthesis, X-ray crystal structure, and molecular modeling of (6<i>R</i>)-isodolastatin 10</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">6127</span><span class="NLM_x">–</span> <span class="NLM_lpage">6130</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00100a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1994&pages=6127-6130&author=G.+R.+Pettitauthor=J.+K.+Sirangamauthor=D.+L.+Heraldauthor=E.+J.+Hamel&title=The+Dolastatins.+21.+Synthesis%2C+X-ray+crystal+structure%2C+and+molecular+modeling+of+%286R%29-isodolastatin+10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjo00100a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00100a001%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSirangam%26aufirst%3DJ.%2BK.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DHamel%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520Dolastatins.%252021.%2520Synthesis%252C%2520X-ray%2520crystal%2520structure%252C%2520and%2520molecular%2520modeling%2520of%2520%25286R%2529-isodolastatin%252010%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1994%26volume%3D59%26spage%3D6127%26epage%3D6130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Pauletti, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangwar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siahaan, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aube, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borchardt, R. T.</span><span> </span><span class="NLM_article-title">Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=235-256&author=G.+M.+Paulettiauthor=S.+Gangwarauthor=T.+J.+Siahaanauthor=J.+Aubeauthor=R.+T.+Borchardt&title=Improvement+of+oral+peptide+bioavailability%3A+Peptidomimetics+and+prodrug+strategies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPauletti%26aufirst%3DG.%2BM.%26aulast%3DGangwar%26aufirst%3DS.%26aulast%3DSiahaan%26aufirst%3DT.%2BJ.%26aulast%3DAube%26aufirst%3DJ.%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26atitle%3DImprovement%2520of%2520oral%2520peptide%2520bioavailability%253A%2520Peptidomimetics%2520and%2520prodrug%2520strategies%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D27%26spage%3D235%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Obach, S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0ljvJLVUR4kSOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Han, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopal, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramchandren, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matous, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grove, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, O. A.</span><span> </span><span class="NLM_article-title">CYP3A-mediated drug–drug interaction potential and excretion of brentuximab vedotin, an antibody–drug conjugate, in patients with CD30-positive hematologic malignancies</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">866</span><span class="NLM_x">–</span> <span class="NLM_lpage">877</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm501649k&amp;key=10.1002%2Fjcph.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=23754575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A280%3ADC%252BC3sjht1eksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=866-877&author=T.+H.+Hanauthor=A.+K.+Gopalauthor=R.+Ramchandrenauthor=A.+Goyauthor=R.+Chenauthor=J.+V.+Matousauthor=M.+Cooperauthor=L.+E.+Groveauthor=S.+C.+Alleyauthor=C.+M.+Lynchauthor=O.+A.+O%E2%80%99Connor&title=CYP3A-mediated+drug%E2%80%93drug+interaction+potential+and+excretion+of+brentuximab+vedotin%2C+an+antibody%E2%80%93drug+conjugate%2C+in+patients+with+CD30-positive+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies</span></div><div class="casAuthors">Han Tae H; Gopal Ajay K; Ramchandren Radhakrishnan; Goy Andre; Chen Robert; Matous Jeffrey V; Cooper Maureen; Grove Laurie E; Alley Stephen C; Lynch Carmel M; O'Connor Owen A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">866-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells.  This study evaluated the CYP3A-mediated drug-drug interaction potential of brentuximab vedotin and the excretion of MMAE.  Two 21-day cycles of brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) were administered to 56 patients with CD30-positive hematologic malignancies.  Each patient also received either a sensitive CYP3A substrate (midazolam), an effective inducer (rifampin), or a strong inhibitor (ketoconazole).  Brentuximab vedotin did not affect midazolam exposures.  ADC exposures were unaffected by concomitant rifampin or ketoconazole; however, MMAE exposures were lower with rifampin and higher with ketoconazole.  The short-term safety profile of brentuximab vedotin in this study was generally consistent with historic clinical observations.  The most common adverse events were nausea, fatigue, diarrhea, headache, pyrexia, and neutropenia.  Over a 1-week period, ∼23.5% of intact MMAE was recovered after administration of brentuximab vedotin; all other species were below the limit of quantitation.  The primary excretion route is via feces (median 72% of the recovered MMAE).  These results suggest that brentuximab vedotin (1.8 mg/kg) and MMAE are neither inhibitors nor inducers of CYP3A; however, MMAE is a substrate of CYP3A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2cCHxNhoKccyail4HZd-ifW6udTcc2ebS82S-Mafqlrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjht1eksw%253D%253D&md5=bef9c273df11824115e7f18ea5fd9d7f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fjcph.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.116%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DT.%2BH.%26aulast%3DGopal%26aufirst%3DA.%2BK.%26aulast%3DRamchandren%26aufirst%3DR.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DMatous%26aufirst%3DJ.%2BV.%26aulast%3DCooper%26aufirst%3DM.%26aulast%3DGrove%26aufirst%3DL.%2BE.%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DLynch%26aufirst%3DC.%2BM.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DO.%2BA.%26atitle%3DCYP3A-mediated%2520drug%25E2%2580%2593drug%2520interaction%2520potential%2520and%2520excretion%2520of%2520brentuximab%2520vedotin%252C%2520an%2520antibody%25E2%2580%2593drug%2520conjugate%252C%2520in%2520patients%2520with%2520CD30-positive%2520hematologic%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D53%26spage%3D866%26epage%3D877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Hirth, J.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strawderman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, L. H.</span><span> </span><span class="NLM_article-title">The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1255</span><span class="NLM_x">–</span> <span class="NLM_lpage">1258</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm501649k&amp;key=10778948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm501649k&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtVOqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=1255-1258&author=J.-A.+Hirthauthor=P.+B.+Watkinsauthor=M.+Strawdermanauthor=A.+Schottauthor=R.+Brunoauthor=L.+H.+Baker&title=The+effect+of+an+individual%E2%80%99s+cytochrome+CYP3A4+activity+on+docetaxel+clearance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance</span></div><div class="casAuthors">Hirth, JoAnn; Watkins, Paul B.; Strawderman, Myla; Schott, Anne; Bruno, Rene; Baker, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1255-1258</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Docetaxel is a chemotherapeutic agent effective in the treatment of various solid tumors.  Patients given a std. dose of docetaxel exhibit wide interpatient variation in clearance (CL) and toxic effects.  Docetaxel undergoes metab. by cytochrome CYP3A4.  Thus, interpatient variability in CYP3A4 activity may account in part for differences in toxicity and CL.  Twenty-one heavily pretreated patients with metastatic sarcomas received docetaxel (100 mg/m2).  Hepatic CYP3A4 activity in each patient was measured by the [14C-N-methyl]erythromycin breath test (ERMBT).  Blood samples were taken at selected times over the next 24 h for pharmacokinetic anal.  Phenotypic expression of hepatic CYP3A4 activity measured by the ERMBT varied over 20-fold (administered 14C exhaled in 1 h: mean, 2.53%; range, 0.25-5.35%), which is similar to a normal control population.  CL of docetaxel varied nearly 6-fold (mean, 21.0 L/h/m2; range, 5.4-29.1 L/h/m2).  The ERMBT was the best predictor of CL when compared with serum alanine aminotransferase, albumin, alk. phosphatase, or serum α-1-acidic glycoprotein.  The natural log of ERMBT accounted for 67% of the interpatient variation in CL.  Multivariate anal. showed that the natural log of ERMBT and albumin together accounted for 72% of the interpatient variation in CL.  The greatest toxicity was seen in patients with the lowest ERMBT.  Hepatic CYP3A4 activity is the strongest predictor of docetaxel CL and accounts for the majority of interpatient differences in CL.  Patients with low CYP3A4 activity are at risk for having decreased CL and may thus experience increased toxicity from docetaxel.  Those with high activity may be receiving a suboptimal dose.  By measuring CYP3A4 activity, the ERMBT may be clin. useful in tailoring doses of CYP3A4 substrates, such as docetaxel, in certain individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCaT0kF0BvwbVg90H21EOLACvtfcHk0lg8yoiX_wU-uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtVOqtrw%253D&md5=e17d1f952562d0c9ccb39081dce0e11f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHirth%26aufirst%3DJ.-A.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DStrawderman%26aufirst%3DM.%26aulast%3DSchott%26aufirst%3DA.%26aulast%3DBruno%26aufirst%3DR.%26aulast%3DBaker%26aufirst%3DL.%2BH.%26atitle%3DThe%2520effect%2520of%2520an%2520individual%25E2%2580%2599s%2520cytochrome%2520CYP3A4%2520activity%2520on%2520docetaxel%2520clearance%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2000%26volume%3D6%26spage%3D1255%26epage%3D1258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Doroski, M. D.; Maderna, A.; O’Donnell, C. J.; Subramanyam, C.; Vetelino, B. C.; Dushin, R. G.; Strop, P.; Graziani, E. I.</span><span> </span><span class="NLM_article-title">Preparation of cytotoxic pentapeptides and their antibody drug conjugates for treating cancer</span>. PCT Int. Appl. WO 2013072813,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+D.+Doroski&author=A.+Maderna&author=C.+J.+O%E2%80%99Donnell&author=C.+Subramanyam&author=B.+C.+Vetelino&author=R.+G.+Dushin&author=P.+Strop&author=E.+I.+Graziani&title=Preparation+of+cytotoxic+pentapeptides+and+their+antibody+drug+conjugates+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDoroski%26aufirst%3DM.%2BD.%26atitle%3DPreparation%2520of%2520cytotoxic%2520pentapeptides%2520and%2520their%2520antibody%2520drug%2520conjugates%2520for%2520treating%2520cancer%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barkoczy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srirangam, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantoci, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groy, T. L.</span><span> </span><span class="NLM_article-title">The Dolastatins. 22. Synthesis of Boc-dolaproinyl-dolaphenine and four related chiral isomers</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2935</span><span class="NLM_x">–</span> <span class="NLM_lpage">2938</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00090a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1994&pages=2935-2938&author=G.+R.+Pettitauthor=J.+Barkoczyauthor=J.+K.+Srirangamauthor=S.+B.+Singhauthor=D.+L.+Heraldauthor=M.+D.+Williamsauthor=D.+Kantociauthor=F.+Hoganauthor=T.+L.+Groy&title=The+Dolastatins.+22.+Synthesis+of+Boc-dolaproinyl-dolaphenine+and+four+related+chiral+isomers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjo00090a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00090a009%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DBarkoczy%26aufirst%3DJ.%26aulast%3DSrirangam%26aufirst%3DJ.%2BK.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DWilliams%26aufirst%3DM.%2BD.%26aulast%3DKantoci%26aufirst%3DD.%26aulast%3DHogan%26aufirst%3DF.%26aulast%3DGroy%26aufirst%3DT.%2BL.%26atitle%3DThe%2520Dolastatins.%252022.%2520Synthesis%2520of%2520Boc-dolaproinyl-dolaphenine%2520and%2520four%2520related%2520chiral%2520isomers%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1994%26volume%3D59%26spage%3D2935%26epage%3D2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3E22" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3E22','PDB','3E22'); return false;">PDB: 3E22</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1I','PDB','4X1I'); return false;">PDB: 4X1I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1K','PDB','4X1K'); return false;">PDB: 4X1K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X20" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X20','PDB','4X20'); return false;">PDB: 4X20</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X1Y','PDB','4X1Y'); return false;">PDB: 4X1Y</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i41"><a href="/doi/suppl/10.1021/jm501649k">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_20474"></div></div></div></div></div><hr /></hr><p class="last">Crystallography materials and methods, determination of the absolute configuration for amino acids <b>19i</b>, <b>19j</b>, <b>19k</b>, and <b>19l</b>, and NMR spectra for all new analogues. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501649k/suppl_file/jm501649k_si_001.pdf">jm501649k_si_001.pdf (1.34 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm501649k&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm501649k%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm501649k" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679992df9e583bf8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
